

CURRICULUM VITAE

Name: **Michael Shechter M.D. Dipl. M.A. Clinical Associate Professor 05226000-7**
(First) (Last) (Academic Degree) (Identity No.)

Faculty/Dept: Cardiology
Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel

Hospital/Dept: Leviev Heart Center
Chaim Sheba Medical Center, Tek Hashomer, Israel

Phone No.: 03-5302617
Email: Michael.Shechter@sheba.health.gov.il
Cellular: 0523599384; 0526667025

Home Address: 14 Echad Ha'am Street., Ramat Gan 5221226, Israel
Phone No.: 03-6740718
Date & Place of Birth: 26/2/54, Israel

ZAHAL (Israeli) Military Service:
11/1979 4/1999
Dates: (Enlisted) (Discharged)

Marital Status: Divorced No. of Children: 2

A. EDUCATION

| <i>Period of Study</i> | <i>Name of University (incl. City and country)</i> | <i>Subject</i> | <i>Degree or Professional License</i> | <i>Date Awarded</i> |
|------------------------|--|---|---------------------------------------|---------------------|
| 1972-1979 | Sackler School of Medicine Tel Aviv University | Medicine | M.D. | 23.6.80 |
| 1980 | Israel Air Force | Aviation Medicine | Diploma | 10.11.80 |
| 1984-1987 | School of Continuing Med Education., Sackler School of Medicine, Tel Aviv University | Internal Medicine | Diploma | 30.6.87 |
| 1984-1990 | School of Continuing Med Education., Sackler School of Medicine, Tel Aviv University | Cardiology | Diploma | 8.7.90 |
| 1984-1991 | Sackler Faculty of Medicine & Sheba Medical Center | Cardiology | Specialist in Cardiology | 1.12.91 |
| 1992 | School of Continuing Med Education., Sackler School of Medicine, Tel Aviv University | Cardiology | Master Cum Laude | 11.6.92 |
| 1992 | Israel Association for Advancement of Trauma Care | ATLS | Diploma | 16.10.92 |
| 1995 | Magen David Adom Sackler School of Medicine Tel Aviv University | ACLS Instructor Course | Diploma | 7.6.95 |
| 1995 | American College of Cardiology, Palo Alto, USA | Exercise Physiology & Cardiac Rehabilitation Course | Diploma | 12.8.95 |
| 1995-1997 | Cedars-Sinai Medical Center UCLA Medical School, Los Angeles, CA, USA | Research Fellowship in Thrombosis Atherosclerosis Lipids, Prevention & Cardiac Rehabilitation | Diploma | 5.7.98 |
| 1995 | American Heart Association, Gladstone Institute, San Francisco, USA | Management of Hyperlipidemia and Risk Factors | Diploma | 2.11.96 |
| 1997-1998 | Cedars-Sinai Medical Center UCLA Medical School, Los Angeles, CA, USA | Research Scientist in Thrombosis Atherosclerosis Lipids, Prevention & Cardiac Rehabilitation | Diploma | 5.7.98 |

| | | | | |
|------|--|---|---------|---------|
| 1995 | The Cleveland Clinic Foundation, Florida USA | Cholesterol & Coronary Disease | Diploma | 5.9.97 |
| 1995 | American College of Cardiology, Cedars-Sinai Medical Center, CA, USA | Clinical Nuclear Cardiology | Diploma | 1.2.98 |
| 1999 | Clinical Small Group Teaching, Sackler School of Medicine, TA University | | | 7.6.99 |
| 2004 | Optimizing lipid management: Reducing Cardiovascular Risk | | Diploma | 14.2.04 |
| 2004 | The Cleveland Clinic Foundation, New Orleans, USA | Myocardial Reperfusion XVII: Concepts and Controversies | Diploma | 6.3.04 |
| 2004 | ACPR –The Association of Clinical Research Professionals: GCP-Israel | Good Clinical Practice for Clinical Reserach Physicians and Investigators (GCP) | Diploma | 14.9.04 |
| 2007 | National Institutes of Health (NIH) | Human Participants Education for Research Teams | Diploma | 17.6.07 |
| 2008 | INNOVIA Education Institute, Chicago, IL | Early Challenges in the Optimal Management of Acute Heart Failure | Diploma | 30.3.08 |
| 2009 | University of Cincinnati College of Medicine, Orlando FL, USA | Anticoagulant therapy in the cardiology patient | Diploma | 28.3.09 |
| 2013 | National Education Center For Health Professions, Chaim Sheba Medical Center | AHA ACLS Review Course | Diploma | 17.5.13 |
| 2015 | National Education Center For Health Professions, Chaim Sheba Medical Center | AHA ACLS Review Course | Diploma | 21.5.15 |

Title of Master's Thesis: The clinical significance of further ST segment elevation during the first hour of thrombolysis in AMI patients.

Names of Supervisors: Prof. Babeth Rabinowitz

Title of Doctoral Dissertation: Treatment of quinidine bisulfate (Quiniduran) versus quinidine sulfate in patients with chronic ventricular arrhythmias.

Name of Supervisors: Prof. Babeth Rabinowitz
Prof. Hillel Halkin

Date of receiving Specialization Certificate: 1.12.91

B. FURTHER STUDIES

| <u>Period of Study</u> | <u>Name of University</u> | <u>Subject</u> | <u>Degree or Professional License</u> | <u>Date Awarded</u> |
|-------------------------------|--|---|---|----------------------------|
| 2008 | Sackler Faculty of Medicine, Tel Aviv University | The Unit of Medical Education | Teaching Improvement Course for Clinical Teachers | 2.12.2008 |
| 2008 | Sackler Faculty of Medicine The Unit of Medical Education, Tel Aviv University | Course in Ethics | | 5.12.2008 |
| 2010 | Israel Ministry of Transportation | Aviation Medicine Course | | 3.3.2010 |
| 2012 | ACC Meeting on Demand | Understanding the Cardiovascular Implications of Dietary Supplements | | 24.11.2012 |
| 2013 | Pfizer Inc. | GCP for Investigational Site Staff (course code 9902A-GPCR-INVESTIGATOR-WBT01-3410) | | 23.5.2013 |
| 2015 | NIH Office of Clinical Research Training and Medical Education – Clinical Research Training Course Certificate | | | 27.7.2015 |
| 2016 | ESC CV Pharmacotherapy, Israel Heart Society | GCP Course | | 30.5.2016 |

LICENSURE

| | |
|---|---------------------|
| <i>Degree or Professional license</i> | <i>Date Awarded</i> |
| M.D. Licence # 14726 | 23.6.80 |
| Specialization in Cardiology, Licence # 11999 | 16.2.92 |

C. ACADEMIC & PROFESSIONAL ACTIVITIES & ACHIEVEMENTS**C1. ACADEMIC EXPERIENCE****APPOINTMENTS**

| | | |
|--------------|--|---|
| 1995-1999 | Sackler Medical School, Tel Aviv University | Lecturer in Cardiology |
| 1999 | Sackler Medical School, Tel Aviv University | Clinical Senior Lecturer in Cardiology |
| 2006 | College of Medicine. University of Florida, USA | Vascular Biology Working Group, International Member |
| 2007-2010 | Sackler Faculty of Medicine Council Tel Aviv University | Representative Elect of Senior Lecturers |
| 2009-to date | Sackler Medical School, Tel Aviv University | Clinical Associate Professor in Cardiology |

TEACHING

| <u>Period</u> | <u>Name of Institution</u> | <u>Department</u> | <u>Rank/Function</u> |
|----------------------|-----------------------------------|--|---|
| 1973-1975 | Tel Aviv University | Anatomy | Demonstrator |
| Apr 1990 | The Hebrew University | Institute of Postgraduate Education | Lecturer, Seminar in Cardiology |
| April-May 1999 | Sheba Medical Center | Heart Institute | Lecturer, Cardiac Physiology, Grade 2 students, N.Y. State American Program |
| Aug 1994 | Israel Aeromedical Center | I.D.F. | Lecturer, Aviation Cardiology Course |
| Aug-Nov 1998 | Sheba Medical Center | Internal Dept. H | Demonstrator, clinical course, Grade 6, American students |
| Aug-Sep 1993 | Sheba Medical Center | Internal Medicine H | Lecturer, clinical course in cardiology |

| | | | |
|-----------------------|--|---|---|
| Dec 1992 | Assaf Harofe Hospital; Tel Aviv University | Update in Cardiology | Lecturer |
| Dec 1992 | Sheba Medical Center | Heart Institute | Tutor of students Grade 6 – Cardiology |
| Dec 1992 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| Dec 1992- Feb 1993 | Sheba Medical Center | | Lecturer, Intensive Cardiac Care Course for Nurses |
| Dec 1993 | Sheba Medical Center | Heart Institute | Tutor of students Grade 4 – Cardiology |
| Dec 1994 | Sheba Medical Center | Emergency Dept. | Lecturer, ACLS for Physicians |
| Feb 1993 | Sheba Medical Center And Magen David Adom Organization | | Lecturer, Clinical Course for Paramedics |
| Feb 1995 | Sheba Medical Center | | Lecturer, Cardiology course for workers in Clinical Microbiology Laboratories |
| Feb 1999 | Ministry of Health, Magen David Adon & IDF | | Lecturer & Organizer Cardiology Course for Paramedics |
| Feb-Mar 1994 | Sheba Medical Center | Dept. of Anesthesiology | Lecturer, clinical course in Cardiology |
| Jan 1993 | Sheba Medical Center | | Lecturer, Emergency Clinical Course for Interns |
| Jan 1994 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| Jan 1994 | Sheba Medical Center | Heart Institute | Tutor of students Grade 6 – Cardiology |
| Jan 1994 | Sheba Medical Center | Heart Institute | Lecturer, students Grade 6 – Cardiology |
| Jan 1995 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| Jan 1995 | Sheba Medical Center | | Lecturer & Organizer, Emergency Clinical Course for Interns |
| Jan-April 1999 | Sheba Medical Center | Heart Institute | Lipid Course for Cardiology Residents |
| Jan-Feb 1992 | Sheba Medical Center | | Lecturer, Emergency Clinical Course For Interns |

| | | | |
|---------------|--|--|--|
| Jan-Feb 1994 | Sheba Medical Center | | Lecturer, Emergency Clinical Course for Interns |
| Jan-July 1994 | Sheba Medical Center | Heart Institute | Lecturer, Clinical Cardiology for Nurses & Technicians |
| Jan-June 1994 | Tel Aviv University | N.Y. State American Program | Lecturer in Cardiology |
| Jan-June 1995 | Tel Aviv University | N.Y. State, American Program | Lecturer, cardiology, USMLE Course |
| July 1993 | Sheba Medical Center | Heart Institute | Tutor of students Grade 6 – Cardiology |
| June 1993 | Sheba Medical Center | Heart Institute | Tutor, Cardiology, students Grade 6 |
| June 1994 | Sheba Medical Center | | Lecturer, Emergency Clinical Course for Interns |
| June 1999 | Sheba Medical Center | Heart Institute | Lecturer, Cardiovascular Physiology Course for Technicians |
| Mar 1992 | Sheba Medical Center | Heart Institute | Lecturer, ECG for Students |
| Mar 1993 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| Mar-Apr 1994 | Sheba Medical Center | Internal Medicine H | Lecturer, clinical course in Cardiology |
| Mar-Apr 1995 | Sheba Medical Center | Heart Institute | ECG Course for Grade 4 students Intern. Med. Dep. G & B |
| Mar-Apr 1995 | Sheba Medical Center & Magen David Adom | | Lecturer & Organizer Cardiology Course, Clinical Course for Paramedics |
| Mar-May 1991 | Sheba Medical Center | Internal Dept. H | Demonstrator for students – Cardiology |
| May 1991 | School of Continuing Medical Education Tel Aviv University | Emergency Medicine Workshop | Lecturer |
| May 1993 | Sheba Medical Center | Heart Institute | Tutor of students Grade 4 – Cardiology |
| May 1994 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| May-June 1988 | Sheba Medical Center | Internal Dept. H | Demonstrator clinical course |
| Nov 1990 | Sheba Medical Center | Heart Institute | Demonstrator for students-Cardiology |

| | | | |
|--------------------|---|--|---|
| Nov 1991 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| Nov 1992 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| Nov 1992 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Heart Institute Postgraduate Cardiology Course |
| Nov 1992 | Sheba Medical Center | Heart Institute | Demonstrator for Students |
| Nov 1992 | Sheba Medical Center | Heart Institute | Tutor of American Grade 6 students in cardiology |
| Nov 1993 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| Nov 1994 | Sheba Medical Center | Heart Institute | Tutor, Grade 6 Cardiology students Intern. Dept. A, G, H |
| Nov 1994 | Tel Aviv University | School of Continuing Medical Education | Lecturer, Emergency Medicine Workshop |
| Nov 1998- Jan 1999 | Sheba Medical Center | Intern. Dept. H | ECG Course Grade 4 Students |
| Nov-Dec 1993 | Sheba Medical Center, And Magen David Adom Organization | | Lecturer, Clinical Course for Paramedics |
| Oct 1989 | Sheba Medical Center | Heart Institute | Demonstrator for Students |
| Oct 1994 | Sheba Medical Center | Heart Institute | Tutor, Grade 6 Cardiology students N.Y. State American Program |
| Oct 1998 | Sheba Medical Center | Heart Institute | Lecturer, Grade 4 Cardiology Students, N.Y. State American Program |
| Oct-Dec 1989 | Sheba Medical Center | | Demonstrator and Lecturer, Intensive Cardiac Care course for nurses |
| Oct-Dec 1991 | Sheba Medical Center | Internal Dep. H | Demonstrator clinical course for American Grade 3 students |
| October 1999 | Sheba Medical Center | Heart Institute | Tutor, 3 rd Grade students, N.Y. State American Program |
| January 2000 | Ministry of Health, Magen David Adom, & Tel Aviv University | | Medical Director, Paramedics Course |
| Feb-March 2000 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Tutor, 4th Grade, students, Tel Aviv University |

| | | | |
|----------------|----------------------|---|--|
| March 2000 | Sheba Medical Center | Heart Institute | Tutor, 6th Grade students, Elective, Tel Aviv University |
| May 2000 | Tel Aviv University | School of Continuing, Medical Education | Lecturer, Cardiology Post Graduate Course |
| June 2000 | Sheba Medical Center | Heart Institute Dep. of Medicine | Tutor, 3rd Grade students (Elective) N.Y. State, American Program |
| July-Aug 2000 | Sheba Medical Center | Heart Institute Dep. of Medicine | Tutor, 3 rd Grade, students (Elective) From Italy |
| Sept 2000 | Sheba Medical Center | Heart Institute Dep. of Medicine | Tutor, 3 rd Grade students N.Y. State American Program |
| Oct 2000 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 3 rd Grade students N.Y. State American Program |
| Feb-April 2001 | Sheba Medical Center | Intern. Dept. H | ECG Course Grade 4, Students N.Y. State American Program |
| Feb 2001 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 3 rd Grade students |
| March 2001 | Sheba Medical Center | | Lecturer, 3 rd Grade student |
| July 2001 | Sheba Medical Center | | Lecturer, Intensive Cardiac Care Course for Nurses |
| Oct 2001 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade students |
| Jan 2002 | Tel Aviv University | School of Continuing Medical Education, Sackler School of Medicine, | Lecturer, Cardiology Post Graduate Course |
| Jan-Mar 2002 | Sheba Medical Center | Intern. Dept. H | ECG Course Grade 4 students |
| Feb 2002 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade students |
| March 2002 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade students |
| April 2002 | Tel Aviv University | School of Continuing Medical Education, Sackler School of Medicine | Lecturer, Intern. Medicine Post Graduate Course – Cardiology, Exam. for Internists |
| October 2002 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 3rd Grade, students N.Y. State American Program |
| Jan 2003 | Sheba Medical Center | | Lecturer, Intensive Cardiac Care Course for Nurses |

| | | | |
|--------------|----------------------|-----------------------------------|---|
| Feb 2003 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 3rd Grade students, TA University |
| March 2003 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade students, TA University |
| April 2003 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 3rd Grade students, TA University |
| October 2003 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 3 rd Grade students N.Y. State American Program |
| March 2004 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade students, TA University |
| April 2004 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade students, TA University |
| Feb 2005 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade students, TA University |
| March 2005 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade students, TA University |
| June 2005 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 6th Grade students, TA University |
| Sept 2005 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4 th Grade students N.Y. State American Program |
| Dec 2005 | Tel Aviv University | Dep. of Engineering | Lecturer |
| March 2006 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade students, TA University |
| April 2006 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade students, TA University |
| May 2006 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| Oct 2006 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer 4 th Grade Students, TA Univeresity |
| Oct 2006 | Sheba Medical Center | Dep. of Medicine H | Oral exam, 6th Grade Students, TA University |
| Oct 2006 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer 3 rd Grade students N.Y. State American Program |
| Oct 2006 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer 4 th Grade Students Inroduction To Medicine Course "CAD Risk Factors" |

| | | | |
|--------------|----------------------|--|--|
| March 2007 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| April 2007 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| May 2007 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| Oct-Nov 2007 | Tel Aviv University | Sackler Faculty of Medicine | CVS Pharmacology Course NY State Students, 2 nd Year American Program Course Director (21 hours course) |
| Dec 2007 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer, Cardiovascular Pharmacology Course, 3 rd Year Students TA Univ. (12 hours course) |
| Jan 2008 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| Feb 2008 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| April 2008 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| Oct-Nov 2008 | Tel Aviv University | Sackler Faculty of Medicine | Course Director (21 hours), CVS Pharmacology Course NY State Students, 2 nd Year American Program |
| Oct 2008 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer, 4 th Grade Students Inroduction to Medicine Course “CAD Prevention” |
| Feb 2009 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| May 2009 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| May 2009 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| June 2009 | Tel Aviv University | Continnuing Medical Education in Cardiology, Sackler Faculty of Medicine | Lecturer |
| October 2009 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer 4 th Grade Students Inroduction to Medicine Course “CAD Prevention” |

| | | | |
|---------------|----------------------|----------------------------------|--|
| October 2009 | Sheba Medical Center | Heart Institute | Lecturer, NY State Students 4 th Grade, TA University |
| November 2009 | Sheba Medical Center | Heart Institute | Lecturer, NY State Students 4 th Grade, TA University |
| Feb 2010 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| Apr 2010 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| May 2010 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| October 2010 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 3rd Grade (4-y Program) Students, TA University |
| November 2010 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 3rd Grade (4-y Program) Students, TA University |
| Nov 2010 | Tel Aviv University | Sackler Faculty of Medicine | CVS Pharmacology Course NY State Students, 2 nd Year American Program Course (9 hours) |
| December 2010 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer 4 th Grade Students Introduction to Medicine Course "CAD Prevention" |
| December 2010 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| Feb2011 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| Feb 2011 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| March 2011 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| Apr 2011 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| July 2011 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer 2 nd Grade Students the 4-year Program, Medical Clinic Approach, Cardiology 1 ^{ry} and 2 ^{ry} CAD Prevention |

| | | | |
|---------------|----------------------|-----------------------------------|---|
| Oct 2011 | Tel Aviv University | Sackler Faculty of Medicine | CVS Pharmacology Course NY State Students, 2 nd Year American Program Course (3 hours) |
| November 2011 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer and Co Director of 4 th Grade Students Introduction to Medicine Course "CAD Prevention" |
| November 2011 | Sheba Medical Center | Heart Institute | Lecturer, NY State Students 4 th Grade, TA University |
| November 2011 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| December 2011 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| February 2011 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| March 2012 | Sheba Medical Center | Heart Institute, Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| October 2012 | Sheba Medical Center | Heart Institute | Lecturer, NY State Students 4 th Grade, TA University |
| October 2012 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer and Co Director of 4 th Grade Students Introduction to Medicine Course "CAD Prevention" |
| November 2012 | Sheba Medical Center | Heart Institute | Lecturer, NY State Students 4 th Grade, TA University |
| October 2013 | Tel Aviv University | Sackler Faculty of Medicine | Lecturer 4 th Grade Students Introduction to Medicine Course, "CAD Prevention" |
| Dec 2013 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| Jan 2014 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, Cyprus |
| Feb 2014 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| March 2014 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |

| | | | |
|------------|----------------------|----------------------------------|--|
| April 2014 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, TA University |
| Feb 2015 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 4th Grade Students, Cyprus |
| April 2015 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 6th Grade Students, TA University |
| April 2016 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 5th Grade Students, TA University |
| Nov 2017 | Sheba Medical Center | Heart Institute Dep. of Medicine | Lecturer, 3rd Grade (4-year) Students, TA Univ |

C2. PROFESSIONAL EXPERIENCE

| <u>Period</u> | <u>Name of Institution</u> | <u>Department</u> | <u>Rank/Function</u> |
|----------------------|--|--------------------------|----------------------------------|
| 1978 | Sheba Medical Center Tel Aviv University | All Depts. | Internship |
| 1979-to date | IDF, Air Force | Rescue Unit | Flight Surgeon |
| 1984-1986 | Sheba Medical Center Tel Aviv University | Internal Dep. H | Resident |
| 1986-1991 | Sheba Medical Center Tel Aviv University | Heart Institute | Resident |
| 1990-1995 | Magen David Adom | | Chief Consultant Cardiologist |
| 1991-to date | Sheba Medical Center Tel Aviv University | Heart Institute | Senior Cardiologist |
| 1991-to date | Human & Science Museum | Petach Tikva | Scientific Consultant |
| 1991-to date | Emergency Medicine Workshop, School of Continuing Medical Education | Tel Aviv University | Lecturer |
| 1993-1994 | Aeromedical Center Israel Air Force | Medical Branch | Director |

| | | | |
|--------------|--|---|--------------------------------------|
| 1994-to date | Israel Aeromedical Center, Israel Air Force | | Consultant, Aviation Cardiologist |
| 1994-to date | Israel Paramedic Association | | Scientific Board |
| 1994-1995 | Israel Ministry of Health Committee on Cardiac Care Mobile Units and Emergency Services Tel Aviv University | | Member |
| 1995-1997 | Save A Heart Foundation Cedars Sinai Medical Center UCLA School of Medicine | Preventive & Rehabilitative Cardiac Center Cedars-Sinai Medical Center, Los Angeles, USA | Research Fellow |
| 1997-1998 | Save A Heart Foundation Cedars Sinai Medical Center UCLA School of Medicine | Preventive & Rehabilitative Cardiac Center Cedars-Sinai Medical Center, Los Angeles, USA | Research Scientist |
| 1997-1999 | Save A Heart Foundation Division of Cardiology Cedars-Sinai Medical Center | Los Angeles, USA | Member, Board of Directors |
| 1998-1999 | National Healthcare Technology Inc., Los Angeles, USA | | President |
| 1998-to date | Israel Aeromedical Center | IDF | Director, Primary Prevention Program |
| 1999-2010 | Sackler Faculty of Medicine Tel Aviv University | | Senior Lecturer in Cardiology |
| 1999-to date | International Academy of Cardiology and the World Congress on Heart Disease | | Member |
| 1999-2009 | Israel Ministry of Transportation | Civil Aviation Authority | Flight Surgeon |
| 2001-to date | Sheba Medical Center Tel Hashomer | Leviev Heart Center | Director, Clinical Research Unit |
| 2002-to date | European Board for the Speciality of Cardiology | European Society of Cardiology | European Cardiologist |
| 2009-to date | Israel Ministry of Transportation | Civil Aviation Authority | Senior Flight Surgeon |

Academic, Organizing and Managing Roles in Societies and Organizations

| | | | |
|--------------|--|---------------------------------|---------------------------------------|
| 1999-to date | International Academy of Cardiology | World Congress on Heart Failure | Scientific Advisory Board |
| 2011-2012 | Cardiovascular Pharmacology And Drug Therapy Working Group | Israel Heart Society | Secretary Elect |
| 2011-2015 | American College of Cardiology | Israel Chapter | Secretary |
| 2015-to date | Beijing Viable Medical Investment Co., Ltd. (BVMI) | China | Distinguished Expert of the committee |
| 2016-2018 | ESC Working Group on Atherosclerosis & Vascular Biology | ESC | Nucleus Member |

GRANT REVIEWER

| | |
|---------------|---|
| 2005- to date | The Sackler Faculty of Medicine, Tel Aviv University, Israel. |
| 2008- to date | German Federal Ministry of Education and Research, Germany. |
| 2008- to date | The Hebrew University Medical School, Jerusalem, Israel. |
| 2009- to date | Technion Faculty of Medicine, Haifa, Israel |

Active Participation in Clinical Trials

- Beneficial effects of magnesium aspartate in patients with mild to moderate chronic congestive heart failure. Nordmark Arzneimittel GmbH/BASF Pharma. Protocol No. MgK 1/93 Cl. Phase III.
Role: PI.
- AZACS - AZITHROMYCIN for ACUTE CORONARY SYNDROMES: Phase III study. A multi-center, international double-blind, placebo-controlled study to investigate the impact of azithromycin on clinical outcome in patients with acute coronary syndrome. Phase III.
Role: Investigator.
- Evaluation of the antianginal efficacy and safety of oral chronic administration of Ivabradine (5 mg bid., then 7.5 mg or 10 mg bid.) compared to Atenolol (50 mg od. then 100 mg od) in patients with stable angina pectoris (Servier). Study No. CL-3-16257-017/018/019/022.

4. A multi-center, multinational, phase III, 4 and a half month parallel group, double-blind, randomized, controlled trial, to compare the efficacy and safety of ivabradine (5 mg b.i.d) to atenolol (50 mg od) during 1 month and secondly ivabradine (7.5 or 10mg bid.) to atenolol (100mg od) during 3 months, given as a monotherapy by oral route to out-patients with chronic stable angina.

Phase III.

Role: PI.

5. GUSTO IV AMI Trial:

A multi-center international trial to investigate the impact of the combination therapy of IIb/IIIa antagonist (ReoPro) and r-PA in patients with acute myocardial infarction.

Role: Investigator.

6. AF-CHF. Atrial Fibrillation and Congestive Heart Failure. A multicenter international (North America, South America, Europe) study evaluating the value of a therapeutic strategy to restore and maintaining sinus rhythm in patients with AF and CHF versus strategy of rate control alone. Canadian Institutes of Health Research.

Role: PI

7. MAGIC (magnesium in coronaries) STUDY.

The National Heart, Lung and Blood Institute international, multi-center, randomized, placebo-controlled trial, that will randomize 10,500 acute myocardial infarction patients at high risk of mortality, to either magnesium or placebo infusion, started within 6 hours of symptom onset and administered over 24 hours.

Role: National Coordinator and local PI.

8. RUTH - Raloxifene Hydrochloride Or Placebo In Postmenopausal Women At Risk For Major Cardiovascular Events: (Lilly). Phase III Study.

A multi center, international, randomized, double-blind, placebo-controlled parallel trial to assess whether chronic treatment (5-7.5 years) with Raloxifen Hcl 60 mg/day compared with placebo reduces the incidence of the combined endpoint of coronary death and nonfatal myocardial infarction in postmenopausal women at risk for coronary events.

Role: PI.

9. THE DEFINITE TRIAL (DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation): Northwestern Memorial Hospital. Protocol No. HT 854.

A multi-center, multinational study to randomize subjects with left ventricular dysfunction, due to non-ischemic dilated cardiomyopathy, to either standard triple oral medical therapy for heart failure (including digoxin, diuretics and ACE-inhibitors) plus beta-blockers, if tolerated, or to standard triple oral medical therapy (as above) plus beta-blockers, if tolerated, and ICD implantation.

Role: Investigator.

10. The Impact Of Oral Magnesium On Cardiac Functional Capacity And Quality Of Life In Cad Patients: Asta Medica.

A multinational, multi-center, double-blind, placebo controlled study to find out the impact of oral magnesium therapy on cardiac functional capacity and quality of life in patients with coronary artery disease.

Phase III.

Role: International PI and local PI.

11. GUSTO V AMI Trial:

A multi-center international trial to investigate the impact of the combination therapy of IIb/IIIa antagonist (ReoPro) and r-PA in patients with acute myocardial infarction.

Phase III.

Role: Investigator.

12. A TO Z STUDY (Merck). Protocol No 987-0C. MK 0733. Phase IV.

A multicenter, randomized, controlled, double-blind study to investigate the clinical efficacy and tolerability of early treatment with simvastatin 40 mg daily for 30 days, followed by simvastatin 80 mg daily thereafter in tirofiban-treated acute coronary syndrome patients who have been randomized to receive enoxaparin or unfractionated heparin in conjunction with aspirin, and optimally-treated ST elevation acute coronary syndrome patients.

Role: Investigator.

13. PRINCESS (Bayer). BAY W6228. Phase III.

Prevention of re-Infarction by early treatment of CERivaStatin Study.

Prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group comparison of cerivastatin versus placebo in early acute treatment of post-myocardial infarction with long term follow-up treatment by cerivastatin in both groups.

Role: Investigator.

14. THE IMPACT OF SHORT-TERM INTRAVENOUS DOBUTAMIN THERAPY ON ENDOTHELIAL FUNCTION IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE:

Investigator-initiated study to evaluate the impact of short-term intravenous dobutamine therapy versus usual care on the brachial artery endothelial function in patients with severe decompensated (NYHA IV, Class IV) heart failure.

Role: PI.

15. GSK ATRIAL FIBRILLATION (SmithKline Beecham, Inc.). Protocol No. SB207266.

A randomized, double-blind, placebo controlled, parallel group study of the safety and efficacy of SB 207266 in patients with symptomatic persistent atrial fibrillation.

Role: Investigator.

16. RUBI: revascularization in Utilizing Baloon Protection in Acute Coronary Ischemic Syndrome. Medicins, Inc.

Role: Investigator.

17. NIR TOP (Medinol)

Clinical trial of the NIRFLEX™ and NIRFLEX™ Premounted Stents

Role: Co P. Investigator.

18. REPLACE II (Medicines, Inc.). Phase IIIb/IV study.

A Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, Part 2: REPLACE 2. Protocol No. TMC-BIV-01-03.

Role: CO-PI.

19. SHOCK II (ArgiNOx Pharmaceuticals, Inc.). Phase II Trial.

A randomized, double-blind, placebo-controlled, dose-ranging study of nitric oxide synthase inhibition with N^G-Monomethyl-L-Arginine (L-NMMA) in patients with cardiogenic shock complicating acute myocardial infarction: Preliminary Evaluation of safety, efficacy and biologic activity.

Role: PI

20. MCC 135 in CHF (Takeda Euro R&D Center, Ltd). Phase II Study.

A double-blind, randomized, placebo-controlled, multi-center study of the 12-week haemodynamic effects of 50 mg, 100mg and 200 mg oral MCC-135 in patients with symptomatic heart failure.

Role: Investigator.

21. SAGE – Study Assessing Goals in the Elderly. Protocol 981-400-421/0981-000-429. (Pfizer).

A prospective, randomized, double-blind, multi-center study comparing the effects of aggressive lipid lowering with moderate lipid lowering on reduction of the total duration of myocardial ischemia in the elderly as measured by holter monitoring by comparing the maximal doses of two statins.

Role: Investigator.

22. Ezetimibe +Simvastatin (MSD). MK 0653. Protocol 801-03. Phase IV.

A randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy, safety and tolerability of ezetimibe 10 mg or placebo added to simvastatin 10 mg or 20 mg in attaining low-density lipoprotein cholesterol target levels in patients with hypercholesterolemia and coronary heart disease

Role: PI

23. SURVIVE (Orion Pharma).

Survival of patients with acute heart failure in need of intravenous inotropic support; a multicenter, parallel-group, randomized, double-blind, double-dummy study of levosimendan versus dobutamine in patients with acute heart failure.

Role: Investigator.

24. MITSUBISHI (EVOLVE) (Mitsubishi Pharma America, Inc.)

A Phase IIa, Randomized, Double Blind, Placebo Controlled Clinical Trial to Examine the Safety and Efficacy of Intravenous MCC 135 as an Adjunct to Standard Therapy with Primary PCI in Patients Diagnosed as Having an ST Elevation Acute Myocardial Infarction.

Role: Investigator.

25. UP FLOW MI (Boston Scientific). A multicenter, prospective randomized and controlled study. The Use of Protective FilterWire EZ® to improve Flow in Acute Myocardial Infarction.

The aim was to assess whether the capture of embolic particles during PCI would improve myocardial reperfusion outcome.

Role: Investigator.

26. OAT (NHLBI). Occluded Artery Trial. (The National Heart, Lung and Blood Institutes).

Role: Investigator.

27. Irbesartan/HCTZ (BMS/Sanofi-Synthelabo). Phase II study. Protocol CV131176/

The efficacy and Safety of Irbesartan/HCTZ combination therapy as first line treatment for severe hypertension.

Role: PI

28. ACCLAIM (Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy) (Vsogen, Inc.).

A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess the effects of Celacade™ (Immune modulation therapy) on mortality and morbidity in patients with chronic heart failure.

Role: Investigator

29. ACCLAIM ENDOTHELIAL FUNCTION STUDY (Vasogen, Inc.). Protocol No. 020206.

A multi-center, randomized, double blind, parallel group, placebo-controlled study to assess the effects of immune modulation therapy (Celacade™) on endothelial function in patients with heart failure.

Role: PI

30. EZETIMIBE IN CAD (MSD).

An open study to evaluate efficacy of ezetimibe 10 mg added on existing statin therapy, in reducing LDL cholesterol to target levels in patients discharged from hospitals after acute coronary syndrome. Phase IV study.

Role: PI

31. ExTRACT TIMI 25. Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis In Myocardial Infarction – Study 25. (TIMI Study Group, CV Therapeutics). Phase III study.

A randomized, double-blind, double-dummy, parallel group, multinational, clinical study to evaluate the efficacy and safety of enoxaparin versus unfractionated heparin in patients with acute ST segment elevation myocardial infarction receiving fibrinolytic therapy.

Role: Investigator.

32. TIMI 36 (MERLIN). Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST Elevation Acute Coronary Syndromes. Protocol No. 3036. (TIMI Study Group, CV Therapeutics). Phase III study.

A randomized, double-blind, parallel-group, placebo-controlled, multinational, clinical trial to evaluate the efficacy and safety of ranolazine versus placebo in patients with non-ST segment elevation acute coronary syndromes.

Role: Investigator.

33. MADIT-CRT. Multicenter Automatic Defibrillator Implantation Cardiac Resynchronization Therapy Trial. NIH.

Role: Investigator.

34. FINESSE. Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events). Protocol No. C0116T40. (Centocor). Protocol 2004-000548-26.

A multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of reteplase and abciximab combination therapy with abciximab alone administered early or just prior to primary percutaneous coronary intervention for acute myocardial infarction.

Role: Investigator

35. DILIPO. (Sanofi-Synthelabo). Phase II. Study No. EFC 5816

A multicenter, randomized, placebo-controlled, double-blind trial evaluating the effect of two doses of a vasopressin V2 receptor antagonist (SR121463B) on serum sodium in patients with dilutional hyponatremia.

Role: Investigator.

36. HORIZONS AMI Trial. Harmonizing Outcomes with RevascularizatiON and Stents. A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibition with bivalirudin and bail-out GP IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS™) or an otherwise uncoated bare metal stent (Express™). (Cardiovascular Research Foundation).

Role: Investigator.

37. ACT 064992 (ACTELION). Protocol No. AC-055-201.

A multi-center, double-blind, randomized, placebo- and active-controlled, parallel group, dose-ranging study to evaluate the efficacy, safety and tolerability of ACT-064992 in subjects with mild-to-moderate essential hypertension.

Role: Co-PI

38. Early ACS. Protocol N. M-INTEG03-062 (Millennium) PO3684 (Schering-Plough).

Double-blind, randomized, multi-national, parallel-group study of eptifibatide vs. placebo (with provisional use of eptifibatide in the catheterization laboratory) used in combination with antithrombotic therapies.

Role: Investigator.

39. CRESCENDO. Sanofi-Aventis. Protocol No. EFC5826.

Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors.

Phase III.

Role: PI.

40. RE-LY. Boehringer Ingelheim. Protocol No. 1160.26. EudraCT No. 2005-003894-26.

Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation; prospective, multi-center, parallel-group, non-inferiority trial (RE-LY).

Phase III.

Role: Investigator.

41. CASSIOPEA. Sanofi-Aventis. Study No. EFC6034.

An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR-adjusted warfarin in the treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis.

Phase III.

Role: Investigator.

42. IMPROVE IT. Schering-Plough. Protocol No. P04103

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of vytorin (ezetimibe/simvastatin tablet) vs simvastatin monotherapy in high-risk subjects presenting with acute

coronary syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)

Phase IV

Role: Investigator.

43. PRINCIPLE TIMI 44. Eli Lilly. Prprotocol No. H7T-MC-TABL(a) [LY640315]. Prasugrel IN comparison to Clopidogrel for Inhibition of Platelet Activation and AggrEgation (PRINCIPLE)-TIMI44.

Phase II.

Role: Investigator.

44. SEPIA. Sanofi-Aventis. Protocol No. DR16624 [XRP0673A/2003]

A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in patients with non-ST elevation acute coronary syndrome and planned early invasive strategy.

Phase: IIb

Role: Investigator,

45. MK-0524. Merck & Co., Inc.. Study No. 69099.

Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK-0524 versus Niacin Extended-Release. Phase III.

Role: PI

46. FOURNIER Laboratories Ireland Ltd. Protocol No. CLF0242780-01 05 04

A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg pravastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease adequately controlled by 40 mg pravastatin alone.

Phase III.

Role: PI.

47. PROTECT-1. KW-39021IV. NovaCardia Inc. Protocol No. CKI-301. Phase III.

A multicenter, randomized, double-blind, placebo-contrlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy.

Role: PI

48. PROTECT-2. KW-39021IV. NovaCardia Inc. Protocol No. CKI-301. Phase III.

A multicenter, randomized, double-blind, placebo-contrlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy.

Role: PI

49. Rocket AF. Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation. Protocol No. 39039039AFL3001. BAY59-7939/11630. Johnson and Johnson Pharmaceutical Research & Development. Parexel.

Phase III.

Role: Co-PI

50. Lavi Cardiovascular. Lavi Cardiovascular, Inc. Evaluation of A New Non-Invasive Device for Detection of Endothelial Dysfunction.

Role: PI.

51. Aliskiren/SPP100A. A 36-week, multi-center, randomized, double-blind, placebo-controlled, parallel group to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post acute myocardial infarction patients, when added to optimized standard therapy. Novartis, Inc. Protocol No. CSPP100A2340.

Phase III.

Role: Investigator.

51. CardioFit™. CardioFit™ system safety and efficacy in treatment of patients diagnosed with NYHA class II-III heart failure. BioCointrol Medical (BCM), Ltd. Protocol No. CF-05-007.

Phase II.

Role: Investigator.

52. Optimize RV Study. Medtronic, Inc.

A multicenter, randomized, single-blinded trial to determine the long-term effect of RV (right ventricular) septal vs. RV apical pacing in subjects who require ventricular pacing due to AV conduction disturbance. The goal of RV septal pacing is to improve how the heart contracts when paced in the ventricle. RV apical pacing can lead to a non-physiologic contraction pattern, resulting in suboptimal hemodynamics and eventually heart failure. By pacing in the septum, it is possible to better emulate the hearts natural contraction pattern.

Phase III.

Role: Investigator.

53. Eisai E5555-G000-201. Eisai Company, Ltd. A randomized, double-blind, placebo-controlled study of the safety and tolerability of E5555, and its effects on markers of intravascular inflammation in subjects with coronary artery disease.

Phase: II.

Role: PI.

54. Eisai E5555-G000-202. Eisai Company, Ltd. A randomized, double-blind, placebo-controlled study of the safety and tolerability of E5555, and its effects on clinical events and biomarkers in patients with acute coronary syndrome.

Phase: II.

Role: Investigator,

55. TIMI 50. TIMI Group, Schering-Plough Research Institute.

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 in addition to standard care in subjects with a history of atherosclerotic disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P-TIMI 50).

Phase: III

Role: Investigator.

56. Roche ACS JTT. F. Hoffmann-La Roche Ltd. Protocol No. NC20971.
A phase III, double-blind, randomized, placebo controlled study, to evaluate the effects of RO4607381 on cardiovascular risk in stable CHD patients, with documented recent Acute Coronary Syndrome.
Phase: III
Role: PI
57. BLAST- Biorest Liposomal Alendronate with Stenting sTudy. BioRest Medinol Ltd. Study No. LA-II-01.
A Phase II dose-finding, randomized, multi-center, prospective, double-blind clinical study to assess the safety and efficacy of Liposomal Alendronate in treatment of de novo stenotic lesions in naïve coronary arteries in a population undergoing PCI with implantation of a bare metal stent (Presillio™ CoCr Coronary Stent).
Phase: II
Role: Investigator.
58. ASCEND-HF. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure. Scios, Inc. Protocol A 093; JNJ-27410084 (nesiritide).
A double-blind, placebo-controlled, multicenter acute study of clinical effectiveness of nesiritide in subjects with decompensated heart failure.
Phase III
Role: Investigator.
59. Efficacy HF. Efect of Ferric Carboxymaltose on exercise Capacity and Cardiac function in patients with iron deficiency and chronic Heart Failure. Vifor International Inc. FER-CARS-03.
To assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with FCM (ferric carboxymaltose) to the basic regimen of ambulatory patients with stable symptomatic chronic CHF and iron deficiency.
Phase: III
Role: Investigator.
60. PACE MI. PACEmaker and Beta-Blocker Therapy After Myocardial Infarction. National Heart, Lung, and Blood Institute (NHLBI).
To test whether beta-blocker therapy enabled by pacemaker implantation is superior to no beta-blocker therapy in patients following a myocardial infarction who have rhythm contraindications to beta-blockers or who have demonstrated intolerance to beta-blockers due to development of symptomatic bradycardia.
Phase: III
Role: Investigator.
61. Inhibition of δ -PROTEin kinase C for the reduction of infarct size in Acute Myocardial Infarction (PROTECTION AMI). KAI Pharmaceuticals, Inc. and BMS.
To evaluate the effect of KAI-9803 compared with placebo on infarct size following anterior STEMI as assessed by CK-MB AUC during the index hospitalization in subjects undergoing primary PCI.
Phase IIb
Role: Investigator.
62. Echocardiography guided Cardiac Resynchronization Therapy. Biotronik.

To evaluate the effects of CRT on mortality and morbidity of patients with heart failure due to left ventricular systolic dysfunction, already receiving current standard HF medication, with a narrow QRS width (<130 ms) and echocardiographic evidence of ventricular dyssynchrony.

Phase: II

Role: Investigator.

63. The bioavailability of oral magnesium citrate (Magnesium Diasporal) compared to magnesium oxide (Magnox 520) in healthy volunteers.

Phase IV study.

Role: PI.

64. The impact of Tredaptive™ (ER niacin/laropiprant) compared to placebo on brachial artery endothelial function in patients with stable coronary artery disease on statin therapy. Merck, Inc.

Phase III study.

Role: PI.

65. Stabilization of plaques using darapladip (SOLID)- TIMI 52. GlaxoSmithKline. A clinical outcomes study of darapladip versus placebo in subjects following acute coronary syndrome to compare the incidence of major adverse cardiovascular events (MACE). SB-480848.

Phase III study.

Role: Co-investigator.

66. A phase II randomized, open label clinical trial in high percutaneous coronary intervention (PCI) patients receiving standard antithrombotic treatment plus either ALX-0081 or PGIIb/IIIa inhibitor (ReoPro) over a period of 24 hours. Ablynx NV, Inc.

ALX-0081-2.1/09.

Phase II study.

Role: PI

67. Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 100 or 300 mg OD with amiodarone as calibrator for the prevention of ICD interventions or death (ALPHEE). Sanofi Aventis. Study DRI10936.

Phase III study.

Role: Co-investigator.

68. SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus). TIMI 53. AstraZeneca.

Phase IV study.

Role: PI

69. The Association of Satisfaction with Life Scale (SLS) and Brachial Artery Flow-Mediated Dilation.

An Investigator Initiated Study.

Role: PI

70. SOURCE (Edwards Sapien™ Aortic Bioprosthesis Multi-Region Outcome Registry XT).

Edwards.Lifesciences.

Phase IV Registry.

Role: Investigator.

71. IK-5001-Vernem-201. A Placebo Controlled, Multicenter, Randomized, Double Blind Trial to Evaluate the Safety and Effectiveness of IK-5001 for the Prevention of Remodelling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction Preservation I Trial. Ikaria Development Subsidiary One LLC. Protocol #IK-5001-Venrem-201.
Phase II.
Role: Investigator.
72. Study of the Wearable Defibrillator: In Heart Failure Patients (SWIFT) – Israel. Zoll Lifecor Corporation.
Role: Investigator.
73. A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedaron 400 mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors. Permanent Atrial fibrillation outcome study using Dronedaron on top of standard therapy (PALLAS). Sanofi Aventis. Study number: EFC 11405.
Phase: III.
Role: Investigator.
74. CoreValve Advance. A Multi-center, International Post Market Release Study. Medtronic Bakken Research Center B.V.
Registry.
Role: Investigator.
75. Protocol MK-0524A-133. A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia. Merck, Inc.
Phase III study.
Role: PI.
76. Protocol MK-0431. TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control. Merck, Inc.
Phase III study.
Role: PI.
77. Protocol NC25608 (DAL-OUTCOMES 2). A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular Events in Adult Patients with Stable Coronary Heart Disease (CHD), CHD Equivalents or at Elevated Risk for Cardiovascular Disease. Hoffmann-La Roch Ltd.
Phase IIIb study.
Role: PI.
78. Protocol 43,735. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention (PCI) with Incomplete Revascularization. Gilead Sciences, Inc.
Phase III study.

Role: PI.

79. The impact of short- and long-term endothelial function assessment by peripheral tonometry (PAT) on clinical outcome in subjects admitted to chest pain unit (CPU).

Phase IV study.

Role: PI

80. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (ODYSSEY). STUDY NUMBER: EFC11570. Sanofi Aventis.

Phase IIIb Study.

Role: PI.

81. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease. Amgen Protocol Number 20110118. FOURIER. Further Cardiovascular **Outcomes Research** with PCSK9 Inhibition in Subjects With **Elevated Risk**. Amgen, Inc.

Phase III Study.

Role: PI.

82. A phase 3B study to evaluate the potential of aleglitazor to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities. Protocol Number: BC28027. Aleglitazar (RO0728804)..F. Hoffmann-La Roche Ltd.

Phase IIIb Study.

Role: PI.

83. A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients with Hypercholesterolemia or Low HDL-C. Merck Sharp & Dohme Corp. **Product:** MK-0859.

Protocol/Amendment No.: 021-00.

Phase III Study.

Role: PI.

84. A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS – Cardiovascular Outcomes for People using Anticoagulation Strategies. Protocol: BAY 59-7939/15786. Bayer Co.

Phase III Study.

Role: Investigator.

85. A Qsymia™ Cardiovascular morbidity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease.

210-003946-34. Vivus, Inc.

Phase III Study.

Role: PI.

86. A randomized, open label, multi-center, active-controlled, parallel group study to determine the efficacy and safety of the REG1 anticoagulation system compared to bivalirudin in patients undergoing percutaneous coronary intervention.
REG1-CLIN310. GegadoBiosciences.
Phase III Study.
Role: Sub investigator.
87. Protocol MK-0431. TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control. Merck, Inc.
Phase III study.
Role: PI.
88. Protocol NC25608 (DAL-OUTCOMES 2). A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular Events in Adult Patients with Stable Coronary Heart Disease (CHD), CHD Equivalents or at Elevated Risk for Cardiovascular Disease. Hoffmann-La Roch Ltd.
Phase IIIb study.
Role: PI.
89. Protocol 43,735. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention (PCI) with Incomplete Revascularization. Gilead Sciences, Inc.
Phase III study.
Role: PI.
90. The impact of short- and long-term endothelial function assessment by peripheral tonometry (PAT) on clinical outcome in subjects admitted to chest pain unit (CPU). A collaboration with Mayo Clinic, USA.
Phase IV study.
Role: PI
91. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (ODYSSEY). STUDY NUMBER: EFC11570. Sanofi Aventis.
Phase IIIb Study.
Role: PI
92. Phase 3 multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of PF-04950615, in reducing the occurrence of major cardiovascular events in high risk subjects.
Pfizer. Protocol Number: B1481022.
Phase III study.
Role: PI

93. Phase 3 multi-center, double-blind, randomized, placebo-controlled, parallel group evaluation of the efficacy, safety, and tolerability of PF-04950615, in reducing the occurrence of major cardiovascular events in high risk subjects.

Pfizer. Protocol Number: B1481038.

Phase III study.

Role: PI.

94. A prospective, randomized, open-label, blinded endpoint evaluation (probe) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin following by warfarin alone in subjects undergoing planned electrical cardioversion of nonvalvular atrial fibrillation (ENSURE-AF).

Phase III study

Daiichi Sankyo LTD

Protocol Number DU176b-F-E308

Role: PI.

95. A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of GS-6615 on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy.

Gilead Sciences, Inc.

IND Number 114152

Role: Sub investigator.

96. A study to evaluate the DC Devices, Inc. IASD TM System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF Trial).

Phase II

DC Devices, Inc.

Protocol Number: 2013-01

Role: Sub investigator.

97. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction.

Novartis Clinical Trial Protocol CLCZ696D2301; EUDRACT # 2013-001747-31

Phase: III

Role: Sub investigator.

98. A Phase III multicenter, double-blind, randomized, parallel group, up to 104 weeks dosing, placebo-controlled trial in high-risk type 2 diabetes mellitus subjects with coronary artery disease to determine whether bromodomain extraterminal domain inhibition treatment with RVX000222 increases the time to major adverse cardiovascular events (MACE).

Resverlogix Corp.

Protocol Number: RVX222-CS-015

Phase III

Role: PI

99. A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalacetrapi on cardiovascular risk in a genetically defined population with a recent acute coronary syndrome: The dal-GenE trial.

DalCor Pharmaceuticals

Phase III

Role: PI

100. A randomized, double-blind, placebo controlled, parallel-group. Multicenter study to determine the effects of Sotagliflozin on Cardiovascular and Renal Events in patients with type 2 Diabetes, cardiovascular risk factors and moderately impaired renal functions. The SCORED Trial.

Sanofi

Study Number: EFC14875

Phase III

Role: PI

101. A randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of MEDI6012 in acute ST elevation myocardial infarction.

MedImmune, LLC, AstraZeneca.

Protocol Number: D5780C00007

Phase 2b

Role: PI

102. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effects of SOtagliflozin on clinical outcomes in hemodynamically STable patients with type 2 diabetes post worsening heart failure.

Sanofi

Study Number: EFC15156

Phase: III

Role: PI

103. A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects with acute coronary syndrome. AEGIS-II Trial.

CSL Behring, Inc.

Phase: III

Protocol Number: CSL112_3001

Role: PI

104. Pemafibrate to Reduce cardiovascular Outcomes by reducing triglycerides IN patiENts with diabeTes. The PROMINENT study.

Phase: III

Kowa Research Inc.

Protocol Number: K-877-302

105. The long-term impact of endothelial function assessment by peripheral tonometry (PAT) on clinical outcome in subjects admitted to chest pain unit (CPU). A collaboration with Mayo Clinic, USA.

Phase IV study.

Role: PI

C3. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS

- 1988 Xth Congress of the European Society of Cardiology, Vienna, Austria.
- 1989 1st International Symposium on Heart Failure, Jerusalem, Israel.
- 1989 11th Hohenheimer Magnesium Symposium, University of Hohenheim, Germany (Guest Lecturer).
- 1990 3rd European Congress on Magnesium, Geneva, Switzerland (Guest Lecturer).
- 1990 XIIth Congress of the European Society of Cardiology, Sweden.
- 1990 12th Hohenheimer Magnesium Symposium. University of Hohenheim, Germany (Guest Lecturer and Chairman of a session).
- 1990 Mgnesiocard Symposium, Frankfurt, Germany (Guest Lecturer).
- 1991 XIIIth Congress of the European Society of Cardiology, Holland.
- 1992 Magnesium Workshop in Cardiology, Cardiac Center of the University Hospital of Geneva, Switzerland (Invited Lecturer).
- 1992 Magnesium Workshop in Cardiology, Cardiac Center of the University Hospital of Bern, Switzerland (Invited Lecturer).
- 1992 IV European Congress on Magnesium, Gissen, Germany (Guest Lecturer and Chairman of the Cardiology Session).
- 1992 Medica - 24th International World Forum for Doctors' Surgeries and Hospitals, Dusseldorf, Germany (Guest Lecturer).
- 1993 Gordon Research Conferences, Los Angeles - Magnesium in Biochemical Processes (Invited Lecturer).
- 1993 Stanford University Medical Center - Magnesium in Cardiology (Invited Lecturer).
- 1993 XVth Congress of the European Society of Cardiology, Nice, France.
- 1993 The Surviving Myocardium Post Myocardial Infarction. Wurzburg, Germany.
- 1993 4th International Conference on Non-Invasive Cardiology. Limassol, Cyprus.
- 1993 66th Scientific Sessions of the American Heart Association. Atlanta, USA.
- 1994 Myocardial Reperfusion - Concepts and Controversies, Seventh Annual International Symposium. The Cleveland Clinic Foundation, Atlanta, USA.
- 1994 43rd Annual Scientific Session of the American College of Cardiology, Atlanta, USA.
- 1994 Clinical Symposium - Magnesium Therapy - State of the Art - Department of Cardiology and Internal Medicine, Vienna, University Clinics, AKH, Austria. (Invited Lecturer).
- 1994 XVIth Congress of the European Society of Cardiology, Berlin, Germany.
- 1994 8th Hamburg Nitroglycerin Symposium: Principles, Standard Uses and Options. Hamburg, Germany.
- 1994 The 10th International Workshop of the George Washington University Medical Center. Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Dallas, Texas, USA.
- 1994 67th Scientific Sessions of the American Heart Association, Dallas, Texas, USA.
- 1995 5th European Magnesium Congress, Vienna, Austria (Invited Lecturer).
- 1995 Munchener Medizinische Wochenschrift Editorial Forum, Munich, Germany (Invited Lecturer).
- 1995 Israel Society of Sports Medicine, Tel-Aviv, Israel (Invited Lecturer).
- 1995 68th Scientific Sessions of the American Heart Association, Anaheim, CA, USA.
- 1996 Gordon Research Conference on Magnesium in Biochemical Processes, Ventura, CA, USA (Invited Lecturer).
- 1996 45th Annual Scientific Session of the American College of Cardiology, Orlando

- Florida, USA.
- 1996 Expert Workshop - Magnesium and Arrhythmias. German Society of Cardiology and Electrophysiology, Germany (Invited Lecturer).
- 1996 69th Scientific Sessions of the American Heart Association, New Orleans, USA.
- 1997 46th Annual Scientific Session of the American College of Cardiology, Anaheim, California, USA.
- 1997 Laverna Titus Young Investigators Forum, American Heart Association Greater Los Angeles, UCLA, California, USA.
- 1997 7th International Symposium on Cardiovascular Pharmacotherapy, Jerusalem, Israel (Invited Lecturer).
- 1997 Summit on Cholesterol & Coronary Disease. 2nd National Conference on Lipids in the Elimination and Prevention of Coronary Artery Disease, Lake Buena Vista, Florida, USA.
- 1997 6th Annual Fall Symposium, American Heart Association, Greater Los Angeles, Los Angeles, CA, USA.
- 1997 70th Scientific Sessions of the American Heart Association, Orlando, USA
- 1998 47th Annual Scientific Session of the American College of Cardiology, Atlanta, Georgia, USA.
- 1998 6th European Magnesium Congress, Budapest, Hungary.
- 1998 Bristol-Myers Squibb Consultants Update Meeting, Beverly Hills, CA, USA (Invited Lecturer).
- 1998 21st Annual Snake River Medical Forum, Idaho, USA (Invited Lecturer).
- 1998 42nd Annual Postgraduate Symposium, San Diego Academy of Family Physicians, San Diego, CA, USA (Invited Lecturer).
- 1998 25th Anniversary of the American College for Advancement in Medicine, Phoenix, Arizona, USA (Invited Lecturer).
- 1999 Gordon Research Conference on Magnesium in Biochemical Processes, Ventura, CA, USA (Invited Lecturer).
- 1999 48th Annual Scientific Session of the American College of Cardiology, New Orleans, USA
- 1999 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 1999 1st International Congress on Heart Disease – New Trends in Research, Diagnosis and Treatment. Washington DC, USA (Invited Lecturer and Chairman of 2 sessions).
- 1999 XXIst Congress of the European Society of Cardiology, Barcelona, Spain.
- 1999 72nd Scientific Sessions of the American Heart Association, Atlanta, USA.
- 2000 49th annual Scientific Session of the American College of Cardiology, Anaheim, USA.
- 2000 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 2000 Magnesium in Biology and Medicine Workshop. Tel Aviv University, Israel.
- 2000 7th World Congress on Heart Failure - Mechanisms and Management, Vancouver, Canada. (Invited Lecturer and chairman of a session).
- 2000 9th International Magnesium Symposium. Vichy, France (Member, International Scientific Board).
- 2001 50th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, USA
- 2001 Israel Heart Society Annual Meeting, Jerusalem, Israel.
- 2001 XXIIIrd Congress of the European Society of Cardiology, Barcelona, Spain.
- 2001 7th European Magnesium Congress, Zaragoza, Spain.
- 2001 74th Scientific Sessions of the American Heart Association, California, USA.
- 2002 Gordon Research Conference on Magnesium in Biochemical Processes, Ventura, CA, USA (Invited Lecturer).

- 2002 6th International Dead Sea Symposium on Cardiac Arrhythmias and Device Therapy. Tel Aviv, Israel (Invited Speaker).
- 2002 Sackler Faculty of Medicine Research Day, Tel Aviv University, Israel (Invited Speaker).
- 2002 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 2002 3rd International Meeting on Intensive Cardiac Care, Tel Aviv, Israel.
- 2002 XXIV Congress of the European Society of Cardiology, Berlin, Germany.
- 2002 4th German-Austrian-Swiss Magnesium Symposion (25th Anniversary to the German Society of Magnesium Research), Fulda, Germany (Invited Lecturer).
- 2002 2nd Scientific meetings of the Israel Society of Magnesium in Biology and Medicine. Tel Aviv, Israel.
- 2003 3rd International Diovan Symposium, Seville, Spain.
- 2003 3rd International Summit on Atherosclerosis, Madrid, Spain.
- 2003 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 2003 Global Cardiovascular Speaker Program, Monte Carlo.
- 2003 XXV Congress of the European Society of Cardiology, Vienna, Austria.
- 2003 44th Annual Meetings of the American College of Nutrition, Nashville, USA (Invited Speaker).
- 2004 Ezetrol Scientific Symposium: Optimizing Lipid Management: Reducing Cardiovascular Risk. Madrid, Spain.
- 2004 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, USA
- 2004 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 2004 Indo-Israel Workshop on CAD: Gem-Heart Seminar, Jaipur, India (Invited Speaker).
- 2004 XXV Congress of the European Society of Cardiology, Munich, Germany (Inveted Chairman).
- 2005 Gordon Research Conference on Magnesium in Biochemical Processes, Ventura, CA, USA (Invited Lecturer).
- 2005 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 2005 XXVI Congress of the European Society of Cardiology, Stockholm, Sweden.
- 2005 3rd European Meeting on Vascular Biology and Medicine 2005, Hamburg, Germany (Invited Chairman).
- 2006 55th Annual Scientific Session of the American College of Cardiology, Atlanta, Georgia, USA
- 2006 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 2006 XXVII Congress of the European Society of Cardiology, Barcelona, Spain.
- 2007 56th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, USA
- 2007 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 2007 XXVIII Congress of the European Society of Cardiology, Vienna, Austria.
- 2007 The 3rd International Summit on Cardiometabolic Syndrome, Prague, Czech Republic.
- 2008 Gordon Research Conference on Magnesium in Biochemical Processes, Ventura, CA, USA (Invited Lecturer).
- 2008 57th Annual Scientific Session of the American College of Cardiology, Chicago, IL, USA.
- 2008 Israel Heart Society Annual Meeting, Tel Aviv, Israel.
- 2008 XXIX Congress of the European Society of Cardiology, Munich, Germany.
- 2008 The 13th Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis, Israel.

| <u>Date</u> | <u>Country</u> | <u>Meeting / Subject</u> | <u>Role</u> (Speaker, Member of Steering Committee, Active Participation etc.) |
|--------------------|-------------------------------|--|--|
| 2009 | Orlando, FL, USA. | 58 th Annual Scientific Session of the American College of Cardiology | Active Participation |
| 2009 | Tel Aviv, Israel. | Israel Heart Society Annual Meeting | Active Participation, abstract presenter |
| 2009 | Barcelona, Spain. | XXX Congress of the European Society of Cardiology | Active Participation |
| 2009 | Fulda, Germany | Magnesium Society Meetings | Invited Speaker |
| 2009 | Orlando, FL, USA. | 82 nd Scientific Sessions of the American Heart Association | Active Participation |
| 2010 | Atlanta, Georgia, USA. | 59 th Annual Scientific Session of the American College of Cardiology | Active Participation |
| 2010 | Tel Aviv, Israel. | Israel Heart Society Annual Meeting | Active Participation |
| 2010 | Los Angeles, CA, USA. | 16 th International Vascular Biology Meeting | Active Participation |
| 2010 | Stockholm, Sweden. | XXXI Congress of the European Society of Cardiology | Active Participation |
| 2011 | New Orleans, LA, USA. | 60 th Annual Scientific Session of the American College of Cardiology | Active Participation |
| 2011 | Paris, France | XXXII Congress of the European Society of Cardiology | Chairman of a lipoprotein session |
| 2012 | Tel Aviv, Israel. | Israel Heart Society Annual Meeting | Active Participation |
| 2012 | Los Angeles, California, USA. | 85 th Scientific Sessions of the American Heart Association | Active Participation |
| 2013 | Jerusalem, Israel. | Israel Heart Society Annual Meeting | Active Participation |
| 2013 | Amsterdam, Netherlands. | XXXV Congress of the European Society of Cardiology | Active Participation, abstract presenter |
| 2013 | Jerusalem, Israel. | 61 st International Congress of Aviation and Space Medicine | Active Participation |
| 2014 | Washington, DC, USA. | 63 rd Annual Scientific Session of the American College of Cardiology | Active Participation, abstract presenter |
| 2014 | Tel Aviv, Israel. | Israel Heart Society Annual Meeting | Active Participation, abstract presenter |
| 2014 | Amsterdam, The Netherlands. | 51 st ERA-EDTA Congress | Active Participation, Invited Speaker |
| 2014 | Barcelona, Spain | XXXVI Congress of the European Society of Cardiology | Chairman of a lipoprotein session |
| 2015 | Burlingame, CA, USA. | International Forum of Magnesium for Health Prevention | Active Participation, Invited Speaker |

| | | | |
|--------------|-----------------------------|---|---|
| 2015 | San Diego, CA, USA. | 64 th Annual Scientific Session of the American College of Cardiology | Active Participation, abstract presenter |
| 2015 | Tel Aviv, Israel. | Israel Heart Society Annual Meeting | |
| 2015 | London, United Kingdom. | XXXVII Congress of the European Society of Cardiology | Abstract presenter, ESC Fellow |
| 2015 | Shanghai, China. | 17 th Scientific Annual Congress of Cinese Society of Cardiology and the 9 th Oriental Congress of Cardiology OCC | Invited speaker |
| 2016 | Tel Aviv, Israel. | Israel Heart Society Annual Meeting | Presenter, Session Chirman |
| 2016 June | Tel Aviv, Israel | EuroCVP. European Cardiovascular Pharmacotherapy Annual Symposium. ESC | Invited Chairman, Invited Greetings on behalf of the Israel Heart Society WG Cardiovascular Pharmacotherapy |
| 2016 | Rome, Italy. | XXXVII Congress of the European Society of Cardiology | Abstract presenter, ESC fellow |
| 2016 | New Orleans, Lousiana, USA. | 89 th Scientific Sessions of the American Heart Association | Abstract presenter |
| 2016 Oct | Haifa, israel. | The 21 st Annual Meeting, Society for Research, Prevention & treatment of Atherosclerosis | Member, attendee Active Participation |
| 2017 | Washington DC, USA. | 66 th Annual Scientific Session of the American College of Cardiology | Abstract presenter |
| 2017 | Tel Aviv, Israel. | Israel Heart Society Annual Meeting | Faculty, Abatract presenter, Session Chirman |
| 2017 June | Geneve | ESC Nucleus WG Atherosclerosis and Vascular Biology Meeting | Invited speaker and Member |
| 2017 June | | Semi Annual Meeting of the Israel Society for Research, Prevention and Treatment of Atherosclerosis | Member, Attandee Active Participation |
| 2017 Nov | Israel | The 22 nd Annual Meeting of the Israel Society for Research, Prevention and Treatment of Atherosclerosis | Member, Attandee Active Participation |
| 2017 Nov | Kfar Bloom, Israel | The Winter Conference, Israel Endocrine Society | Invited Speaker Active Participation |
| 2018 | Orlando, Florida, USA. | 67 th Annual Scientific Session of the American College of Cardiology | Abstract presenter |
| 2018-Apr | Vienna, Austria | ESC Nucleus WG Atherosclerosis and Vascular Biology meeting | Invited speaker and Member |
| 2018 | Tel Aviv, Israel | Israel Heart Society Annual Meeting | Faculty, Abatract presenter |

C4. MEMBERSHIP IN PROFESSIONAL SOCIETIES

| <i>Year</i> | <i>Name of Organization</i> | <i>Country</i> | <i>Role</i> |
|---------------|---|----------------|---|
| 1979- to date | Israel Medical Association | Israel | Fellow |
| 1986- to date | Israel Society of Internal Medicine | Israel | Fellow |
| 1987- 1992 | Israel Heart Society | Israel | Associate |
| 1988- to date | New York Academy of Sciences | USA | Fellow |
| 1991- to date | European Society of Cardiology | Europe | Fellow |
| 1991- to date | American College of Angiology | USA | Fellow |
| 1992- to date | Israel Heart Society | Israel | Fellow |
| 1992- to date | Israel Society of Aerospace Medicine | Israel | Fellow |
| 1993- to date | Israel Association for Emergency Medicine | Israel | Fellow |
| 1995- to date | Clinical Cardiology, American Heart Association | USA | Fellow |
| 1995- 1997 | American College of Cardiology | USA | Associate Fellow |
| 1997- to date | American College of Cardiology | USA | Fellow |
| 1998- to date | European Society of Cardiology | Europe | Working Group on Cardiac Rehabilitation & Exercise Physiology |
| 1998- to date | Israel Heart Society | Israel | Working Group on Intensive Cardiac Care |
| 1998- to date | Israel Heart Society | Israel | Working Group on Cardiac Rehabilitation, Executive Board |
| 1999- to date | Society for Research, Prevention and Treatment of Atherosclerosis | Israel | Member |
| 2000- 2009 | Israel Society of Magnesium Research | Israel | General Secretary |
| 2000- to date | Israel Heart Society | Israel | Working Group on Congestive Heart Failure |
| 2001- 2016 | Save A Heart Foundation | Israel | Secretary Elect |
| 2002- to date | ESC - European Cardiologist | Europe | Fellow |
| 2002- to date | German Society of Magnesium | Germany | Honorary Member |
| 2003- to date | American College of Nutrition | USA | Fellow |
| 2005- to date | Association of Clinical Research Professionals | USA | Fellow |
| 2005- to date | Academy of Pharmaceutical Physician & Investigators | USA | Fellow |

| | | | |
|---------------|--|--------|--|
| 2006- to date | European Vascular Biology Organisation | Europe | Member |
| 2006- to date | Israel Society of Physiology & Pharmacology (ISPP) | Israel | Member |
| 2007- to date | European Society of Cardiology (WG27). | Europe | Working Group on Acute Cardiac Care |
| 2007- to date | European Society of Cardiology (WG23). | Europe | Working Group on Atherosclerosis and Vascular Biology |
| 2007- to date | European Society of Cardiology (WG03). | Europe | Working Group on Cardiovascular Pharmacology and Drug Therapy |
| 2007- to date | European Society of Cardiology (WG18). | Europe | Working Group on Thrombosis |
| 2010- to date | The Israeli Association for the Advancement of the Biomedical Research Community | Israel | Managing Committee |
| 2013- 2017 | Israel Heart Society | Israel | Chairman, Cardiovascular Pharmacology And Drug Therapy Working Group |
| 2014- to date | European Society of Cardiology | Europe | Working Group on Myocardial and Pericardial Diseases |
| 2015- 2017 | Israel Heart Society | Israel | Board Member |
| 2016- to date | ESC Working Group on Thrombosis and Vascular Biology. | Europe | Nucleus Member |
| 2017- to date | European Atherosclerosis Society (EAS) | Europe | Fellow |

D. DOCTORAL STUDENTS MENTORED BY CANDIDATE**Thesis****M.D. STUDENTS SUPERVISED BY CANDIDATE**

| <i>Years</i> | <i>Name of Student</i> | <i>Subject of Thesis</i> | <i>Academic Institution</i> | <i>In collaboration with</i> |
|--------------|------------------------|--|---|--|
| 2002-2003 | Roy Beigel | The efficacy & safety of the use of statins for primary prevention in air crew personnel in Israel | Sackler Faculty of Medicine, Tel Aviv University | |
| 2004-2005 | Asaf Ysaschar | Endothelial Function Assessment using a Non-Invasive Ultrasonographic Method of the Brachial Artery in Healthy Subjects and in Patients with Coronary Artery Disease – a Single Center Experience. | Sackler Faculty of Medicine, Tel Aviv University | |
| 2004-2005 | Langerman Isabel | The impact of heart failure day care clinic on patients with advanced Refractory chronic heart failure (Stage D) –the Sheba Medical Center 3-year experience. | Sackler Faculty of Medicine, Tel Aviv University | Dov Fereimark, MD, Heart Institute, Sheba Medical Center |
| 2004-2008 | Gershovitz Liron | The additive value of statins to β -blockers on recurrent cardiovascular events in Severe chronic heart failure patients | Sackler Faculty of Medicine, Tel Aviv University | |
| 2005-2006 | Guy Ron | The Impact of Adiponectin on Endothelial Function Assesed by a Non-Invasive Ultrasonographic Method of the Brachial Artery in Healthy Subjects-a Single Center Experience | Medical School,The Hebrew University Hadassah Jerusalem | |
| 2006-2007 | Alon Shechter | The Association Between Platelet Function and Endothelial Function of the Brachial Artery in Healthy Subjects and Patients with Coronary Artery Disease (Cum Laude). | Sackler Faculty of Medicine, Tel Aviv University | |

| | | | | |
|-----------|----------------|---|---|--|
| 2007-2008 | Yael Shachar | The long-term association of endothelial function assessment in the brachial artery and cardiovascular events in healthy subjects without evidence of heart disease. | Sackler Faculty of Medicine, Tel Aviv University | |
| 2007-2009 | Liran Hirsh | The association of early morning hours and endothelial function assessment in the brachial artery in healthy subjects without heart disease and long term follow-up for cardiovascular events | Sackler Faculty of Medicine, Tel Aviv University | |
| 2009-2012 | Tomer Saed | The absorption of magnesium oxide compared to citrate in healthy subjects | Sackler Faculty of Medicine, Tel Aviv University | |
| 2015-2017 | Ameer Barbara | Retrospective cohort study: A long-term association between brachial artery endothelial function and platelet function in healthy subjects without heart disease. | Sackler Faculty of Medicine, Tel Aviv University | |
| 2015-2017 | Roy Rubinstein | Trends in mortality rates from acute coronary syndrome octogenarian patients in Israel during the period. 2000-2013 (Cum Laude). | Sackler Faculty of Medicine, Tel Aviv University | |
| 2016-2018 | Cohn Herold | Long-term association between endothelial function assessed by peripheral arterial tonometry and clinical outcomes in patients presenting to the emergency department chest pain unit | Sackler Faculty of Medicine, Tel Aviv University. | |

Ph.D. STUDENTS SUPERVISED BY CANDIDATE

| <i>Years</i> | <i>Name of Student</i> | <i>Subject of Thesis</i> | <i>Academic Institution</i> | <i>In collaboration with</i> |
|--------------|------------------------|---|--|---|
| 2003-2008 | Talya Lavi | The impact of food supplements on endothelial function. | Sackler Faculty of Medicine, Tel Aviv University | Avi Karasik, MD, Endocrinology Dep., Sheba Medical Center |

| | | | | |
|-----------|-------------------|---|---|--------------------------------------|
| 2005-2016 | Nir Shlomo | The impact of air pollution, inflammatory markers and endothelial Function in healthy subjects. | School of Medicine, Beer Sheva University | |
| 2014-2016 | Meital Shlezinger | The effect of drinking water derived from desalinated seawater on serum magnesium level and health. | Dep. of Management, Bar Ilan University | Yona Amitai, MD, Bar Ilan University |

RESIDENTS' BASIC SCIENCE SUPERVISED BY CANDIDATE

| <i>Years</i> | <i>Name of Student</i> | <i>Subject of Thesis</i> | <i>Academic Institution</i> | <i>In collaboration with</i> |
|--------------|------------------------|--|---|--|
| 2002-2003 | Eran Peleg | A non-invasive technique for the assessment of endothelial dependent vasoreactivity | Master of Science in Biomedical Engineering Tel Aviv University | |
| 2003-2005 | Mari Ibrahim | The impact of thrombogenic/immunogenic factors and coronary heart disease risk factors on endothelial function in normal volunteers and patients with coronary heart disease | Sackler Faculty of Medicine, Tel Aviv University | |
| 2004-2005 | Silbina Matzkin Levi | Correlation between arterial Elasticity and Endothelial Dysfunction | Sackler Faculty of Medicine, Tel Aviv University | Reuven Zimlichman, Hypertension Unit, Wolfson Medical Center |
| 2007-2010 | Guy Shalmon | The impact of caffeine on myocardial perfusion and brachial artery endothelial function in patients with ischemic heart disease. | Sackler Faculty of Medicine, Tel Aviv University | |

E. M.A./M.Sc. STUDENTS

| Years (period) | Name of Student | Subject | Academic Institute | In collaboration with |
|----------------|-----------------|---------|--------------------|-----------------------|
| | | | | |

F. GRANTS

| <i>Years</i> | <i>Investigator (Principal/ other)</i> | <i>Subject</i> | <i>Granted by Institute/Company</i> | <i>Total Amount</i> |
|--------------|--|--|--|---------------------|
| 2010 | PI | The impact of Tredaptive™ (ER niacin/laropiprant) compared to placebo on brachial artery endothelial function in patients with stable coronary artery disease on statin therapy. | MSD | \$121,000 |
| 2010 | PI | The bioavailability of oral magnesium citrate (Magnesium Diasporal) compared to magnesium oxide (Magnox 520) in healthy volunteers. | Naveh Pharma, Ltd. | \$120,000 |
| 2012 | PI | The impact of short- and long term endothelial function assessment by peripheral tonometry (PAT) on clinical outcome in subjects admitted to chest pain unit (CPU). | Mayo Clinic-Sheba Medical Center (Khan Foundation) | \$50,000 |
| 2013 | PI | Endothelial Function in Hypertrophic Cardiomyopathy Research | Friends of Sheba, Los Angeles, CA, USA | \$50,000 |
| 2014 | Co-PI | Evaluation of adverse health effects in the Israeli population from lack of magnesium and iodide in drinking water from desalinated sea water (PGA 1403) | Environment and Health Fund, Israel | \$30,000 |

G. AWARDS**ACADEMIC AND PROFESSIONAL AWARDS**

| <u>Year</u> | <u>Name of institution (city, country)</u> | <u>Award</u> |
|--------------------|--|----------------------------------|
| 1992 | School of Continuing Medical Education Sackler School of Medicine, Tel Aviv University | Master in Cardiology (Cum Laude) |

| | | |
|------|--|--|
| 1994 | Heart Institute, Sheba Medical Center And Sackler Faculty of Medicine, Tel Aviv University | Jacob Klapholz Prize for Cardiovascular Research |
| 1995 | Israel Medical Association World Fellowship | Dr. Silberberg Prize for Cardiology Research (Cum Laude) |
| 1996 | Bristol-Myers-Squibb Cardiology Fellow Program, American College of Cardiology, Anaheim, CA, USA | Cardiology Fellow Program |
| 2000 | Sheba Medical Center, Tel Hashomer | Best Abstract Award, 2000 Research Day |
| 2002 | The German Magnesium Society, Stuttgart, Germany | Life Honoree for Magnesium Research |
| 2003 | The American College of Nutrition Award, Nashville Tennessee, USA. “In recognition of his excellence in magnesium research and his contribution to understanding the role of magnesium in human physiology”. | The Seelig Magnesium 44 th Annual Award Recipient |
| 2010 | Israel Heart Society and Friends of the Israel Heart Society | Meltzer Prize for Contribution in Research of Endothelial Function. |
| 2011 | The highest ranking best abstract submitted from Israel and accepted for presentation at the ACC’s Annual Scientific Sessions in New Orleans April 4, 2011 | ACC 2011 and i2 Summit |

LIST OF SCIENTIFIC PUBLICATIONS

A. BOOKS AND MONOGRAPHS

- - - NONE - - -

B.1. ORIGINAL ARTICLES

B.1. Original Articles:

1. Published

1. Farfel Z, **Shechter M**, Vered Z, Rath S, Goor D, Gafni J.
Review of echocardiographically diagnosed right heart entrapment of pulmonary emboli-in-transit with emphasis on management.
Am Heart J 1987;113:171-178

- (CARDIAC & CARDIOVASCULAR SYSTEMS-13/75; IF: 3.649).
2. **Shechter M**, Hod H, Marks N, Behar S, Kaplinsky E, Rabinowitz B.
Beneficial effect of magnesium sulfate in acute myocardial infarction.
Am J Cardiol 1990;66:271-274
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603).
 3. **Shechter M**, Hod H.
Magnesium therapy in aged patients with acute myocardial infarction.
Magnesium Bull 1991;13:7-9. **This Journal was discontinued in 2000.**
 4. **Shechter M**, Hod H, Rath S, Rabinowitz B, Kaplinsky E, Agranat O.
Acute myocardial infarction associated with a myocardial bridge.
Coronary Artery Disease 1991;2:511-516
(PERIPHERAL VASCULAR DISEASE- 33/54; IF: 1.556).
 5. **Shechter M**, Rabinowitz B, Kaplinsky E, Hod H.
Additional ST-segment elevation during the first hour of thrombolysis: An electrocardiographic sign predicting a favorable clinical outcome.
J Am Coll Cardiol 1992;20:1460-1464
(CARDIAC & CARDIOVASCULAR SYSTEMS-2/75; IF:11.054).
 6. **Shechter M**, Kaplinsky E, Rabinowitz B.
The rationale of magnesium supplementation in acute myocardial infarction. A review of the literature.
Arch Intern Med 1992;152:2189-2196
(MEDICINE, GENERAL & INTERNAL-8/100; IF: 8.391).
 7. Behar S, Reicher-Reiss H, **Shechter M**, Rabinowitz B, Kaplinsky E, Abinder E.
Secondary ventricular fibrillation complicating acute myocardial infarction: Incidence and prognostic significance.
Am J Cardiol 1993;71:152-156
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603).
 8. **Shechter M**.
Magnesium for acute myocardial infarction.
Emergency Med J 1993;25:135-139
(EMERGENCY MEDICINE-7/12; IF: 0.929).
 9. **Shechter M**, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B.
Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy.
Am J Cardiol 1995;75:321-323
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603).
 10. **Shechter M**, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B.

Magnesium as alternative therapy in patients with acute myocardial infarction who are not candidates for thrombolytic therapy.

Magnesium Bull 1995;17:1-4. **This Journal was discontinued in 2000.**

11. **Shechter M**, Hod H, Kaplinsky E, Rabinowitz B.
The rationale of magnesium as alternative therapy in patients with acute myocardial infarction without thrombolytic therapy.
Am Heart J 1996;132:483-486
(CARDIAC & CARDIOVASCULAR SYSTEMS-13/75; IF: 3.649).
12. **Shechter M**, Kaplinsky E, Rabinowitz B.
Review of clinical evidence - is there a role for supplemental magnesium in acute myocardial infarction in high risk population (patients ineligible for thrombolysis and the elderly)?
Coronary Artery Disease 1996;7:352-358
(PERIPHERAL VASCULAR DISEASE- 33/54; IF: 1.556).
13. **Shechter M**, Agranat O, Har-Zahav Y, Rath S, Kaplinsky E, Rabinowitz B.
Prostaglandin E1 during angioplasty (PTCA) as preventive therapy of coronary restenosis.
Am J Therap 1997;4:395-400. **(In reply to an e-mail sent to the American Journal of Therapy, I was informed that the AJT was accepted for indexing by ISI Thomson in 2008 and therefore no Impact Factor will appear until 2011).**

14. **Shechter M**, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B.
Acute myocardial infarction without thrombolytic therapy: Beneficial effects of magnesium sulfate.
Herz 1997;22:73-76
(CARDIAC & CARDIOVASCULAR SYSTEMS-74/75; IF: 0.405).
15. Meisel RM, Pauzner H, **Shechter M**, Zeidan Z, David D.
Peripheral monocytosis following acute myocardial infarction: Incidence and its possible role as a bedside marker of the extent of cardiac injury.
Cardiology 1998;90:52-57
(CARDIAC & CARDIOVASCULAR SYSTEMS-42/75; IF: 1.701).
16. **Shechter M**, Paul-Labrador M, Rude RK, Bairey Merz CN.
Intracellular magnesium predicts functional capacity in patients with coronary artery disease.
Cardiology 1998;90:168-172
(CARDIAC & CARDIOVASCULAR SYSTEMS-42/75; IF: 1.701).
17. **Shechter M**, Bairey Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S.
Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease.
Am J Cardiol 1999;84:152-156
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603)..
18. **Shechter M**, Bairey Merz CN, Paul-Labrador M, Shah PK, Kaul S.
Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease
Cardiology 1999;92:151-155
(CARDIAC & CARDIOVASCULAR SYSTEMS-42/75; IF: 1.701).
19. **Shechter M**, Merz Bairey CN, Paul-Labrador M, Kaul S.
Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease.
J Am Coll Cardiol 2000;35:300-307
(CARDIAC & CARDIOVASCULAR SYSTEMS-2/75; IF:11.054).
20. **Shechter M**, Bairey Merz CN, Rude RK, Paul-Labrador M, Meisel SR, Molloy MD, Cercek B, Shah PK, Kaul S.
Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients.
Magnesium Res 2000;13:275-284
(BIOCHEMISTRY & MOLECULAR BIOLOGY-224/263; IF: 1.208).
21. **Shechter M**, Bairey Merz CN, Rude RK, Paul-Labrador M, Meisel SR, Molloy MD, Cercek B, Shah PK, Kaul S.
Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease.
Am Heart J 2000;140:212-218
(CARDIAC & CARDIOVASCULAR SYSTEMS-13/75; IF: 3.649).

22. **Shechter M**, Sharir M, Paul Labrador M, Forrester J, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease.
Circulation 2000;102:2353-2358
(CARDIAC & CARDIOVASCULAR SYSTEMS-1/75; IF: 12.755).
23. **Shechter M**, Sharir M, Paul Labrador M, Forrester J, Silver B, Bairey Merz CN. Improvement in endothelium-dependent brachial artery flow-mediated vasodilation with low-density lipoprotein cholesterol levels below 100 mg/dl.
Am J Cardiol 2000;86:1256-1259
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603).
24. Rukshin V, Azarbal B, Shah PK, Tsang VT, **Shechter M**, Cercek B, Kaul S. Intravenous magnesium in experimental stent thrombosis in swine.
Arterioscler Thromb Vasc Biol 2001;21:1544-1549
(PERIPHERAL VASCULAR DISEASE 3/54; IF: 7.221).
25. **Shechter M**, Bairey Merz CN, Stuehlinger H-G, Slany J, Pachinger O, Rabinowitz B. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease.
Am J Cardiol 2003;91:517-521
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603) .
26. Meisel SR, **Shechter M**, Xu XP, Edgington TS, Cercek B, Shah PK. Platelet-induced expression of tissue factor procoagulant activity in freshly isolated human mononuclear cells.
Clin Lab Haematol 2003;25:321-325
(HEMATOLOGY- 56/63; IF: 1.107).
27. **Shechter M**, Hod H, Rabinowitz B, Boyko V, Chouraqui P. Long-term outcome of intravenous magnesium therapy on thrombolysis-ineligible patients with acute myocardial infarction.
Cardiology 2003;99:205-210
(CARDIAC & CARDIOVASCULAR SYSTEMS-42/75; IF: 1.701).
28. **Shechter M**, Matetzky S, Feinberg MS, Chouraqui P, Rotstein Z, Hod H. External counterpulsation (ECP) therapy improves endothelial function in patients with refractory angina pectoris.
J Am Coll Cardiol. 2003;42:2090-2095
(CARDIAC & CARDIOVASCULAR SYSTEMS-2/75; IF:11.054).
29. Chouraqui P, Assman A, Stenberg M, Baron J, Guetta V, Livschitz S, Di Segni E, **Shechter M**. Noninvasive detection of collateral flow to the infarct-related coronary artery in patients after myocardial infarction by Thallium-201 tomographic imaging.
J Nucl Cardiol 2003;10:669-675
(CARDIAC & CARDIOVASCULAR SYSTEMS-26/75; IF:2.359).

30. Goldenberg I, **Shechter M**, Matetzky M, Jonas M, Adam M, Pres H, Elian D, Agranat O, Har-Zahav Y, Di Segni E, Rath S, Guetta V.
Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
Eur Heart J 2004;25:212-218
(CARDIAC & CARDIOVASCULAR SYSTEMS-4/75; IF:7.924).
31. Chouraqui P, Livschitz S, Moalem I, Baron J, **Shechter M**.
The assessment of infarct size in post myocardial infarction patients undergoing Thallium-201 tomographic imaging using attenuation correction.
Clin Nucl Med 2004;29:352-357
(RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-15/87; IF:3.321).
32. Matetzky S, Shenkman B, Guetta V, **Shechter M**, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H.
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Circulation 2004; 109:3171-3175
(CARDIAC & CARDIOVASCULAR SYSTEMS-1/75; IF: 12.755).
33. Freimark D, Feinberg M, Matetzky S, **Shechter M**.
The impact of intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure.
Am Heart J 2004;148:878-882
(CARDIAC & CARDIOVASCULAR SYSTEMS-13/75; IF: 3.649).
34. Beigel R, Barenboim E, Azaria Sofer B, Matetzky S, Beigel Y, Goldstein L, **Shechter M**.
Statin efficacy and safety for lipid modification in apparently healthy male military air crew.
Aviat Space Environ Med 2005;76(9):857-860
(PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH- 83/100; IF:0.832).
35. Carasso S, Sandach A, Kuperstein R, Schwammenthal E, Glikson M, Luria D, Guetta V, **Shechter M**, Eldar M, Feinberg MS.
Atrial fibrillation in dobutamine stress echocardiography.
Int J Cardiol 2006;111:53-58
(CARDIAC & CARDIOVASCULAR SYSTEMS- 22/75; IF:2.878).
36. Tenenbaum A, Freimark D, Ahron E, Schwammenthal E, Fisman EZ, **Shechter M**, Tanne D, Kachlon D, Motro M, Adler Y.
Long-Term Versus Intermediate-Term Supervised Exercise Training in Advanced Heart Failure: Effects on Exercise Tolerance and Mortality.
Int J Cardiol 2006;113:364-370
(CARDIAC & CARDIOVASCULAR SYSTEMS- 16/124; IF:5.509).

37. **Shechter M**, Beigel R, Freimark D, Matezky S, Feinberg MS.
Short-Term Sibutramine Therapy is Associated with Weight Loss and Improved Endothelial Function in Obese Patients with Coronary Artery Disease.
Am J Cardiol 2006;97:1650-1653
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603).
38. Pokan R, Hofmann P, von Duvillard SP, Smekal G, Wonisch M, Lettner K, Schmid P, **Shechter M**, Silver B, Bachl N.
Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients.
Br J Sports Med 2006;40:773-778
(SPORT SCIENCES- 7/72; IF: 2.463).
39. Arbel Y, Dvir.D, Feinberg MS, Beigel R, **Shechter M**.
The association between right coronary artery morphology and vascular endothelial function.
Int J Cardiol 2007;115:19-23
(CARDIAC & CARDIOVASCULAR SYSTEMS- 22/75; IF:2.878).
40. **Shechter M**, Ginzberg S, Scheinowitz M, Feinberg MS, Laron Z..
Obese Adults with Primary Growth Hormone Resistance (Laron Syndrome) have Normal Endothelial Function.
Growth Horm IGF Res 2007;17:165-170.
(CELL BIOLOGY- 116/156; IF: 1.831).
41. Freimark D, **Shechter M**, Schwamenthal E, Tanna D, Elmaleh E, Motro M, Adler Y.
Improved exercise tolerance and cardiac function in severe chronic heart failure patients undergoing a supervised exercise program.
Int J Cardiol 2007;116:309-14
(CARDIAC & CARDIOVASCULAR SYSTEMS- 22/75; IF:2.878).
42. **Shechter M**, Marai I, Mrai S, Sherer Y, Ben Ami S, Feinberg MS, Shoenfeld Y.
The association of endothelial dysfunction and cardiovascular events in healthy subjects and patients with cardiovascular disease.
Isr Med Assoc J 2007;9:271-276
(MEDICINE, GENERAL & INTERNAL- 75/100; IF:0.577).
43. Guetta V, Mosseri M, **Shechter M**, Matetzky S, Assali A, Almagor Y, Gruber L, Benderly M, Lotan C, Kornowski R, for the Up Flow MI Study Investigators.
Safety and efficacy of the FilterWire EZ® in acute ST-segment elevation myocardial infarction.
Am J Cardiol 2007;99:911-915.
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603).
44. Arad M, Adler Y, Arad M, Koren-Morag N, Natanzon S, Sela BA, Ben Dov I, **Shechter M**, Schwammenthal E, Freimark D.
Exercise training in advanced heart failure patients: Discordance between improved exercise tolerance and unchanged NT-oroBNP levels.
Int J Cardiol 2008 May 7;126(1):114-119.
(CARDIAC & CARDIOVASCULAR SYSTEMS- 16/124; IF:5.509).

45. Barsheshet A, Hod H, **Shechter M**, Shrabani-Yosef O, Rosenthal E, Barbash IM, Matetzky S, Tal R, Bentancur AG, Sela BA, Nagler A, Leor J.
The effects of external counter pulsation therapy on circulating endothelial progenitor cells in patients with angina pectoris.
Cardiology 2007;110:160-166
(CARDIAC & CARDIOVASCULAR SYSTEMS-42/75; IF: 1.701).
46. Beinart R, Matetzky S, **Shechter M**, Fefer P, Rozen E, Beinart T, Asman A, Chouraqui P.
Stress-induced ST-segment elevation in patients without prior Q-wave myocardial infarction.
J Electrocardiol 2008;41:312-317.
(CARDIAC & CARDIOVASCULAR SYSTEMS-56/75; IF: 1.069).
47. Marai I, **Shechter M**, Langevitz P, Gilburd B, Rubenstein A, Matssura E, Sherer Y, Shoenfeld Y.
Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease.
Am J Cardiol 2008;101:1094-1097
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603).
48. Fefer P, Hod H, Ilany J, **Shechter M**, Segev A, Novikov I, Guetta V, Matetsky S. Comparison of myocardial reperfusion in patients with fasting blood glucose ≤ 100 , 101 to 125, and >125 mg/dl and ST-elevation myocardial infarction with percutaneous coronary intervention.
Am J Cardiol 2008;102(11):1457-1462
(CARDIAC & CARDIOVASCULAR SYSTEMS-14/75; IF: 3.603).
49. **Shechter M**, Issachar A, Marai I, Koren Morag N, Freimark D, Shahar Y, Shechter A, Feinberg MS.
Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease.
Int J Cardiol 2009;134:52-58.
(CARDIAC & CARDIOVASCULAR SYSTEMS- 16/124; IF:5.509).
50. **Shechter M**, Arad M, Matetzky S, Feinberg MS, Freimark D.
Vascular endothelial function predicts mortality risk in patients with advanced ischemic chronic heart failure.
Eur J Heart Fail 2009;11:588-593.
(Cardiac & Cardiovascular Systems 21/75, IF 2.986).
51. Talia L, Karasik A, Feinberg MS, **Shechter M**.
The acute effect of various glycemic index dietary carbohydrates on endothelial function in nondiabetic overweight and obese subjects.
J Am Coll Cardiol 2009;53:2283-2287.
(CARDIAC & CARDIOVASCULAR SYSTEMS-2/75; IF:11.054).
52. Freimark D, Arad M, DeNeen I, Matetzky S, Gershovitz L, Koren Morag N, Hochberg N, Makmal Y, **Shechter M**.
An Advanced Heart Failure Day Care Service: A Five-Year Single Center Experience.
Isr Med Assoc J 2009;11:78-84.
(MEDICINE, GENERAL & INTERNAL- 75/100; IF:0.577).

Since last promotion

- B1-53. Beinart R, Abu Sham'a R, Segev A, Hod H, Guetta V, **Shechter M**, Boyko V, Behar Shlomo, Matetzky S.
The incidence and clinical predictors of early stent thrombosis in patients with acute coronary syndrome.
Am Heart J 2010;159:118-224.
(CARDIAC & CARDIOVASCULAR SYSTEMS-34/126; IF4.436, Q2)
Times Cited: 14 (from Web of Science Core Collection)
- B1-54. Beigel R, Dvir D, Arbel Y, Shechter A, Feinberg MS, **Shechter M**.
Pulse pressure is a predictor of vascular endothelial function in healthy volunteers with no apparent heart disease.
Vasc Med 2010;15:299-305.
(PERIPHERAL VASCULAR DISEASE 45/63, IF 1.866, Q3).
Times Cited: 12 (from Web of Science Core Collection)
- B1-55. Hirsch L, Feinberg MS, Koren-Morag N, **Shechter M**.
The impact of early compared to late morning hours on brachial endothelial function and long-term cardiovascular events in healthy subjects with no apparent coronary heart disease.
Intern J Cardiol 2011;151:342-347.
(CARDIAC & CARDIOVASCULAR SYSTEMS 16/126; IF6.189, Q1).
Times Cited: 10 (from Web of Science Core Collection)
- B1-56. Matetzky S, Fefer P, Shenkman B, **Shechter M**, Novikov I, Savion N, Varon D, Hod H.
Statins have an early antiplatelet effect in patients with acute myocardial infarction.
Platelets 2011;22(2):103-110.
(Hematology 39/70, IF 2.465, Q3)
Times Cited: 17 (from Web of Science Core Collection)
- B1-57. **Shechter M**, Shalmon G; Scheinowitz M, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Sharabi Y, Chouraqui P.
Impact of acute caffeine ingestion on endothelial function in subjects with and without coronary artery disease.
Am J Cardiol 2011;107:1255-1261.
(CARDIAC & CARDIOVASCULAR SYSTEMS 47/126, IF 3.398, Q2).
Times Cited: 35 (from Web of Science Core Collection)
- B1-58. **Shechter M**, Shechter A, Hod H, Fefer P, Shenkman B, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Varon D, Savion N, Matetzky S.
endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction.
Platelets 2012;23:202-10.
(Hematology 39/70, IF 2.465, Q3)
Times Cited: 4 (from Web of Science Core Collection)

- B1-59. **Shechter M**, Saad T, Shechter A, Koren-Morag N, Silver BB, Matetzky S.
Comparison of magnesium status using X-ray dispersion analysis following magnesium oxide and magnesium citrate treatment of healthy subjects.
Magnes Res 2012;25:28-39.
(BIOCHEMISTRY & MOLECULAR BIOLOGY 254/290, IF 1.156, Q4).
Times Cited: 9 (from Web of Science Core Collection)
- B1-60. Buber J, Goldenberg I, Moss A, McNitt S, Eldar M, Barsheshet A, **Shechter M**.
Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy).
J Am Coll Cardiol 2012;60(8):749-55.
(CARDIAC & CARDIOVASCULAR SYSTEMS 2/126, IF 19.896, Q1).
Times Cited: 17 (from Web of Science Core Collection)
- B1-61. Fefer P, Beigel R, Varon D, Shenkman B, **Shechter M**, Savion N, Hod H, Matetzky S.
Bimodal response to aspirin loading in acute ST-elevation myocardial infarction.
Platelets 2013;24(6):435-40.
(Hematology 39/70, IF 2.465, Q3)
Times Cited: 0 (from Web of Science Core Collection)
- B1-62. **Shechter M**, Shechter A, Koren-Morag N, Feinberg MS, Hirsch L.
Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease..
Am J Cardiol 2014;113:162-7.
(CARDIAC & CARDIOVASCULAR SYSTEMS 47/126, IF 3.398, Q2).
Times Cited: 48 (from Web of Science Core Collection)
- B1-63. Asher E, Fefer P, **Shechter M**, Beigel R, Varon D, Savion N, Shenckman B, Hod H, Matetzky S.
Increased mean platelet volume is associated with non-responsiveness to clopidogrel.
Throm Haemos 2014;112 (1): 137-141
(Hematology 11/70, IF 5.627, Q1).
Times Cited: 19 (from Web of Science Core Collection)
- B1-64. Fefer P, Beigel R, Rosenberg N, **Shechter M**, Gannot S, Varon D, Savion N, Hod H, Matetzky S.
Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice.
Platelets 2014 26(2): 127-131
(Hematology 39/70, IF 2.465, Q3)
Times Cited: 1 (from Web of Science Core Collection)

- B1-65. Weisz G, Génereux P, Iñiguez A, Zurakowski A, **Shechter M**, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW; RIVER-PCI investigators.
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet 2016;387:136-145.
(MEDICINE, GENERAL & INTERNAL 2/155, IF 47.831, Q1)
Times Cited: 36 (from Web of Science Core Collection)
- B1-66. Shlezinger M, Amitai Y, Goldenberg I, **Shechter M**.
Desalinated seawater supply and all-cause mortality in hospitalized acute myocardial infarction patients from the Acute Coronary Syndrome Israeli Survey 2002-2013.
Int J Cardiol 2016;220:544-550.
(CARDIAC & CARDIOVASCULAR SYSTEMS 16/126, IF 6.189, Q1)
Times Cited: 9 (from Web of Science Core Collection)
- B1-67. Koifman E, Beigel R, Herscovici R, Fefer P, Rozenberg N, Sabbag A, Biton Y, Segev A, **Shechter M**, Asher E, Matetzky S.
Immediate response to prasugrel loading in patients with ST-elevation myocardial infarction: Predictors and outcome.
Thromb Res 2016;144:176-181.
doi: 10.1016/j.thromres.2016.05.005.
(Hematology 34/70, IF 2.65, Q2)
Times Cited: 0 (from Web of Science Core Collection)
- B1-68. Chernomordik F, Freimark D, Arad M, **Shechter M**, Matetzky S, Savir Y, Shlomo N, Peled A, Goldenberg I, Peled Y.
Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting.
ESC Heart Failure 2017;4:122-129.
(CARDIAC & CARDIOVASCULAR SYSTEMS 12/126, IF 6.968, Q1)
Times Cited: 0 (from Web of Science Core Collection)
- B1-69. **Shechter M**, Matetzky S, Prasad M, Koren-Morag N, Lerman A.
Endothelial function predicts 1-year clinical outcome in patients hospitalized in chest pain unit.
Int J Cardiol 2017. 2017 Aug 1;240:14-19.
doi: 10.1016/j.ijcard.2017.04.101. [Epub ahead of print]
(CARDIAC & CARDIOVASCULAR SYSTEMS 16/126, IF 6.189, Q1)
Times Cited: 1 (from Web of Science Core Collection)
- B1-70. **Shechter M**, Rubinstein R, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Comparison of outcomes of acute coronary syndrome in patients > 80 years versus those ≤ 80 years in Israel from 2000-2013.
Am J Cardiol 2017 Oct 15;120(8):1230-1237.
doi: 10.1016/j.amjcard.2017.07.003. Epub 2017 Jul 24
(CARDIAC & CARDIOVASCULAR SYSTEMS 47/126, IF 3.398, Q2).
Times Cited: 0 (from Web of Science Core Collection)

- B1-71. Dibaba DT, Xun P, Song Y, Rosanoff A, **Shechter M**, H e K.
The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic disease: a meta-analysis of randomized controlled trials.
Am J Clin Nutr 2017;106:921-929.
doi: 10.3945/ajcn.117.155291. Epub 2017 Jul 19
(**NUTRITION & DIETETICS 3/81, IF 6.926, Q1**).
Times Cited: 6 (from Web of Science Core Collection)
- B1-72 Beigel R, Mazin I, Koifman E, **Shechter M**, Pres H, Shlomo N, Rosenberg N, Asher E, Matetzky S.
Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction.
J Thromb Haemost. 2018 Feb 14. doi: 10.1111/jth.13977. [Epub ahead of print] PubMed PMID: 29443445.
(**HEMATOLOGY 13/70 IF 5.287 Q1**)
Times Cited: 0(from Web of Science Core Collection)

B.1. Accepted for Publication

B.1. Submitted for Publication

1. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Peripheral endothelial function predicts 1-year clinical outcomes in patients hospitalized in chest pain unit - data from 2 sites.
Int J Cardiol 2018
2. Rubinstein R, Matetzky S, Beigel R, Iakobishvili Z, **Shechter M** on behalf of the ACIS investigators.
Comparision of outcomes of caute coronary syndrome in women ≥ 80 years versus those < 80 years in Israel from 2000-2016.
Int J Cardiol 2018
3. Shlezinger M, Amitai Y, Akriv A, Gabay H, **Shechter M**, Leventer-Roberts M.
Association between exposure to desalinated sea water and ischemic heart disease, diabetes mellitus and colorectal cancer; a population-based study in Israel.
Environmental Res, 2018

B.2. Case Reports:

B.2. Case Reports published

- B2-1. Leor J, Hod H, Kaplinsky E, **Shechter M**, Motro M.
Pseudokinesis: a radionuclide ventriculography sign for subacute heart rupture and tamponade early after acute myocardial infarction.
Am Heart J 1989;118:612-614.

- B2-2. Glikson M, Freimark D, Leor R, **Shechter M**, Kaplinsky E, Rabonowitz B.
Unstable anginal syndrome and pulmonary oedema due to thyrotoxicosis.
Postgrad Med J 1991;67:81-83.
- B2-3. Graif M, Schwartz E, Strauss S, Mouallem M, **Shechter M**, Morag B.
Occult infection of hip prosthesis: sonographic evaluation.
JAGS 1991;39:203-204.
- B2-4. **Shechter M**, Glikson M, Agranat O, Motro M.
Echocardiographic demonstration of mitral block caused by left atrial spindle cell sarcoma.
Am Heart J 1992;123:232-234.
- B2-5. Zwas ST, Lorberboym M, **Shechter M**.
Occult aortic arch mycotic aneurysm diagnosed by radio-gallium scintigraphy.
Clin Nucl Med 1992;17:797-799.
- B2-6. **Shechter M**, Agranat O, Rosenblatt S, Rabinowitz B, Motro M, Kaplinsky E.
Magnesium reduces pulmonary artery pressure in primary pulmonary hypertension.
Magnesium Bull 1995;17:115-117.

B.2. Case Reports Accepted

- - - NONE - - -

B.2. Case Reports Submitted

- - - NONE - - -

B. 3. Review Articles

B.3. Review Articles Published

- B3-1. **Shechter M**, Rabinowitz B.
Magnesium and heart disease.
Harefuah 1989;1:60-64.
- B3-2. **Shechter M**.
Beneficial effect of magnesium in acute myocardial infarction - a review of the literature.
Magnesium Bull 1990;12(1):1-5.
- B3-3. **Shechter M**
Experten in Redaktionsgespräch. Magnesium: Gesicherts, fragliches und spekulatives.
Munchener Medizinische Wochenschrift 1995;137: S433-S454.
- B3-4. **Shechter M**.

The role of magnesium as antithrombotic therapy.
Wien Med Wochenschr 2000;150:343-347.

- B3-5. **Shechter M**, Sherer Y.
Endothelial dysfunction: A crystal ball prediction for enhanced cardiovascular risk?
Isr Med Assoc J 2003;5:736-738 (Editorial).
- B3-6. **Shechter M**.
Does magnesium have a role in the treatment of patients with coronary artery disease?
Am J Cardiovasc Drugs 2003;4:231-239.
- B3-7. **Shechter M**, Beigel R, Matetzky S, Chouraqui P.
The intensive statin therapy myth.
Isr Med Assoc J 2005;11:683-687.
- B3-8. **Shechter M**, Shechter A.
Magnesium and myocardial infarction.
Clin Calcium 2005;15(11):1873-1877.

Since last promotion

- B3-9. **Shechter M**.
Magnesium and cardiovascular system.
Magnes Res. 2010 Jun;23(2):60-72.
doi: 10.1684/mrh.2010.0202. Epub 2010 Mar 31. PubMed PMID: 20353903.
- B3-10. **Shechter M**.
[Body magnesium--the spark of life].
Harefuah. 2011Jan;150(1):41-5, 67. Hebrew.
PubMed PMID: 21449156.
- B3-11 Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher TF, **Shechter M**, Taddei S, Vita JA, Lerman A.
The assessment of endothelial function: from research into clinical practice.
Circulation. 2012 Aug 7;126(6):753-67.
doi: 10.1161/CIRCULATIONAHA.112.093245.. PMID:22869857
- B3-12 **Shechter M**, Amir O, Lerman A, Shemesh J, Maor E, Rubinshtein R.
[ENDOTHELIAL DYSFUNCTION: A POSITION PAPER OF THE ISRAEL HEART SOCIETY].
Harefuah. 2018 Feb;157(2):122-126. Hebrew.
PubMed PMID: 29484870.

B.3. Review Articles Accepted

- - - NONE - - -

B.3. Review Articles Submitted for Publication

1. **Shechter M**, Lerman A, Adler Y, Back M, Dorobantu M, Drexel H, Ducker DJ, Lewis BS, Linhart A, MD, Rocca B, Sibbing D, Evans P.
Non-invasive Assessment of Endothelial Dysfunction: A Consensus Statement paper of the ESC WG on Atherosclerosis and Vascular Biology, the WG on Coronary Pathophysiology and Microcirculation, the WG on Cardiovascular Pharmacotherapy, the WG on Myocardial and Pericardial Diseases and the WG on Thrombosis.
Eur Heart J 2018.

C. Chapters in Books

C1.

C1-1. Shechter M.

Beneficial effects of magnesium sulfate in acute myocardial infarction. A review of the literature.
In: Lasserre B, Durlach J (eds.).
Magnesium - A relevant ion? John Libbey and Co. Ltd., London, 1991, pp. 427-434.

Since last promotion

C1-2. Shechter M.

The role of magnesium as antithrombotic therapy.
In: Rayssiguier Y, Mazur A, Durlach J (eds.).
Advances in Magnesium Research:
Nutrition and Health. John Libbey and Co. Ltd., London, 2001, pp. 333-340.

C1-3. Shechter M, Shechter A.

Magnesium in cardiovascular system.
In: Watson RW, Preedy VR, Zibadi S (eds.).
Magnesium in Human Health and Disease.
Springer Sciences and Co. Humana Press, London, 2013, pp.191-204.

C2. Monographs

C2-1. Ben Zvi S, Shechter M.

Living with Heart Disease.
Educational material for hospitalized patients with coronary artery disease. 1st Ed. 2000.

- C2-2. Drory I, Shenowitz M, Marom-Klivansky R, Golan R, Grodgiinovsky E, **Shechter M.**
A Position Document: Physical activity as a part of primary prevention of coronary artery disease.
A report the Working Group's committee of Cardiac Rehabilitation, Israel Heart Society and Israel Medical Association, 2001.
- C2-3. **Shechter M.**, Sharir M, Labrador MJP, Forrester J, Silver B, Bairey Merz CN.
Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Ann Bibliog of significant Advances in Dietary Supp Res 2000:4.
- C2-4. Lavi T, **Shechter M.**
Food and Coronary Heart Disease – All Starts from Endothelial Dysfunction. In: Food, Selected Issues, Eds. Niba Shapira, Aurora, pp. 25-28, 2007.

Since last promotion

- C2-5. Ben Zvi S, **Shechter M.**
Living with Heart Disease.
Educational material for hospitalized patients with coronary artery disease. (Hebrew)
Heart Center, Chaim Sheba Medical Center, Israel. 4th Ed. 2009.
- C2-6. Ayelet-Adar S, Hankin J, Lipovetchky N, Yosefi H, Shai I, Gavish D, **Shechter M.**, Golburt U.
Israel Heart Society, Atid Organization (the Israel Dietitians and Nutritionists Association).
Position Paper: Dietary recommendations to prevent cardiovascular disease.
The Israel Medical Association. April 2011. Hebrew
- C2-7. **Shechter M.**
The Magnesium Chapter
In Position Paper: Nutritional Recommendations for Cardiovascular Prevention.
Israel Heart Society and the ATID Society (the Israel Dietitians and Nutritionists Association)
Israel Medical Association. April 2015. Hebrew
position paper
- C2-8. Ayelet-Adar S, Hankin J, Lipovetchky N, Yosefi H, Shai I, Gavish D, **Shechter M.**, Golburt U.
Israel Heart Society, Atid Organization (the Israel Dietitians and Nutritionists Association).
Position Paper: Dietary recommendations to prevent cardiovascular disease.
The Israel Medical Association. April 2015. . Hebrew
- C2-9. **Shechter M.**, Tzur B, Zivoni D, Hasdai D, Klein Y, Shemesh Y.
Israel Heart Society
Position Paper: The cardiac patient and sexual activity in the phosphodiesterase 5 type inhibitors.
Israel Medical Association. April 2016 . Hebrew
Chairman of the writing committee.

- C2-10. **Shechter M.** Amir O, Lerman A, Shemesh J, Maor E.
Rubinshtein R, The Israel Heart Society.
Endothelial dysfunction: A position paper
Israel Medical Association. January 2017. . Hebrew

D. 1. Invited Papers in Scientific Meetings

- D1-1. **Shechter M.**
Beneficial effect of magnesium in acute myocardial infarction.
11th Hohenheimer Magnesium Symposium, September 1989, Germany.
- D1-2. **Shechter M.**
Beneficial effect of magnesium in acute myocardial infarction.
3rd European Congress on Magnesium, March 1990, Geneva, Switzerland.
- D1-3. **Shechter M.**
Magnesium in Cardiology.
Seminar in Cardiology for Post Graduate Physicians. The Hebrew University,
Jerusalem (The University Institute of Postgraduate Medical Education), April
1990, Israel.
- D1-4. **Shechter M.**
Magnesium therapy in aged patients with acute myocardial infarction.
12th Hohenheimer Magnesium Symposium. September 1990, Germany.
- D1-5. **Shechter M.**
Magnesium sulfate in acute myocardial infarction.
Magnesiocard Symposium, Frankfurt, February 1991, Germany.
- D1-6. **Shechter M.**
Magnesium sulfate in acute myocardial infarction.
Department of Hormone Research, Weitzman Institute of Science, February 1991, Rehovot,
Israel.
- D1-7. **Shechter M.**
The interaction of Heparin and Nitrates.
Department of Cardiac Surgery, Hadassah Medical Center, The Hebrew University, Jerusalem,
December 1991, Israel.
- D1-8. **Shechter M.**
Magnesium in acute myocardial infarction.
Magnesium Workshop, Cardiac Center, University Hospitals of Geneva and Bern, February
1992, Switzerland.
- D1-9. **Shechter M.**
Magnesium reduces mortality in acute myocardial infarction patients unsuitable for
thrombolytic therapy.
IV European Congress on Magnesium, September 1992, Gissen, Germany.

D1-10. **Shechter M.**

Magnesium therapy in acute myocardial infarction.
School of Continuing Medical Education, Sackler School of Medicine.
Postgraduate Course in Cardiology, November 1992. Heart Institute, Sheba
Medical Center, Israel.

D1-11. **Shechter M.**

Magnesium in cardiac infarction and arrhythmias.
Medica, November 1992, Dusseldorf, Germany.

D1-12. **Shechter M.**

Magnesium in acute myocardial infarction. Asaf Harofe Hospital, The Hebrew University,
Zerifim, December 1992, Israel.

D1-13. **Shechter M.**

The interaction of Heparin and Nitrates.
Heart Institute, Rambam Medical Center, Technion University, January 1993,
Haifa, Israel.

D1-14. **Shechter M.**

Magnesium in acute myocardial infarction.
Israel Heart Society, Tel Aviv Branch, January 1993, Israel.

D1-15. **Shechter M.**

Magnesium in AMI patients who are unsuitable candidates for thrombolysis.
Gordon Research Conferences, Oxnard, California, February 1993, USA.

D1-16. **Shechter M.**

The rationale of magnesium in acute myocardial infarction.
Internal Medicine Grand Round, Stanford University Medical Center, March
1993, USA.

D1-17. **Shechter M.**

Additional ST-segment elevation during the first hour of thrombolysis:
An electrocardiographic sign predicting a favorable clinical outcome.
Heart Institute, Meir General Hospital, Sapir Medical Center, Kfar Saba, October
1993, Israel.

D1-18. **Shechter M.**

Magnesium therapy: State of the Art. New Strategies based on LIMIT-2 and
ISIS-4. Clinical Symposium - Department of Cardiology and Internal Medicine,
Vienna University Clinics (AKH), June 1994, Austria.

D1-19. **Shechter M.**

Magnesium therapy in acute myocardial infarction and ischemic heart disease. School of
Continuing Medical Education, Sackler School of Medicine, Tel Aviv
University, October 1994, Israel.

- D1-20. **Shechter M.**
Cardiological Aspects of Aviation Safety.
Israel Society of Sports Medicine, Tel Aviv, April 1995, Israel.
- D1-21. **Shechter M.**
The clinical value of magnesium in acute myocardial infarction.
Munchener Medizinische Wochenschrift Editorial Forum, Munich, April 1995, Germany.
- D1-22. **Shechter M.**
Magnesium in acute myocardial infarction without thrombolytic therapy.
5th European Magnesium Congress, Vienna, June 1995, Austria.
- D1-23. **Shechter M.**
Magnesium and coronary artery disease: Rationale and clinical trials.
Cardiology Grand Rounds Presentation. Cedars-Sinai Medical Center, Los Angeles, September 1995, USA.
- D1-24. **Shechter M.**
LIMIT-2 and Israeli Magnesium Trials.
Gordon Research Conferences on Magnesium in Biochemical Processes.
Ventura, California, January 1996, USA.
- D1-25. **Shechter M.**
The rationale of magnesium as alternative therapy in patients with acute myocardial infarction without thrombolytic therapy.
Department of Cardiology and Internal Medicine, Vienna University Clinics (AKH), March 1996, Austria.
- D1-26. **Shechter M.**
Acute myocardial infarction without thrombolytic therapy: Beneficial effects of magnesium sulfate. Expert Workshop: Importance of electrolytes in the therapy of cardiac arrhythmias - basic, research and clinics. University of Dusseldorf, Germany, September 1996.
- D1-27. **Shechter M.**
Magnesium therapy in acute myocardial infarction - State of the Art. Cardiology Grand Round, Department of Cardiology, Soroka Medical Center, September 1996.
- D1-28. **Shechter M.**
Lipid lowering in 1997 - LDL-reduction is not the whole story. Persian Academy of Physicians, Los Angeles, April 1997, USA.
- D1-29. **Shechter M.**
Lipid lowering - State of the Art. Residents of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, May 1997, USA.
- D1-30. **Shechter M.**

Magnesium as adjuvant to thrombolytic therapy - State of the Art. 7th International Symposium on Cardiovascular Pharmacotherapy, Jerusalem, June 1997.

D1-31. **Shechter M.**

Magnesium treatment in the thrombolytic era. Grand Round, Division of Cardiology University of South Alabama Medical Center, Mobile, Alabama, July 1997, USA.

D1-32. **Shechter M.**

Prevention of myocardial infarction: An evidence based approach. Med/Surg Grand Rounds, Brotman Medical Center, Los Angeles, CA, September 1997, USA.

D1-33. **Shechter M.**

Review of the significant presentations from the 70th Annual Scientific Sessions of the American Heart Association. Cardiology Grand Rounds Presentation. Cedars-Sinai Medical Center, Los Angeles, December 1997, USA.

D1-34. **Shechter M.**

Can we prevent heart disease in diabetic patients? Grand Round, Kaiser Permanente Medical Center, Southern California Region, Harbor City Conference Center, February 1998, USA.

D1-35. **Shechter M.**

Magnesium as adjuvant therapy to thrombolysis in AMI and CAD patients. Grand Round, City of Hope National Medical Center, Duarte, California, March 1998, USA.

D1-36. **Shechter M.**

Magnesium as antithrombotic therapy in CAD patients. Grand Round, Dep. of Medicine, Methodist Hospital, Indiana Medical Center, Indianapolis, March 1998, USA.

D1-37. **Shechter M.**

Magnesium as adjuvant therapy to AMI and antithrombotic therapy in CAD patients. Grand Round, Dep. of Medicine, St. Vincent Hospital, Indiana Medical Center, Indianapolis, March 1998, USA.

D1-38. **Shechter M.**

Prevention of Cardiovascular Events: What have we learned? Bristol-Myers Squibb Consultants Update Meeting, April 1998, Beverly Hills, CA, USA.

D1-39. **Shechter M.**

New Advances in Antiplatelet Therapy. Grand Round, Dep. of Medicine, Long Beach VA Medical Center in Long Beach, June 1998, CA, USA.

D1-40. **Shechter M.**

Reductase Inhibitors Monotherapy and Stroke Prevention. 21st Annual Snake River Medical Forum, St. Joseph Regional Medical Center, June 1998, Idaho, USA.

D1-41. **Shechter M.**

Clopidogrel in Patients at Risk of Ischemic Events and Strokes. 21st Annual Snake River Medical Forum, St. Joseph Regional Medical Center, June 1998, Idaho, USA.

- D1-42. **Shechter M.**
Magnesium Therapy in Acute Myocardial Infarction - Update. Grand Round, Dep. of Medicine, Nothridge Hospital Medical Center, June 1998, Northridge, CA, USA.
- D1-43. **Shechter M.**
New Advances in Antiplatelet Therapy. Grand Round, Dep. of Medicine, Baptist Medical Center, June 1998, Kansas City, MO, USA.
- D1-44. **Shechter M.**
Prevention of Myocardial Infarction: An Evidenced Based Approach. 42nd Annual Postgraduate Symposium, The San Diego Academy of Family Physicians, San Diego, June 1998, CA, USA.
- D1-45. **Shechter M.**
New Advances in Antiplatelet Therapy. Grand Round, Dep. of Medicine, Sepulveda VA Medical Center, June 1998, Sepulveda, CA, USA.
- D1-46. **Shechter M.**
Progress in Stroke Prevention. Grand Round, Dep. of Medicine, Los Angeles County Rancho Los Amigos, June 1998, Downey, CA, USA.
- D1-47. **Shechter M.**
Cardiovascular Disease: Advances in Treatment and Prevention. Grand Round, Dep. of Medicine, Maricopa Medical Center, July 1998, Phoenix, Arizona, USA.
- D1-48. **Shechter M.**
Progress in Stroke Prevention. Grand Round, Dep. of Medicine, Olive View-UCLA Medical Center, July 1998, Sylmar, CA, USA.
- D1-49. **Shechter M.**
Progress in Stroke Prevention. Grand Round, Harbor UCLA Dep. of Family Medicine, July 1998, Torrance, CA, USA
- D1-50. **Shechter M.**
Magnesium as antithrombotic therapy. Grand Round, Dep. of Medicine, Sheba Medical Center, October 1998.
- D1-51. **Shechter M.**
Magnesium as Antithrombotic Therapy. The Heart Institute, Sheba Medical Center, October 1998.
- D1-52. **Shechter M.**
Prevention of Myocardial Infarction: An Evidenced Based Approach. Grand Round, Dep. of Medicine, Laniado Medical Center, Nethania, November 1998.
- D1-53. **Shechter M.**
Magnesium as Antithrombotic Therapy. 25th Anniversary of the American College of Advancement in Medicine, November 1998, Phoenix, Arizona, USA.

- D1-54. **Shechter M.**
The Rationale of Magnesium as Antithrombotic Therapy in CAD Patients (Invited Lecture).
Gordon Research Conferences, February 1999, Ventura, CA, USA.
- D1-55 **Shechter M.**
Lipid Lowering Medications and Stroke Prevention. Primary care physicians. Maccabi
Association, 1999, Tel Aviv, Israel.
- D1-56. **Shechter M.**
The Rationale of Magnesium as Antithrombotic Treatment for Patients with Coronary Artery
Disease (Invited Lecture). 1st International Congress on Heart Disease – New trends in
Research, Diagnosis and Treatment. May 1999, Washington DC, USA.
- D1-57. **Shechter M.**
Overweight – A Cardiovascular Risk Factor: New Approach for Weight Reduction. Seminar
for primary care physicians, June 1999, Jerusalem.
- D1-58. **Shechter M.**
New Concepts in Lipid Management. An interactive seminar for primary care Physicians. June
1999, Nazareth, Israel.
- D1-59. **Shechter M.**
Overweight – A Cardiovascular Risk Factor: New Approach for Weight Reduction. Seminar
for primary care physicians, June 1999, Nethania, Israel.
- D1-60. **Shechter M.**
Stroke prevention and lipid lowering therapy in the new millennium. Primary care physicians,
Kupat Holim, September 1999, Cesarea, Israel.
- D1-61. **Shechter M.**
Aggressive lipid lowering and Coronary Artery Disease. Atherosclerosis Seminar,
Annual Meetings of the Israel Family Physicians, Eilat, Israel, November, 1999
- D1-62. **Shechter M.**
Overweight – A Cardiovascular Risk Factor: New Approach for Weight Reduction. The Heart
Institute, Sheba Medical Center, December, 1999.
- D1-63. **Shechter M.**
Stroke prevention and lipid lowering therapy in the new millennium.
Grand Round, Dep. of Neurology, Sheba Medical Center, January 2000, Israel.
- D1-64. **Shechter M.**
New Concepts in Lipid Lowering. Grand Round, Dep. of Cardiac Surgery, Sheba Medical
Center, January 2000, Isarel.
- D1-65. **Shechter M.**
Antithrombotic and antiinflammatory effects of statins. Primary Care Physicians, The Dead Sea
Symposium, March 2000, Israel.

- D1-66. **Shechter M.**
The New Millennium Israel Pravastatin Survey. Research Meeting.
Family and Primary Care Physicians Meetings, The Dead Sea, March 2000, Israel.
- D1-67. **Shechter M.**
Endothelial Function Assessment.
Annual Meetings of the Working Group of Cardiologists in the Community, Israel Heart Society, Nazareth, May 2000, Israel..
- D1-68. **Shechter M.**
Inflammation and Coronary Artery Disease.
Post Graduate Course, Sackler School of Medicine, Tel Aviv University, May 2000.
- D1-69. **Shechter M.**
The rationale of magnesium as antithrombotic treatment for patients with coronary artery disease.
7th World Congress on Heart failure - Mechanisms and Management, Vancouver, Canada, July 2000.
- D1-70. **Shechter M.**
Obesity and cardiovascular risk.
Israel Society of Family Physicians. Eilat, September, 2000, Israel.
- D1-71. **Shechter M.**
Lipid Update. Cardiology Grand Round. The Heart Institute, Sheba Medical Center. October 2000.
- D1-72. **Shechter M.**
Endothelial function and exercise. Israel Working Group on Cardiac Rehabilitation, Israel Heart Society, Tel Aviv, December 2000.
- D1-73. **Shechter M.**
Non-invasive assessment of endothelial function The Heart Institute, Sheba Medical Center. January 2001.
- D1-74. **Shechter M.**
Early (in-hospital) cardiac rehabilitation (Phase I). The Heart Institute, Sheba Medical Center. February 2001.
- D1-75. **Shechter M.**
Non-invasive assessment of endothelial function. Internal Medicine Grand Round, Sheba Medical Center. March 2001.
- D1-76. **Shechter M.**
Lipid update in the year 2001. Primary care physicians. Kupat Holim, Herzlia, March, 2001.
- D1-77. **Shechter M.**
State of the Art Lecture: Magnesium in acute myocardial infarction and MAGIC trial. Israel Heart Society, Working Group on Intensive Cardiac Care. Dead Sea, April 2001, Israel.

D1-78 **Shechter M.**

Oral magnesium therapy improves exercise tolerance, exercise-induced angina, and quality of life in patients with coronary artery disease. The Expert Report, Austrian Ministry of Health, Vienna, Austria, June 2001.

D1-79. **Shechter M.**

Non-invasive assessment of endothelial function - current and future. The Heart Institute, Sheba Medical Center, July 2001.

D1-80 **Shechter M.**

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) ATPIII. Israel Working Group on Cardiac Rehabilitation, December 2001.

D1-81. **Shechter M.**

Contraversies in Cardiology: (1) Srtatins in Acute MI; (2) Statins for all IHD Patients. Post Graduate for Cardiologists. Sackler School of Medicine, January 2002.

D1-82 **Shechter M.**

Benefits of Magnesium in Chronic Ischemic Heart Disease. Gordon Research Conference on Magnesium in Biochemical Process and Medicine. Ventura, CA, USA, February 2002.

D1-83. **Shechter M**

Should statins be used in all elderly patients with arrhythmia? 6th International Dead Sea Symposium on Cardiac Arrhythmias and Device Therapy. Tel Aviv, Israel, March 2002.

D1-84. **Shechter M**

Effect of dobutamine on endothelial function in severe chronic heart failure. Sackler Medical School Research Day, Tel Aviv University, Israel, March 2002.

D1-85. **Shechter M**

Intermittent dobutamine therapy in severe chronic heart failure patients. Seminar in Congestive Heart Failure, MACCABI, Israel, June 2002.

D1-86. **Shechter M**

Intravenous inotropic support in end-stage heart failure patients. 3rd International Meeting on Intensive Cardiac Care, June 2002, Tel Aviv, Iasrael.

D1-87. **Shechter M**

Benefits of magnesium in chronic ischemic heart disease. 25th anniversary of the German Magnesium Society, 4th German-Austrian-Swiss Magnesium Symposium, September 2002, Fulda, Germany.

D1-88. **Shechter M**

Intermittent dobutamine therapy in severe chronic heart failure patients. Controversies and State of the Art. The Heart Institute Grand Round, Sheba Medical Center, Tel Hashomer, Israel, September 2002.

D1-89 **Shechter M.**

Magnesium therapy in patients with chronic ischemic heart disease. Current status and future studies. 2nd Scientific Conference of the Israel Society of Magnesium Research in Biology and Medicine. Sackler Faculty of Medicine, Tel Aviv University, October 2002, Israel.

D1-90. **Shechter M.**

Results of Magnesium in Coronaries (MAGIC) Trial. 2nd Scientific Conference of the Israel Society of Magnesium Research in Biology and Medicine. Sackler Faculty of Medicine, Tel Aviv University, October 2002, Israel.

D1-91. **Shechter M.**

Endothelial function - a research tool and current clinical implication.
Primary care physicians and cardiologists - Maccabi Health System, November 2002, Israel.

D1-92. **Shechter M.**

High cholesterol - an increased risk for coronary artery disease in diabetic patients.
National Israel Diabetic Faire, November 2002.

D1-93. **Shechter M.**

Endothelial function assessment: Clinical use – State of the Art. Preventive & Rehabilitative Cardiac Center, Cedars Sinai Medical Center, Los Angeles, USA, January 2003.

D1-94. **Shechter M.**

Statins are the aspirin of the new millennium. Primary Care Physicians, Kupat Holim, Tel Aviv, January 2003.

D1-95. **Shechter M.**

Statins – State of the Art. Physicians in the Arab Sector at the West Bank, Jerusalem, February 2003.

D1-96. **Shechter M.**

Endothelial dysfunction – a risk factor for atherosclerosis. Grand Round, Dep. of Medicine, Sheba Medical Center, Israel, June 2003.

D1-97. **Shechter M.**

High cholesterol - an increased risk for coronary artery disease in diabetic patients.
National Israel Diabetic Faire, Haifa, Israel, June 2003.

D1-98. **Shechter M.**

Does magnesium have a role in the treatment of patients with coronary artery disease? 44th Annual Meetings of the American College of Nutrition, Nashville, Tennessee, USA October 2003.

D1-99. **Shechter M.**

Statins – Update February 2004. Cardiology Grand Round, Heart Institute, Sheba Medical Center, February 2004.

D1-100. **Shechter M.**

Non-invasive assessment of vascular endothelial function and its implications.
The Working Group of Cardiology in the Community, Israel Heart Society, April 2004.

- D1-101. **Shechter M.**
Endothelial function- a marker of cardiovascular disease risk. Indo-Israel Workshop on CAD. Gem-Heart Seminar. Jaipur, India, May 2004.
- D1-102. **Shechter M.**
The role of magnesium therapy in patients with coronary artery disease. Indo-Israel Workshop on CAD. Gem-Heart Seminar. Jaipur, India, May 2004.
- D1-103. **Shechter M.**
New developments in lipid lowering therapy – is lower cholesterol better? Indo-Israel Workshop on CAD. Gem-Heart Seminar. Jaipur, India, May 2004.
- D1-104. **Shechter M.**, Beigel R, Sofer BA, Goldstein L, Barenboim E.
The efficacy and safety of statins for primary prevention of atherosclerosis in military air crew personnel in Israel.
The Israel National Aviation Medicine Meeting, Herzlia, Israel, December 22, 2004.
- D1-105. **Shechter M.**
Magnesium in Chronic Ischemic Heart Disease. Gordon Research Conferences, Ventura, California, February 2005, USA.
- D1-106. **Shechter M.**
Endothelium and inflammation. The 6th Research Fair of the Sackler Faculty of Medicine, Tel Aviv University, April 2005.
- D1-107. **Shechter M.**
Endothelial dysfunction – implications and treatment in obese patients.
The IV Annual Conference of the Israel Society of Research and Treatment of Obesity, Tel Aviv, May 2005.
- D1-108. **Shechter M.**
Obesity and endothelial function: Implications and treatment. Cardiology Grand Round, Heart Institute, Sheba Medical Center, May 2005.
- D1-109. **Shechter M.**
Atorvastatin Safety Profile. Evidence based strategies for Reducing Cardio-Vascular Events. Israel Heart Society Meeting. Eilat, June 2006.
- D1-110. **Shechter M.**
The Efficacy and Safety of Statins in Acute Coronary Syndrome.
Israel Neurological Association, Carmel Forest, June 2006.
- D1-111. **Shechter M.**
Endothelial function under elevated blood pressure.
The Israel Society for Physiology and Pharmacology Annual Meeting, Tel Aviv University, September 2006.
- D1-112. **Shechter M.**

Hypertension and endothelial dysfunction: fact or fantasy?.
Cardiology Grand Round, Heart Institute, Sheba Medical Center, October 2006.

D1-113. **Shechter M.**

Endothelial function – the risk of the risk factors.
Medicine Grand Round, Dep. of Medicine H, Sheba Medical Center, October 2006.

D1-114. **Shechter M.**

Invasive and noninvasive evaluation of endothelial dysfunction in CAD. A Joint Meeting of the Israel Heart Society, the Israel Society of Nephrology and Hypertension and the Israel Society of Hypertension, January 2007, Tel Aviv, Israel.

D1-115. **Shechter M**

The issue of statin safety: where do we stand?
Cardiology Grand Round, Heart Institute, Sheba Medical Center, February 2007.

D1-116. **Shechter M.**

Endothelial Function Predicts Mortality in Patients with Severe Chronic Heart Failure.
Cardiology Grand Round, Cedars-Sinai Medical Center, Los Angeles, USA July 3rd, 2007.

D1-117. **Shechter M.**

Endothelial function predicts outcome in patients with advanced chronic heart failure.
Cardiology Grand Round, Heart Institute, Sheba Medical Center, September 2007.

D1-118. **Shechter M.**

The good, the bad and the target: update on statin therapy and safety in patients with coronary artery disease. Primary Care Physicians, Maccabi, Ramat Gan, December 2007.

D1-119. **Shechter M.**

Mechanisms of endothelial function and dysfunction. Cardiology Course, Sackler Faculty of Medicine, School of Continuing Medical Education, February 2008, Tel Aviv University.

D1-120. **Shechter M.**

Clinical evaluation of endothelial function – is it possible and how? Cardiology Grand Round, Rambam Medical Center and the Technion Faculty of Medicine, Haifa, Feb 2008.

D1-121. **Shechter M.**

Magnesium in Chronic Ischemic Heart Disease. Gordon Research Conferences, Ventura, California, February 2008, USA.

D1-122. **Shechter M.**

Assessment of endothelial function by flow-mediated dilation (FMD). The 2nd Conference on Obesity, Diabetes and Hypertension. Tel Aviv, March 2008, Israel.

D1-123. **Shechter M.**

The pharmacological therapy in obese patients with coronary artery disease. Primary care physicians, MACCABI, Ramat Hasharon, April 2008, Israel.

D1-124. **Shechter M.**

Endothelial function: the good, the bad and the target. Hematology Grand Round. The Amalia Biron Research Institute, Hematology Dep., Sheba Medical Center, May 2008.

D1-125. **Shechter M.**

Heart Disease and Cardiac Rehabilitation. Bar Ilan University, The Louis and Gabi Weisfeld School of Social Work, May 2008.

D1-126 **Shechter M.**

Abrupt withdrawal of statins.
Cardiology Grand Round, Heart Institute, Sheba Medical Center, November 2008.

D1-127. **Shechter M.**

Endothelial function: the good, the bad and the target. The 2nd Israeli Conference on Thrombosis and Anticoagulation. Ramat Gan, May 2009.

D1-128. **Shechter M.**

Secondary Prevention in Acute Coronary Syndrome Patients. Cardiology Course, Sackler Faculty of Medicine, School of Continuing Medical Education, June 2009, Tel Aviv University.

D1-129. **Shechter M.**

Magnesium- the mineral for life.
Dep. of Medicine B Grand Round, September 2009.

D1-130. **Shechter M.**

Beneficial effect of magnesium in acute medicine and cardiovascular field.
German Society of Magnesium annual meeting, Fulda, Germany, October 2009.

D1-131. **Shechter M.**

Coronary artery disease risk factors in aviation medicine.
Aviation Medicine Course, Sackler Faculty of Medicine, School of Continuing Medical Education, December 2009, Tel Aviv University.

Since last promotion

D1-132. **Shechter M.**

Magnesium and cardiovascular disease.
Working Groups of Prevention and Rehabilitation, and Preicardial Disease, Israel Heart Society, February, 2010.

D1-133. **Shechter M.**

Magnesium- the mineral for life: Magnesium in Cardiovascular System.
Dep. of Geophysics and Planetary Sciences, Tel Aviv University, May 2010.

D1-134. **Shechter M.**

Endothelial Dysfunction – A Marker of Atherosclerotic Risk.
16th International Vascular Biology Meeting, UCLA, Los Angeles, CA, USA June 2010.

Cardiology Grand Round, Cedars-Sinai Medical Center, Los Angeles, June 2010.

D1-135. **Shechter M.**

Magnesium – a mineral for life: the good, the bad and the target.
Dep. of Specific Sciences and Geophysics, Tel Aviv University, September 2010.

D1-136. **Shechter M.**

Vascular endothelium: Pathophysiology, functional measurement and possible mechanisms of training effects. Annual Meeting of the Israel Society of Sports Medicine. Ramat Gan, October 2010.

D1-137. **Shechter M.**

Magnesium in chronic heart disease – beyond the antiplatelet effects.
The 3rd Annual Israel Society of Thrombosis and Anticoagulations. Ramat Gan December 2010.

D1-138. **Shechter M.**

Endothelial Dysfunction.
Cardiology Course, Sackler Faculty of Medicine, School of Continuing Medical Education, February 2011, Tel Aviv University.

D1-139. **Shechter M.**

Primary prevention of coronary heart disease.
Cardiology Course, Sackler Faculty of Medicine, School of Continuing Medical Education, June 2011, Tel Aviv University.

D1-140. **Shechter M.**

Lipid therapy in high-risk groups, such as renal failure and diabetes.
Israel Heart Society Meeting, Tiberias, June 2011.

D1-141. **Shechter M.**

Endothelial Function: Past, Present and Future.
Cardiovascular Pharmacology and Drug Therapy Working Group Meeting, Israel Heart Society, Ramat Gan, June 2011.

D1-142. **Shechter M.**

Trial eligible ACS patients – do they understand informed consent form?
7th International Meeting on Intensive Cardiac Care, Tel Aviv, October 2011.

D1-143. **Shechter M.**

Lipid therapy in high-risk populations.
Cardiology Grand Round, Heart Institute, Sheba Medical Center, November 2011.

D1-144. **Shechter M.**

Secondary prevention of atherosclerosis.
Cardiology Course, Sackler Faculty of Medicine, School of Continuing Medical Education, June 2012, Tel Aviv University.

D1-145. **Shechter M.**

Magnesium- the sparkle of life and in atherosclerosis.
Internal Dep. of Medicine H Grand Round, Sheba Medical Center, September 2012.

D1-146. **Shechter M.**

Magnesium – the Mineral of Life.
The 3rd Israel Congress for Early Treatment in Hypertension, Diabetes and Dyslipidemia.
Ramat Gan, May 2013.

D1-147. **Shechter M.**

Magnesium – the spark of life.
The National Israel Nutrition Conference, Tel Aviv, January 2014.

D1-148. **Shechter M.**

Endothelial function and dysfunction – from basic science to clinical practice.
Israel Heart Society Winter Scientific Meetings, Eilat, January 2014.

D1-149. **Shechter M.**

The Novel Anticoagulant Treatments – A Symposium. Moderator and Lecturer.
Working Group (WG) of Cardiovascular Pharmacotherapy and Drug Therapy, WG of
Epidemiology and Cardiovascular Prevention, WG of Cardiology in the Community, WG of
Cardiac Rehabilitation; WG of Nuclear Cardiology and Cardiac CT,
Royal Beach Hotel, Tel Aviv, February 2014.

D1-150. **Shechter M.**

New Frontiers and treatment Paradigms for Stroke Prevention in Atrial fibrillation and VTE.
Internal Medicine Departments, Hacarmel Medical Center, Haifa, March 2014.

D1-151. **Shechter M.**

Endothelial function and dysfunction – from basic science to clinical practice.
Hematology Dep. Grand Round, Sheba Medical Center, March 2014.

D1-152. **Shechter M.**

Endothelial function assessment ready for clinical use. In the management of cardiovascular
risks. Lunches Symposium, Israel Heart Society Annual Meeting, Tel Aviv, April 2014.

D1-153. **Shechter M.**

Magnesium in cardiology: an old friend revisited. 51st ERA-EDTA Congress.
Amsterdam, June 2014 (Invited Speaker and Chair of the Symposium 5: “Magnesium:
opportunities in kidney disease”).

D1-154. **Shechter M.**

Endothelial function as a non-invasive tool for detection of atherosclerosis.
A joint symposium of the Israel Heart Society and Israel Family Physicians Association. Tel
Aviv, June 2014, Israel.

D1-155. **Shechter M.**

New frontiers and treatment paradigms for stroke prevention in atrial fibrillation patients and
venous thromboembolism. Cardiologies in the Community Meeting, Netanya and Hasharon
Region, June 2014 Netania.

- D1-156. **Shechter M.**
Endothelial Function – From Basic Research to Clinical Practice. The 4th Congress of Hot Topics in Medicine. MedicalMedia. Dan Panorama Hotel, Tel Aviv, September 2014.
- D1-157. **Shechter M.**
New frontiers in treatment for stroke prevention in AF patients. Dep. of Medicine 6, Sheba Medical Center, Tel Hashomer. October 2014. Tel Aviv.
- D1-158. **Shechter M.**
Impact of age and gender on endothelial function.
Cardio Femme. The 1st Women Cardiovascular Health Conference 2014. Tel Aviv, Israel.
- D1-159. **Shechter M.**
New frontiers in treatment for stroke prevention in AF patients. Dep. of Medicine 6, Sheba Medical Center, Tel Hashomer. December 2014. Tel Aviv.
- D1-160. **Shechter M.**
New frontiers in treatment for stroke prevention in AF patients. Dep. of Cardiology, Maeney Hayeshua Medical Center, Bnei Brak. December 2014. Tel Aviv.
- D1-161. **Shechter M.**
Endothelial function as a non-invasive tool for detection of atherosclerosis.
Cradiology Grand Round, Cedars-Sinai Medical Center, Los Angeles, USA, January 2015.
- D1-167. **Shechter M.**
Approches to Assessment of Peripheral Vascular Function.
Barbra Streisand Women's Heart Center Research Seminar, Cedars-Sinai Medical Center, Los Angeles, USA, January 2015.
- D1-168. **Shechter M.**
Magnesium for cardiovascular disease treatment and prevention.
International Forum of Magnesium for Health Prevention Seminar. San Francisco Airport Marriott Hotel, Burlingame, CA, USA, January 17-18, 2015.
- D1-169. **Shechter M.**
New frontiers in treatment for stroke prevention in AF patients. Dep. of Medicine 3, Sheba Medical Center, Tel Hashomer. February 2015. Tel Aviv.
- D1-170. **Shechter M.**
New frontiers in treatment for stroke prevention in AF patients. Dep. of Cardiology, Lanyado Medical Center, Netanya. March 2015. Netanya.
- D1-171. **Shechter M.**
New frontiers in treatment for stroke prevention in AF patients. Dep. of Medicine 6, Asaf Harofe Medical Center, Zrifin. April 2015. Rehovot.
- D1-172. **Shechter M.**

New frontiers in treatment for stroke prevention in AF patients. Dep. of Medicine 5, Sheba Medical Center, Tel Hashomer. May 2015. Tel Aviv.

D1-173. **Shechter M.**

Practical issues in the use of non-vitamin K oral anticoagulants (NOACs).
Department of Medicine (G and A)'s Grand Round, Sheba Medical Center, June 2015.

D1-174. **Shechter M.**

Endothelila function – now ready for clinical practice.
Satelite symposium on Clinical Application of Vascular Endothelial Function Detecting Techniques. The 17th Scientific Annual Congress of Chinese Society of Cardiology and the 9th Oriental Congress of Cardiology, Shanghai, China, Sep 2015.

D1-175. **Shechter M.**

Practical issues in the use of non-vitamin K oral anticoagulants (NOACs).
Department of Medicine (G) Barzilay Medical Center, November 2015.

D1-176. **Shechter M.**

Noninvasive endothelial function evaluation – what is its role?
The 3rd Mayo Clinic-Sheba Cardiovascular Symposium, December 17, 2015, Sheba Medical Center, Israel.

D1-177. **Shechter M.**

Novel approaches for the prevention of cardiovascular atherosclerotic diseases.
Cardiology Course, Chaim Sheba Medical Center, Israel-Poland, July 12, 2016.

D1-178. **Shechter M.**

Cardiovascular Primary Prevention Imaging: Endothelial Function. Israel Heart Society WG on Prevention and Epidemiology, Community Cardiology and Cardiovascular Pharmacotherapy Symposium. October 2016, Tel Aviv.

D1-179. **Shechter M.**

The impact of low-body magnesium on cardiovascular events.
Annual meeting of the Israel Association of Medical Laboratory, March 2017, Tel Aviv.

D1-180. **Shechter M.**

Lipid therapy in the year 2017: New update and therapy following the FOURIER study.
Ophtalmologic Department Grand Round- Meir Medical Center, March 2017, Kfar Saba.

D1-181. **Shechter M.**

Lipid therapy in the year 2017: New update and therapy following the FOURIER study.
Cardiology Dep., Sheba Medical Center, April 2017.

D1-182. **Shechter M.**

A 3-meeting course for cardiology fellows in Lipid therapy update: Past, present and future directions. Heart Institute, Leviev Heart Center, June 2017.

D1-183. **Shechter M.**

Magnesium in cardiovascular system. Updates 2017.

Bucharest, Romania, October 2017.

D1-184. **Shechter M.**

Clinical outcomes and trends in patients with acute coronary syndrome \geq age 80 years in Israel during 2000-2013.

The 22nd Israel Conference on the 3rd Age Group of Patients. Herzlia, Nov. 2017, Israel.

D1-185. **Shechter M.**

Testosterone replacement therapy and cardiometabolic effects. The Cardiologist perspective. The Winter Conference, Israel Endocrinologist Association, Kfar Bloom, Israel, November 2017.

D1-186. **Shechter M.**

Testosterone replacement therapy and cardiovascular adverse events. Cardiology Grandround, Heart Center, Sheba Medical Center, Jan 2018.

D1-187. **Shechter M.**

Cardiology Resaerch Seminar Co-Chairman with C. Noel Bairey Merz. Brabra Streisend Women's Heart Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA Jan 3, 2018.

D1-188. **Shechter M.**

Desilinated seawater and adding minerals. Nutrition Israel Conference 2018. Tel Aviv, Israel, Feb 2018. Invited Lecturer and Session Chairman.

D1-189. **Shechter M.**

Magnesium – the ion for healthy life. The 2nd Israel Geriatric Rehabilitation Conference. Herzleia, Israel, March 2018. Invited Lecturer.

D1-190. Benthall T, Durst R, Finkelstein A, Kornovsky R, **Shechter M.** An Expert Panel Discussion. How ORBITA study changes the way I treat my patients. Israel Heart Society Symposium on the topic: Stabel Coronary Artery Disease: Orbita Study – An Influential Study or a Temporary Anectodal Event? Tel Aviv, Israel, April 2018.

D. 2. Papers Presented at International Scientific Meetings:

D2-1. **Shechter M.**, Hod H, Mrks N, Behar S, Kaplinsky E, Rabinowitz B. Magnesium therapy and mortality in acute myocardial infarction. Xth Congress of the European Society of Cardiology, Vienna, Austria, 1988.

D2-2. **Shechter M.**, Hod H, Behar S, Kaplinsky E, Rabinowitz B. Magnesium therapy and mortality in acute myocardial infarction. Israel Heart Society Scientific Meetings, Herzlia, April, 1966.

D2-3. **Shechter M.**, Hod H, Behar S, Kaplinsky E, Rabinowitz B. Effect of magnesium sulfate on mortality in patients with acute myocardial infarction complicated by pump failure. 1st International Symposium on Heart Failure - Mechanisms and Management, Herzlia, 1989.

- D2-4. **Shechter M.**
Beneficial effect of magnesium in acute myocardial infarction - a review of the literature.
11th Hohenheimer Magnesium Symposium, September 1989, University of Hohenheim,
Germany. (Invited Lecture)
- D2-5. **Shechter M.**
Gunstige Magnesium - Wirkung beim akuten Myokardinfarktein Literature -
uberblick.
11th Hohenheimer Magnesium Symposium, September 1989, University of Hohenheim,
Germany. (Invited Lecture)
- D2-6. **Shechter M.**, Hod H, Modan M, Kaplinsky E, Rabinowitz B.
New ECG sign during the first hour of thrombolysis: its significance in relation to ejection
fraction.
Israel Heart Society Scientific Meetings, April, Tel Aviv, 1990.
- D2-7. **Shechter M.**, Hod H, Modan M, Kaplinsky E, Rabinowitz B.
New electrocardiographic sign during the first hour of thrombolysis: its significance in relation
to ejection fraction.
XIIth Congress of the European Society of Cardiology, Sweden, September 1990.
- D2-8. **Shechter M.**
Beneficial effect of magnesium in acute myocardial infarction. A review of the literature.
3rd European Congress on Magnesium, Geneva, Switzerland, 1990. (Invited Lecture).
- D2-9. **Shechter M.**
Beneficial effect of magnesium sulfate in acute myocardial infarction.
Magnesiocard Symposium, Frankfurt, Germany, 1990. (Invited Lecture)
- D2-10. **Shechter M.**, Hod H, Kaplinsky E, Rabinowitz B.
Magnesium administration in patients with acute myocardial infarction who are not candidates
for thrombolytic therapy.
XIIIth Congress of the European Society of Cardiology, Holland, September 1991.
- D2-11. **Shechter M.**
Magnesium sulfate in acute myocardial infarction.
- Magnesiocard Symposium, Frankfurt, Germany, February 1991. (Invited Lecture)
- Magnesium Workshop in Cardiology. Cardiac Center, University Hospital of Geneva,
Switzerland, February 1992. (Invited Lecture)
- Magnesium Workshop in Cardiology. University of Bern, Switzerland, February 1992.
(Invited Lecture)
- D2-12. **Shechter M.**, Hod H, Kaplinsky E, Rabinowitz B.
Magnesium reduces mortality in acute myocardial infarction in patients unsuitable for
thrombolytic therapy.
IV European Congress on Magnesium. September 1992, Gissen, Germany (Chairman of
Cardiology Session). (Invited Lecture)
- D2-13. **Shechter M.**, Kaplinsky E, Rabinowitz B.

- Magnesium in AMI patients who are unsuitable for thrombolysis.
Gordon Research Conferences. Los Angeles, February 1992, USA (Invited Lecturer).
- D2-14. **Shechter M.** Kaplinsky E, Rabinowitz B
Magnesium in myocardial infarction and arrhythmias.
Medica, November 1992, Dusseldorf, Germany. (Invited Lecture)
- D2-15. **Shechter M.** Kaplinsky E, Rabinowitz B.
Magnesium reduces mortality in myocardial infarction.
4th International Conference on Non-Invasive Cardiology. Cyprus, 1993;91.
- D2-16. **Shechter M.** Hod H, Kaplinsky E, Rabinowitz B.
Intravenous magnesium as alternative therapy in acute myocardial infarction patients unsuitable for thrombolytic therapy.
4th International Conference on Non-Invasive Cardiology. Cyprus 1993:111.
- D2-17. **Shechter M.** Hod H, Kaplinsky E, Rabinowitz B.
Magnesium as alternative therapy in acute myocardial infarction patients unsuited for thrombolysis.
66th Scientific Sessions of the American Heart Association. Atlanta, USA, November 1993.
- D2-18. **Shechter M.**
Intravenous magnesium supplementation in AMI patients.
Gordon Research Conferences: Magnesium in Biochemical Process. Science J. Oxnard, CA, February 1993, USA.
- D2-19. **Shechter M.**
Magnesium Therapy – State of the Art. New strategies based on LIMIT-2 and ISIS-4. Vienna university Clinics (AKH), June 1994, Austria. (Invited Lecture)
- D2-20. **Shechter M.**
The role of magnesium in AMI. Munchener Medizinische Wochenschrift Editorial Forum. “Magnesium-the Established, the Dubious and the Speculative”. Munich, Germany, 1995. (Invited Lecture)
- D2-21. **Shechter M.**
Magnesium in acute myocardial infarction without thrombolytic therapy. State of the Art. 5th European Magnesium Congress. Vienna, June 1995, Austria. (Invited Lecture)
- D2-22. Chouraqui P, **Shechter M.**, Livchitz S, Rabinowitz B, Brill Z, DiSegni E.
Significance of distal reversibility in infarct territory as determined by SPECT Talium-201: A sign of collateral flow with occluded infarct-related coronary artery.
Israel Heart Society Scientific Meetings, Tel Aviv, April 1996.
- D2-23. Chouraqui P, **Shechter M.**, Livchitz S, Rabinowitz B, Brill Z, DiSegni E.
Significance of distal reversibility in infarct territory as determined by SPECT Talium-201: A sign of collateral flow with occluded infarct-related coronary artery.
69th Scientific Sessions of the American Heart Association, New Orleans, USA, November 1996.

- D2-24. **Shechter M**, Bairey Merz CN, Rude RK, Paul-Labrador M, Meisel S, Molloy MD, Cercek B, Shah PK, Kaul S.
Low intracellular magnesium levels promote platelet-dependent thrombus formation in patients with coronary artery disease.
46th Annual Scientific Session of the American College of Cardiology, Anaheim, California, USA, March 1997.
- D2-25. **Shechter M**, Merz Bairey N, Paul-Labrador M, Rude RK
Intracellular magnesium predicts functional capacity in patients with coronary artery disease.
46th Annual Scientific Session of the American College of Cardiology, Anaheim, California, USA, March 1997.
- D2-26. **Shechter M**, Bairey Merz CN, Paul Labrador M, Molloy MD, Agarwala A, Kaul S.
Fasting blood sugar is related to platelet-dependent thrombosis in patients with coronary artery disease and controlled lipid levels.
70th Scientific Sessions of the American Heart Association, Orlando, USA, November 1997.
- D2-27. **Shechter M**, Bairey Merz CN, Paul-Labrador M, Molloy MD, Cercek B, Shah PK, Kaul S.
Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease.
47th Annual Scientific Session of the American College of Cardiology, Atlanta, Georgia, USA, March 1998.
- D2-28. **Shechter M**, Bairey Merz CN, Meisel SR, Paul-Labrador M, Molloy MD, Agarwala A, Cercek B, Shah PK, Kaul S.
Oral magnesium supplementation reduces platelet-dependent thrombosis in patients with coronary artery disease.
6th European Magnesium Congress, May 1998, Budapest, Hungary.
- D2-29. **Shechter M**, Meisel SR, Bairey Merz CN, Paul-Labrador M, Cercek B, Shah PK, Kaul S.
Protective effects of magnesium against monocyte-associated tissue factor procoagulant activity in patients with coronary artery disease.
6th European Magnesium Congress, May 1998, Budapest, Hungary.
- D2-30. **Shechter M**, Paul-Labrador M, Rude RK, Merz Bairey CN
Intracellular magnesium predicts functional capacity in patients with coronary artery disease.
6th European Magnesium Congress, May 1998, Budapest, Hungary.
- D2-31. **Shechter M**, Bairey Merz CN, Rude RK, Paul-Labrador M, Meisel SR, Molloy MD, Cercek B, Shah PK, Kaul S.
Low intracellular magnesium levels promote platelet-dependent thrombus formation in patients with coronary artery disease.
6th European Magnesium Congress, May 1998, Budapest, Hungary.
- D2-32. **Shechter M**, Bairey Merz CN, Meisel SR, Paul-Labrador M, Molloy MD, Agarwala A, Cercek B, Shah PK, Kaul S.

- Oral magnesium supplementation reduces platelet-dependent thrombosis in patients with coronary artery disease.
Gordon Research Conferences, Science J., January 1999, Ventura, CA, USA.
- D2-33. **Shechter M.** Merz Bairey N, Paul-Labrador M, Rude RK
Intracellular magnesium predicts functional capacity in patients with coronary artery disease.
Gordon Research Conferences, Science J, January 1999, Ventura, CA, USA.
- D2-34. **Shechter M.** Sharir M, Forrester JS, Bairey Merz CN.
Is there a benefit to lowering low-density lipoprotein below 100 mg/dl in patients with coronary artery disease?
48th Annual Scientific Session of the American College of Cardiology, New Orleans, USA, March 1999.
- D2-35. **Shechter M.**
The Rationale of Magnesium as Antithrombotic Therapy in CAD Patients. (Invited Lecture)
Gordon Research Conferences, Science J., February 1999, Ventura, CA, USA.
- D2-36. **Shechter M**
The Rationale of Magnesium as Antithrombotic Therapy in CAD Patients (Invited Lecture).
1st International Congress on Heart Disease – New Trends in Research, Diagnosis and Treatment. May 1999, Washington DC, USA.
- D2-37. **Shechter M.** Bairey Merz CN, Paul-Labrador M, Molloy MD, Meisel SR, Shah PK, Kaul S.
Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease.
Israel Heart Society Scientific Meetings, Tel Aviv, April 1999.
- D2-38. **Shechter M.** Sharir M, Forrester JS, Bairey Merz CN.
Is there a benefit to lowering low-density lipoprotein below 100 mg/dl in patients with coronary artery disease?
Israel Heart Society Scientific Meetings, Tel Aviv, April 1999.
- D2-39. **Shechter M.** Bairey Merz CN, Paul-Labrador M, Meisel SR, Molloy MD, Rude RK, Shah PK, Kaul S.
Oral magnesium supplementation reduces platelet-dependent thrombosis in patients with coronary artery disease.
Israel Heart Society Scientific Meetings, Tel Aviv, April 1999.
- D2-40. **Shechter M.** Sharir M, Platt LD, Forrester JS, Bairey Merz CN.
Is vessel flow or diameter a better measure of endothelial-dependent vasoreactivity?
Israel Heart Society Scientific Meetings, Tel Aviv, April 1999.
- D2-40 **Shechter M.** C.N. Bairey Merz, M. Paul-Labrador, M.D. Molloy, R.K. Rude, P.K. Shah, S. Kaul.
Oral magnesium supplementation reduces platelet-dependent thrombosis in patients with coronary artery disease.
XXIst Congress of the European Society of Cardiology, Barcelona, Spain. August 1999.

- D2-41 **Shechter M**, M. Paul-Labrador, C.N. Bairey Merz, S. Kaul.
Serum glucose but not insulin modulates platelet-dependent thrombosis in patients with coronary artery disease.
XXIst Congress of the European Society of Cardiology, Barcelona, Spain., August 1999.
- D2-42. **Shechter M**, M. Paul-Labrador, C.N. Bairey Merz, S. Kaul.
Serum glucose but not insulin modulates platelet-dependent thrombosis in patients with coronary artery disease.
49th annual Scientific Session of the American College of Cardiology, Anaheim, USA, March 2000.
- D2-43. **Shechter M**.
The rationale of magnesium as antithrombotic treatment for patients with coronary artery disease.
7th World Congress on Heart failure - Mechanisms and Management, Vancouver, Canada, July 2000.
- D2-44. **Shechter M**.
The role of magnesium as antithrombotic therapy.
9th International Magnesium Symposium, Vichy, France, September 2000.
- D2-45. **Shechter M**, Sharir M, Paul-Labrador M, Forrester J, Silver B, Bairey Merz CN.
Oral magnesium improves endothelial function in patients with coronary artery disease.
73rd Scientific Sessions of the American Heart Association, Atlanta, USA, November 2000.
- D2-46. **Shechter M**, Bairey Merz CN, Stuehlinger H-G, slany J, Pachinger O, Rabinowitz B.
Oral magnesium supplementation improves exercise duration and quality of life in patients with coronary artery disease.
50th Annual Scientific Session of the American College of Cardiology, Orlando, Florida, USA, March 2001.
47. **Shechter M**, Hod H, Rabinowitz B, Boyko V, Chouraqui P.
Long-term outcome in thrombolysis-ineligible acute myocardial infarction patients treated with intravenous magnesium.
XXIIIrd Congress of the European Society of Cardiology, Barcelona, Spain, September 2001.
48. **Shechter M**, Bairey Merz CN, Stuehlinger H-G, Slany J, Pachinger O, Rabinowitz B.
Oral magnesium supplementation improves exercise tolerance, exercise-induced angina and quality of life in patients with coronary artery disease.
7th European Magnesium Congress, Zaragoza, Spain, August 2001.
49. **Shechter M**, Hod H, Rabinowitz B, Boyko V, Chouraqui P.
Long-term outcome in thrombolysis-ineligible acute myocardial infarction patients treated with intravenous magnesium.
74th Scientific Sessions of the American Heart Association, California, USA, November 2001.
50. **Shechter M**.

- Benefits of Magnesium in Chronic Ischemic Heart Disease. Gordon Research Conference on Magnesium in Biochemical Process and Medicine. Science J., Ventura, CA, USA, February 2002 (invited speaker).
51. **Shechter M**
Should statins be used in all elderly patients with arrhythmia? 6th International Dead Sea Symposium on Cardiac Arrhythmias and Device Therapy. Tel Aviv, Israel, March 2002 (invited speaker).
 52. **Shechter M**, Feinberg M, Matetzky S, Freimark D.
Abnormal vascular responses in chronic severe heart failure are both endothelium-dependent and -independent.
Israel Heart Society Annual Meetings, Tel Aviv, April 2002.
 53. **Shechter M**, Feinberg M, Matetzky S, Freimark D.
The impact of intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure.
Israel Heart Society Annual Meetings, Tel Aviv, April 2002.
 54. **Shechter M**, Matetzky S, Feinberg M, Chouraqui P, Rotstein Z, Hod H.
Endothelial function in patients with severe coronary artery disease treated with enhanced counterpulsation therapy (ECPT).
Israel Heart Society Annual Meetings, Tel Aviv, April 2002.
 55. **Shechter M**
Intravenous inotropic support in end-stage heart failure patients. 3rd International Meeting on Intensive Cardiac Care, June 2002, Tel Aviv, Israel.
 56. **Shechter M**, Feinberg M, Matetzky S, Freimark D.
The impact of intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure.
XXIV Congress of the European Society of Cardiology, Berlin, Germany, August 2002.
 57. **Shechter M**, Matetzky S, Feinberg M, Chouraqui P, Rotstein Z, Hod H.
Endothelial function in patients with severe coronary artery disease treated with enhanced counterpulsation therapy (ECPT).
XXIV Congress of the European Society of Cardiology, Berlin, Germany, August 2002.
 58. **Shechter M**.
Benefits of magnesium in chronic ischemic heart disease. 25th anniversary of the German Magnesium Society, 4th German-Austrian-Swiss Magnesium Symposium, September 2002, Fulda, Germany.
 59. **Shechter M**, Matetzky S, Feinberg M, Chouraqui P, Rotstein Z, Hod H.
External counterpulsation therapy improves endothelial function in patients with severe coronary artery disease.
J Am Coll Cardiol, 2003,41:269A.

60. Goldenberg I, Jonas M, Matezki S, **Shechter M**, Agranat O, Har-Zahav Y, Guetta V. Contrast-associated nephropathy and clinical outcome of patients with chronic renal insufficiency undergoing cardiac catheterization: Lack of additive benefit to saline hydration. 52nd Annual Scientific Session of the American College of Cardiology, Orlando, Florida, USA, March 2003.
61. **Shechter M**, Feinberg MS, Matetzky S, Usmanov V, Freimark D. The impact of intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure. XXV Congress of the European Society of Cardiology, Vienna, Austria, August 2003.
62. **Shechter M**, Feinberg MS, Guetta V, Agranat O, Freimark D, Usmanov V, DiSegni E. Long-term L-arginine therapy improves endothelial function assessed by a brachial artery vasoreactivity testing in patients with normal coronary arteries. XXV Congress of the European Society of Cardiology, Vienna, Austria, August 2003.
63. **Shechter M**. Does magnesium have a role in the treatment of patients with coronary artery disease? 44th Annual Meetings of the American College of Nutrition, Nashville, USA (Invited Speaker), October 2003.
64. **Shechter M**, Freimark D, Usmanov V, Feinberg MS. Baseline brachial artery diameter is a predictor of endothelial function assessed by brachial artery vasoreactivity testing. 53rd Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, USA, March 2004.
65. **Shechter M**, Usmanov V, Stanislava G, Feinberg MS. Short-term sibutramine therapy improves flow-mediated endothelium-dependent vasodilation of the brachial artery in obese patients with coronary artery disease. Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2004.
66. Lavi T, Karasik A, Feinberg MS, **Shechter M**. Carbohydrate-based meals rapidly suppress flow-mediated endothelium-dependent vasodilation of the brachial artery in healthy volunteers. Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2004.
67. **Shechter M**, Usmanov V, Stanislava G, Feinberg MS. Reduced low-density lipoprotein cholesterol levels improve endothelial function in normal volunteers. Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2004.
68. **Shechter M**, Benderly M, Boyko V, Behar S, Jukema JW, Hellitz J, Eldar M. Abrupt withdrawal of statin therapy does not increase the risk of cardiac events or mortality in post myocardial infarction patients. Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2004.
69. Beigel R, Barenboim E, Sofer BA, Goldstein L, **Shechter M**.

- The efficacy and safety of statins for primary prevention of atherosclerosis in military air crew personnel in Israel.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2004.
70. Amitzur G, Chaleva N, Peleg E, Feldman S, Einav S, Leor J, Feinberg MS, Usmanov V, **Shechter M.**
A novel method for non-invasive assessment of endothelial and autonomic function.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2004.
71. **Shechter M.**
Endothelial function- a marker of cardiovascular disease risk. Indo-Israel Workshop on CAD. Gem-Heart Seminar. Jaipur, India, May 2004.
72. **Shechter M.**
The role of magnesium therapy in patients with coronary artery disease. Indo-Israel Workshop on CAD. Gem-Heart Seminar. Jaipur, India, May 2004.
73. **Shechter M.**
New developments in lipid lowering therapy – is lower cholesterol better? Indo-Israel Workshop on CAD. Gem-Heart Seminar. Jaipur, India, May 2004.
74. Stanislava G, Feinberg MS, Guetta V, Agranat O, Freimark D, Usmanov V, DiSegni E, **Shechter M.**
Long-term L-arginine therapy improves endothelial function assessed by a brachial artery vasoreactivity testing in patients with normal coronary arteries.
European Society of Echocardiography Meetings, Greece, 2004.
75. Freimark D, Koren-Morag N, Schwammenthal E, **Shechter M.**, Sela B, Fisman EZ, Weisman D, Adler A.
The impact of a supervised exercise and rehabilitation program on the relation between N-terminal pro brain natriuretic peptide and exercise tolerance.
XXV Congress of the European Society of Cardiology, Munich, Germany (Invited Chairman), August 2004.
76. Freimark D, Koren-Morag N, **Shechter M.**, Schwammenthal E, Sela B, Fisman EZ, Weisman D, Adler A.
Consistent improvement of exercise tolerance and survival in severe heart failure patients undergoing a long-term exercise and rehabilitation program.
XXV Congress of the European Society of Cardiology, Munich, Germany (Invited Chairman), August 2004.
77. **Shechter M.**, Usmanov V, Stanislava G, Feinberg MS.
Short-term sibutramine therapy improves flow-mediated endothelium-dependent vasodilation of brachial artery in obese patients with coronary artery disease.
XXV Congress of the European Society of Cardiology, Munich, Germany (Invited Chairman), August 2004.
78. Osherov A, Beinart R, Matetzky S, Hod H, Di Segni E, **Shechter M.**, Feinberg MS, Elian D.
Left ventricular apical ballooning – a case series in Israeli patients.

- XXV Congress of the European Society of Cardiology, Munich, Germany (Invited Chairman), August 2004.
79. **Shechter M.**
Magnesium in Chronic Ischemic Heart Disease. Gordon Research Conferences, Science J., Ventura, California, February 2005, USA.
80. Tenenbaum A, Freimark D, **Shechter M.**, Schwammenthal E, Fisman EZ, Tanne D, Elmaleh E, Motro M, Adler Y.
Long-term versus short-term exercise training in advanced heart failure: effects on clinical outcomes and exercise tolerance. The 69th Annual Scientific Meeting of the Japanese Circulation Society, March 2005, Japan.
81. Feinberg MS, Carasso S, Marai I, Sandach A, Kuperstein R, Freimark D, Guetta V, **Shechter M.**
The association between brachial artery flow-mediated vasodilation and left ventricular diastolic function.
European Association of Echocardiography, Florence, December 2005.
82. Lavi T, Karasik A, Feinberg MS, **Shechter M.**
The acute effect of various glycemic index carbohydrates.
XXVI Congress of the European Society of Cardiology, Stockholm, Sweden, August 2005.
83. Sandach A, **Shechter M.**, DavidZadeh O, Matetzky S, Guetta V, Hod H, Behar S, Snyder M, Schwammenthal E.
Prediction of all-cause mortality at 6 months in 30-day survivors of acute coronary syndrome: prospective validation of the ACSIS score.
XXVI Congress of the European Society of Cardiology, Stockholm, Sweden, August 2005.
84. Dvir D, Kornowski R, **Shechter M.**, Aravot D.
C-shaped versus Sigma-shaped right coronary artery: an association between morphology and atherosclerotic stenosis.
XXVI Congress of the European Society of Cardiology, Stockholm, Sweden, August 2005.
85. **Shechter M.**, Issachar A, Marai I, Koren Morag N, Freimark D, Matetzky S, Usmanov V, Gilman S, Feinberg MS.
Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with not apparent heart disease.
55th Annual Scientific Session of the American College of Cardiology, Atlanta, Georgia, USA, March 2006.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2006.
86. Carasso S, **Shechter M.**, Marai I, Sandach A, Issachar A, Kuperstein R, Freimark D, Guetta V, Feinberg MS.
The association between brachial artery flow-mediated vasodilation and left ventricular diastolic function.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2006.

87. Barsheshwt A, Hod H, **Shechter M**, Sharabani-Yosef O, Rosenthal E, Barabash IM, Matetzky S, Nagler A, Leor J.
External counter pulsation therapy (ECPT) increases number and function of circulating endothelial progenitor cells in patients with angina pectoris.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2006.
88. **Shechter M**, Arad M, Gershovitz L, Matetzky S, Langerman I, Koren Morag N, Hochenberg N, Makmal Y, Freimark D.
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality in refractory end-stage chronic heart failure patients.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2006.
89. **Shechter M**, Marai I, Marai S, Sherer Y, Sela BA, Feinberg MS, Rubinstein A, Shoenfeld Y.
Peripheral vascular endothelial function is associated with an increased risk of cardiovascular events in healthy subjects and patients with coronary artery disease.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2006.
90. **Shechter M**, Arad M, Gershovitz L, Matetzky S, Langerman I, Koren Morag N, Hochenberg N, Makmal Y, Freimark D.
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality in refractory end-stage chronic heart failure patients.
XXVII Congress of the European Society of Cardiology, Barcelona, Spain, August 2006.
91. Barsheshet A, Hod H, **Shechter M**, Sharabani-Yosef O, Rosenthal E, Barbash IM, Matetzky S, Tal R, Betancur AG, Sela B, Nagler A, Leor J.
The effects of external counter pulsation therapy on circulating endothelial progenitor cells in patients with angina pectoris.
56th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, USA, March 2007.
92. **Shechter M**, Marai I, Sherer Y, Feinberg MS, Shoenfeld Y, Inbal A.
Circulating endothelium- and platelet-derived microparticles in healthy subjects and patients with coronary artery disease.
56th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, USA, March 2007.
93. Freimark D, Arad M, Matetzky S, Gershovitz L, Langerman I, Koren Morag N, Hochberg N, Makmal Y, **Shechter M**.
Refractory end-stage chronic heart failure day care service: a five-year single center experience.
56th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, USA, March 2007.
94. **Shechter M**, Arbel Y, Usmanov V, Gilman S, Feinberg MS, Dvir D.
Pulse pressure ia a predictor of vascular endothelial function in healthy volunteers.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2007.
95. **Shechter M**, Marai I, Sherer Y, Feinberg MS, Shoenfeld Y, Inbal A.

- Circulating endothelium- and platelet derived microparticles in healthy subjects and patients with coronary artery disease.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2007.
96. **Shechter M.** Arad M, Matetzky S, Feinberg MS, Eizenberg N, Hochenberg N, Guttman M, Makmal Y, Freimark D.
Vascular endothelial function predicts mortality risk in patients with severe ischemic chronic heart failure.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2007.
97. **Shechter M.** Arbel Y, Feinberg MS, Eldar M, Koren Morag N, Eizenberg N, Usmanov V, Gilman S, Freimark D.
The effect of immune modulation therapy using the Celecade System on endothelial function in patients with severe chronic heart failure: data from the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) Trial.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2007.
98. **Shechter M.** Shechter A, Fefer P, Hod H, Feinberg MS, Usmanov V, Gilman S, Matetzky S.
The association between platelet function and endothelial function of the brachial artery in healthy subjects and in patients with coronary artery disease.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2007.
99. **Shechter M.** Sharabi Y, Marai I, Carasso S, Marai S, Peleg E, Kamari Y, Grossman E, Feinberg MS, Sela BA, Sherer Y, Shoenfeld Y.
The association of plasma adiponectin levels and forearm vascular endothelial function in healthy volunteers and patients with coronary artery disease.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2007.
100. **Shechter M.** Ginsberg S, Scheinowitz M, Feinberg MS, Laron Z.
Obese adults with primary hormone resistance (Laron Syndrome) have normal endothelial function.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2007.
101. **Shechter M.** Shechter A, Fefer P, Hod H, Feinberg MS, Usmanov V, Gilman S, Matetzky S.
The association between platelet function and endothelial function of the brachial artery in healthy subjects and in patients with coronary artery disease.
XXVIII Congress of the European Society of Cardiology, Vienna, Austria, September 2007.
102. **Shechter M.** Issachar A, Marai I, Koren Morag N, Shahar Y, Freimark D, Feinberg MS.
Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects.
XXVIII Congress of the European Society of Cardiology, Vienna, Austria, September 2007.
103. **Shechter M.** Arbel Y, Beigel R, Feinberg MS, Dvir D.
Pulse pressure is a predictor of vascular endothelial function in healthy volunteers.
XXVIII Congress of the European Society of Cardiology, Vienna, Austria, September 2007.
104. **Shechter M.** Arbel Y, Feinberg MS, Eldar M, Koren Morag N, Eizenberg N, Usmanov V, Gilman S, Freimark D.

- The effect of immune modulation therapy using on endothelial function in patients with severe chronic heart failure: data from the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) Trial.
XXVIII Congress of the European Society of Cardiology, Vienna, Austria, September 2007.
105. **Shechter M**, Ginsberg S, Scheinowitz M, Feinberg MS, Laron Z.
Obese adults with primary hormone resistance (Laron Syndrome) have normal endothelial function.
XXVIII Congress of the European Society of Cardiology, Vienna, Austria, September 2007.
106. **Shechter M**, Guetta V, Feinberg MS, Agranat O, Freimark D, Arad M, DiSegni E.
Oral L-arginine therapy improves endothelial dysfunction in patients with recurrent chest pain and normal coronary arteries.
XXVIII Congress of the European Society of Cardiology, Vienna, Austria, September 2007.
107. **Shechter M**.
Magnesium in Chronic Ischemic Heart Disease. Gordon Research Conferences, Science J. Ventura, California, February 2008, USA. Guest Lecturer.
108. **Shechter M**, Arbel Y, Feinberg MS, Eldar M, Koren Morag N, Eizenberg N, Usmanov V, Gilman S, Freimark D.
The effect of immune modulation therapy using on endothelial function in patients with severe chronic heart failure: data from the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) Trial.
57th Annual Scientific Session of the American College of Cardiology, Chicago, IL, USA, April 2008.
109. **Shechter M**, Arbel Y, Beigel R, Feinberg MS, Dvir D.
Pulse pressure is a predictor of vascular endothelial function in healthy volunteers.
57th Annual Scientific Session of the American College of Cardiology, Chicago, IL, USA, April 2008.
110. **Shechter M**, Arad M, Matetzky S, Feinberg MS, Eizenberg N, Hochenberg N, Guttman M, Makmal Y, Freimark D.
Vascular endothelial function predicts mortality risk in patients with severe ischemic chronic heart failure.
57th Annual Scientific Session of the American College of Cardiology, Chicago, IL, USA, April 2008.
111. Matetzky S, Fefer P, Shenkman B, **Shechter M**, Levi N, Varon D, Savion N, Hod H.
Platelet Responsiveness to Aspirin Loading in Patients With ST- Elevation Myocardial Undergoing Primary Percutaneous Intervention Is Associated With Myocardial Reperfusion and Clinical Outcome.
57th Annual Scientific Session of the American College of Cardiology, Chicago, IL, USA, April 2008.
112. **Shechter M**, Shechter A, Fefer P, Koren-Morag N, Hod H, Feinberg MS, Haratz D, Sela BA, Matetzky S.

- Brachial artery flow-mediated dilation predicts platelet function in healthy subjects and in patients with acute coronary syndrome.
XXVIX Congress of the European Society of Cardiology, Munich, Germany, September 2008.
113. Freimark D, Arad M, Matetzky S, Deneen I, Gershovitz L, Koren-Morag N, **Shechter M.**
An advanced chronic heart failure day care service: a five-year single center experience.
XXVIX Congress of the European Society of Cardiology, Munich, Germany, September 2008.
114. **Shechter M.** Issachar I, Marai I, Koren-Morag N, Shahar Y, Shechter A, Feinberg MS.
Brachial flow-mediated dilation is associated with long-term cardiovascular events in healthy subjects.
XXVIX Congress of the European Society of Cardiology, Munich, Germany, September 2008.
115. **Shechter M.** Hammerman H, Boyko V, Hod H, Behar S, Matetzky S.
The obesity paradox in acute coronary syndrome patients in Israel.
XXVIX Congress of the European Society of Cardiology, Munich, Germany, September 2008.
116. Matetzky S, Fefer P, Shenkman B, **Shechter M.** Levi N, Savion N, Hod H.
Platelet responsiveness to aspirin loading in patients with ST elevation MI undergoing percutaneous intervention is associated with myocardial reperfusion and clinical outcome.
50th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA, USA December 2008.
117. **Shechter M.** Hammerman H, Boyko V, Hod H, Behar S, Matetzky.
The obesity paradox in acute coronary syndrome patients in Israel.
58th Annual Scientific Session of the American College of Cardiology, Orlando, FL, USA, March 2009.
118. **Shechter M.** Arad M, Matetzky S, Feinberg MS, Freimark D.
Brachial artery endothelial function predicts mortality risk in patients with advanced ischemic chronic heart failure.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2009.
119. **Shechter M.** Roth A, Atar S, Boyko V, Behar S, Matetzky S.
Outcome of acute coronary syndrome octogenarian patients in Israel.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2009.
120. **Shechter M.** Shechter A, Hod H, Fefer P, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Matetzky S.
Brachial artery endothelial function predicts platelet function in healthy subjects and in patients with acute coronary syndrome.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2009.
121. **Shechter M.** Karasil A, Koren-Morag N, Kanety H, Feinberg MS, Lavi T.
The aute effect of various glycemic index dietary carbohydrates on endothelial function in non-diabetic overweight and obese subjects.
XXVIX Congress of the European Society of Cardiology, Barcelona, Spain, September 2009.
122. **Shechter M.** Matetzky S, Arad M, Feinberg MS, Freimark D.

- Vascular endothelial function predicts mortality risk in patients with advanced ischemic chronic heart failure.
XXVX Congress of the European Society of Cardiology, Barcelona, Spain, September 2009.
123. **Shechter M.** Roth A, Atar S, Boyko V, Behar S, Matetzky S.
Outcome of acute coronary syndrome octogenarian patients in Israel.
XXVX Congress of the European Society of Cardiology, Barcelona, Spain, September 2009.
124. **Shechter M.**
Beneficial effect of magnesium in acute medicine and cardiovascular field.
German Society of Magnesium Annual Meeting, Fulda, Germany, October 2009
125. **Shechter M.** Hirsch L, Koren-Morag N, Feinberg MS.
The impact of early compared to late morning hours on brachial endothelial function and long-term cardiovascular events in healthy subjects with no apparent coronary artery disease.
59th Annual Scientific Session of the American College of Cardiology, Atlanta, Georgia, USA, March 2010.
126. **Shechter M.**
Endothelial Dysfunction – A Marker of Atherosclerotic Risk.
16th International Vascular Biology Meeting, UCLA, Los Angeles, CA, USA June 2010.
Cardiology Grand Round, Cedars-Sinai Medical Center, Los Angeles, June 2010.
127. Beigel R, Dvir D, Arbel Y, Shechter A, Feinberg MS, **Shechter M.**
Pulse pressure is a predictor of vascular endothelial function in middle-aged subjects with no apparent heart disease.
XXVXI Congress of the European Society of Cardiology, Stockholm, Sweden, August 2010.
128. **Shechter M.** Shechter A, Hod Hm Shenkman B, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Savion N, Matetzky S.
Brachial artery endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction.
XXVXI Congress of the European Society of Cardiology, Stockholm, Sweden, August 2010.
129. **Shechter M.** Shalmon G, Sceinowitz M, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Sharabi Y, Chouraqui P.
The impact of caffeine on brachial endothelial function in healthy subjects and in patients with ischemic heart disease.
XXVXI Congress of the European Society of Cardiology, Stockholm, Sweden, August 2010.
130. **Shechter M.** Hirsch L, Koren-Morag N, Feinberg MS.
The impact of early compared to late morning hours on brachial endothelial function and long-term cardiovascular events in healthy subjects with no apparent heart disease.
XXVXI Congress of the European Society of Cardiology, Stockholm, Sweden, August 2010.
131. Arad M, Nussbaum T, Feinberg MS, **Shechter M.** Freimark D.
Prevalence and short-term implications of reverse remodeling in dilated cardiomyopathy.
XXVXI Congress of the European Society of Cardiology, Stockholm, Sweden, August 2010.

132. **Shechter M.**
Vascular endothelium: Pathophysiology, functional measurement and possible mechanisms of training effects. Annual Meeting of the Israel Society of Sports Medicine. Ramat Gan, October 2010
133. **Shechter M.**, Shechter A, Koren-Morag N, Issachar A, Marai I, Shahar Y, Feinberg MS, Hirsch L.
Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease.
60th Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA, April 2011. Received the ACC President Prize for best abstract received from Israel.
- 134.. **Shechter M.**
Endothelial dysfunction – the risk of the risk factors: the good, the bad and the target.
The 4th Complex Coronary Angioplasty Live Conference, Jaipur, India, April 2011.
135. Buber Y, Goldenberg I, Moss A, Eldar M, Glikson M, Bar-Sheshet A, **Shechter M.**
Statin use is associated with a reduction in VF/Fast VT in NICM patients. Insights from MADIT-CRT.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2011.
136. Beigel R, Fefer P, Shenkman B, **Shechter M.**, Gannot S, Hod H, Matetzky S.
Assessment of platelet reactivity in ACS patients treated with double-dose clopidogrel.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2011.
137. **Shechter M.**
Lipid Therapy in Special Populations at High Cardiovascular Risk. Israel Heart Society Meeting, July 2011, Tiberias, Israel.
138. Buber Y, Goldenberg I, Moss A, Eldar M, Glikson M, Barsheshet A, **Shechter M.**
Treatment with statins Statin is associated with a reduction in ventricular fibrillation and fast ventricular tachycardia in patients with non ischemic cardiomyopathy.
XXVXII Congress of the European Society of Cardiology, Paris, France, August 2011.
139. **Shechter M.**
Trial eligible ACS patients – do they understand informed consent form?
7th International Meeting on Intensive Cardiac Care, Tel Aviv, October 2011.
140. Hirsch L, Shechter A, Koren-Morag N, Feinberg MS, **Shechter M.**
The association of brachial artery flow-mediated vasodilation and long-term cardiovascular events in middle-aged subjects without heart disease.
Israel Heart Society Annual Scientific Meetings 2013.
141. **Shechter M.**, Saad T, Shechter A, Koren-Morag N, Matetzky S.
Short-term magnesium oxide monohydrate treatment improves lipids and inflammation in healthy subjects.
Israel Heart Society Annual Scientific Meetings 2013.
142. **Shechter M.**, Shechter A, Koren-Morag N, Feinberg MS, Hirsch L.

- Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease.
XXV Congress of the European Society of Cardiology, Amsterdam, Netherlands, August 2013.
143. **Shechter M.**
Take Home Message and Conclusions, Effective Communication and Facing the Complicated Patient Unresponsive to Standard Medical Therapy.
Cardiology Meeting of the Israel Heart Society Working Group of Cardiology in the Community, Working Group of Epidemiology and Cardiovascular Prevention and Working Group of Cardiovascular Pharmacology and Drug Therapy.
Dan Accadia, Israel, December 2013.
144. **Shechter M.**
Endothelial function and dysfunction - from basic science to clinical practice.
Israel Heart Society Winter Meeting, Eilat, Israel, January 2014.
145. **Shechter M.**
Magnesium in cardiology: an old friend revisited. 51st ERA-EDTA Congress.
Amsterdam, June 2014 (Invited Speaker and Chair of the Symposium 5: “Magnesium: opportunities in kidney disease”).
146. **Shechter M.**
Magnesium for cardiovascular disease treatment and prevention.
International Forum of Magnesium for Health Prevention Seminar. San Francisco Airport Marriott Hotel, Burlingame, CA, USA, January 17-18, 2015.
147. **Shechter M.**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Mortality rates from acute coronary syndrome in octogenarian patients in Israel during the period 2000-2006 compared to 2008-2013.
64th Annual Scientific Session of the American College of Cardiology, San Diego, CA, USA, March 2015.
148. **Shechter M.**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Trends in mortality rates from acute coronary syndrome octogenarian patients in Israel during the period 2000-2013.
64th Annual Scientific Session of the American College of Cardiology, San Diego, CA, USA, March 2015.
149. **Shechter M.**, Saad T, Shechter A, Koren-Morag N, Matetzky S.
Short-term magnesium oxide monohydrate treatment improves lipids and inflammation in healthy subjects.
64th Annual Scientific Session of the American College of Cardiology, San Diego, CA, USA, March 2015.
150. **Shechter M.**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Peripheral endothelial function predicts 1-year adverse clinical outcome in patients hospitalized in the emergency department.

- 67th Annual Scientific Session of the American College of Cardiology, Orlando, FL, USA, March 2015.
151. Cohen H, Bitzur R, **Shechter M**, Harats D, Modan D.
Cardiovascular risk assessment and carotid intima-media thickness in young adults, survivors of Hodgkin's lymphoma.

The 17th Triennial Congress of the International Atherosclerosis Society (ISA) Meeting, May 2015, Amsterdam, The Netherlands.
152. **Shechter M**.
Endothelila function – now ready for clinical practice.
Satelite symposium on Clinical Application of Vascular Endothelial Function Detecting Techniques. The 17th Scientific Annual Congress of Chinese Society of Cardiology and the 9th Oriental Congress of Cardiology, Shanghai, China, Sep 2015.
153. Shlezinger M, **Shechter M**, Goldenberg I, Amital Y.
The association of desalinated drinking water and all-cause mortality in hospitalized patients with acute myocardial infarction from the Acute Coronary Syndrome Israeli Survey 2002-2013.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2016.
154. **Shechter M**, Shlezinger M, Amity Y, Goldenberg I.
Temporal trends in all cause mortality patients with acute myocardial infarction in regions with compared to without desalinated drinking water from the Acute Coronary Syndrome Israeli Survey (ACSIS).
Annual Congress of the European Society of Cardiology, London, United Kingdom, August 2015.
155. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Trend in mortality rates from acute coronary syndrome in octogenarian patients in Israel during the period 2000-2006 compared to 2008-2013.
Annual Congress of the European Society of Cardiology, London, United Kingdom, August 2015.
156. **Shechter M**, Shechter A, Hod H, Beigel R, Koren-Morag N, Matetzky S.
Usefulness of brachial flow-mediated dilation and platelet function to predict long-term events in subjects without heart disease.
Annual Congress of the European Society of Cardiology, London, United Kingdom, August 2015.
157. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Outcome of acute coronary syndrome octogenarian patients in Israel.
Annual Congress of the European Society of Cardiology, London, United Kingdom, August 2015.
158. **Shechter M**.
Novel approaches for the prevention of cardiovascular atherosclerotic diseases.
Cardiology Course, Chaim Sheba Medical Center, Israel-Poland, July 12, 2016.

159. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Endothelial function predicts 1-year clinical outcome in patients hospitalized in chest pain unit.
American Heart Association Scientific Sessions, New Orleans, Louisiana, USA,
Nov 12-16, 2016.
160. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Endothelial function predicts 1-year clinical outcome in patients hospitalized in chest pain unit.
Annual Congress of the European Society of Cardiology, Rome, Italy, August 2016.
161. Shlezinger M, Amital Y, Goldenberg I, **Shechter M**.
The association of desalinated drinking water and all-cause mortality in hospitalized patients
with acute myocardial infarction from the Acute Coronary Syndrome Israeli Survey 2002-
2013.
The 21st annual meeting of the Israeli Society for Research, Prevention & Treatment of
Atherosclerosis. October 27-30, Haifa, Israel, 2016.
162. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Endothelial function predicts 1-year clinical outcome in patients hospitalized in chest pain unit.
American Heart Association Scientific Sessions, New Orleans, Louisiana, USA,
Nov 12-16, 2016.
163. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Peripheral endothelial function predicts 1-year adverse clinical outcome in patients hospitalized
in the emergency department.
67th Annual Scientific Session of the American College of Cardiology, Orlando, FL, USA,
March 2018.

D.3. **Abstracts and Proceedings**

1. **Shechter M**, Hod H, Mrks N, Behar S, Kaplinsky E, Rabinowitz B.
Magnesium therapy and mortality in acute myocardial infarction.
Eur Heart J 1988;9:226.
2. **Shechter M**, Hod H, Behar S, Kaplinsky E, Rabinowitz B.
Magnesium therapy and mortality in acute myocardial infarction.
Israel J Med Sci 1988;24:440.
3. **Shechter M**, Hod H, Behar S, Kaplinsky E, Rabinowitz B.
Effect of magnesium sulfate on mortality in patients with acute myocardial infarction
complicated by pump failure.
1st International Symposium on Heart Failure - Mechanisms and Management 1989;318.
4. **Shechter M**.
Beneficial effect of magnesium in acute myocardial infarction - a review of the literature.
Magnesium Res 1989;2:292.

5. **Shechter M.**
Gunstige Magnesium - Wirkung beim akuten Myokardinfarktein Literature -
uberblick.
Magnesium Bull 1989;11:184.
6. **Shechter M,** Hod H, Modan M, Kaplinsky E, Rabinowitz B.
New ECG sign during the first hour of thrombolysis: its significance in relation to ejection
fraction.
Isr J Med Sci 1990;26:226.
7. **Shechter M,** Hod H, Modan M, Kaplinsky E, Rabinowitz B.
New electrocardiographic sign during the first hour of thrombolysis: its significance in relation
to ejection fraction.
Eur Heart J 1990;11:354.
8. **Shechter M.**
Beneficial effect of magnesium in acute myocardial infarction. A review of the literature.
Magnesium Res 1990;155:73.
9. **Shechter M.**
Beneficial effect of magnesium sulfate in acute myocardial infarction.
Cardiol Digest 1991;1:30.
10. **Shechter M,** Hod H, Kaplinsky E, Rabinowitz B.
Magnesium administration in patients with acute myocardial infarction who are not candidates
for thrombolytic therapy.
Eur Heart J 1991;12:401.
11. **Shechter M,** Hod H, Kaplinsky E, Rabinowitz B.
Magnesium administration in patients with acute myocardial infarction who are not candidates
for thrombolytic therapy.
Magnesium 1991;9:333.
Magnesium Res 1991;4:243.
12. **Shechter M**
Magnesium sulfate in acute myocardial infarction.
Magnesiocard Symposium, Frankfurt, Germany, February 1991.
Magnesium Workshop in Cardiology. Cardiac Center, University Hospital of Geneva,
Switzerland, February 1992 (Guest Lecturer).
Magnesium Workshop in Cardiology. University of Bern, Switzerland, February 1992.
13. **Shechter M,** Hod H, Kaplinsky E, Rabinowitz B.
Magnesium reduces mortality in acute myocardial infarction in patients unsuitable for
thrombolytic therapy.
IV European Congress on Magnesium. September 1992, Gissen, Germany (Guest Lecturer and
Chairman of Cardiology Session).
14. **Shechter M,** Kaplinsky E, Rabinowitz B.
Magnesium in AMI patients who are unsuitable for thrombolysis.

- Gordon Research Conferences. Los Angeles, February 1992, USA.
15. **Shechter M**, Kaplinsky E, Rabinowitz B
Magnesium in myocardial infarction and arrhythmias.
Medica, November 1992, Dusseldorf, Germany.
 16. **Shechter M**, Kaplinsky E, Rabinowitz B.
Magnesium reduces mortality in myocardial infarction.
4th International Conference on Non-Invasive Cardiology. Cyprus, 1993;91.
Am J Card Imaging, 1994.
 17. **Shechter M**, Hod H, Kaplinsky E, Rabinowitz B.
Intravenous magnesium as alternative therapy in acute myocardial infarction patients unsuitable for thrombolytic therapy.
4th International Conference on Non-Invasive Cardiology. Cyprus 1993:111.
Am J Card Imaging 1994.
 18. **Shechter M**, Hod H, Kaplinsky E, Rabinowitz B.
Magnesium as alternative therapy in acute myocardial infarction patients unsuited for thrombolysis.
Circulation 1993;88:I-394.
 19. **Shechter M**.
Intravenous magnesium supplementation in AMI patients.
Gordon Research Conferences: Magnesium in Biochemical Process. Los Angeles, CA, February 1993, USA.
 20. **Shechter M**.
Magnesium Therapy – State of the Art. New strategies based on LIMIT-2 and ISIS-4. Vienna university Clinics (AKH), June 1994, Austria.
 21. **Shechter M**.
The role of magnesium in AMI. Munchener Medizinische Wochenschrift Editorial Forum.
“Magnesium-the Established, the Dubious and the Speculative”. Munich, Germany, 1995.
 22. **Shechter M**, Hod H, Kaplinsky E, Chouraqui P, Rabinowitz B.
Magnesium als Alternativtherapie bei Patienten mit akuten Myocardinfarkt und Kontraindikationen für eine thrombolytische Therapie.
J Mineralstoffwechsel 1995;3:28.
 23. **Shechter M**.
Magnesium in acute myocardial infarction without thrombolytic therapy. State of the Art. 5th European Magnesium Congress. Vienna, June 1995, Austria.
Magnesium Res 1995;8:63.
 24. Chouraqui P, **Shechter M**, Livchitz S, Rabinowitz B, Brill Z, DiSegni E.
Significance of distal reversibility in infarct territory as determined by SPECT Talium-201: A sign of collateral flow with occluded infarct-related coronary artery.
Israel J Med Sci 1996;32:S-17.

25. Chouraqui P, **Shechter M.**, Livchitz S, Rabinowitz B, Brill Z, DiSegni E. Significance of distal reversibility in infarct territory as determined by SPECT Talium-201: A sign of collateral flow with occluded infarct-related coronary artery. Circulation 1996;94:I-205.
26. **Shechter M.**, Bairey Merz CN, Rude RK, Paul-Labrador M, Meisel S, Molloy MD, Cercek B, Shah PK, Kaul S. Low intracellular magnesium levels promote platelet-dependent thrombus formation in patients with coronary artery disease.
- J Am Coll Cardiol 1997;29: 179A.
- American Heart Association Laverna Titus Young Investigators Forum, Los Angeles, CA, USA, May 28, 1999.
27. **Shechter M.**, Merz Bairey N, Paul-Labrador M, Rude RK. Intracellular magnesium predicts functional capacity in patients with coronary artery disease. J Am Coll Cardiol, 1997;29: 379A.
28. **Shechter M.**, Bairey Merz CN, Paul Labrador M, Molloy MD, Agarwala A, Kaul S. Fasting blood sugar is related to platelet-dependent thrombosis in patients with coronary artery disease and controlled lipid levels. Circulation 1997;96:I-438.
29. **Shechter M.**, Bairey Merz CN, Paul-Labrador M, Molloy MD, Cercek B, Shah PK, Kaul S. Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 1998;31:146A.
30. **Shechter M.**, Bairey Merz CN, Meisel SR, Paul-Labrador M, Molloy MD, Agarwala A, Cercek B, Shah PK, Kaul S. Oral magnesium supplementation reduces platelet-dependent thrombosis in patients with coronary artery disease. 6th European Magnesium Congress, May 1998, Budapest, Hungary.
31. **Shechter M.**, Meisel SR, Bairey Merz CN, Paul-Labrador M, Cercek B, Shah PK, Kaul S. Protective effects of magnesium against monocyte-associated tissue factor procoagulant activity in patients with coronary artery disease. 6th European Magnesium Congress, May 1998, Budapest, Hungary.
32. **Shechter M.**, Paul-Labrador M, Rude RK, Merz Bairey CN. Intracellular magnesium predicts functional capacity in patients with coronary artery disease. 6th European Magnesium Congress, May 1998, Budapest, Hungary.
33. **Shechter M.**, Bairey Merz CN, Rude RK, Paul-Labrador M, Meisel SR, Molloy MD, Cercek B, Shah PK, Kaul S. Low intracellular magnesium levels promote platelet-dependent thrombus formation in patients with coronary artery disease. 6th European Magnesium Congress, May 1998, Budapest, Hungary.

34. **Shechter M**, Bairey Merz CN, Paul-Labrador M, Meisel SR, , Molloy MD, Dwyer J, Shah PK, Kaul S.
Oral magnesium supplementation reduces platelet-dependent thrombosis in patients with coronary artery disease.
Gordon Research Conferences, January 1999, Ventura, CA, USA.
35. **Shechter M**, Merz Bairey N, Paul-Labrador M, Rude RK
Intracellular magnesium predicts functional capacity in patients with coronary artery disease.
Gordon Research Conferences, January 1999, Ventura, CA, USA.
36. **Shechter M**, Sharir M, Forrester JS, Bairey Merz CN.
Is there a benefit to lowering low-density lipoprotein below 100 mg/dl in patients with coronary artery disease?
J Am Coll Cardiol 1999;33:271A.
37. **Shechter M**, Bairey Merz CN, Paul-Labrador M, Molloy MD, Meisel SR, Shah PK, Kaul S.
Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease.
Israel Heart Society J, 1999;Suppl:23.
38. **Shechter M**, Sharir M, Forrester JS, Bairey Merz CN.
Is there a benefit to lowering low-density lipoprotein below 100 mg/dl in patients with coronary artery disease?
Israel Heart Society J, 1999;Suppl:47.
39. **Shechter M**, Bairey Merz CN, Paul-Labrador M, Meisel SR, Molloy MD, Rude RK, Shah PK, Kaul S.
Oral magnesium supplementation reduces platelet-dependent thrombosis in patients with coronary artery disease.
Israel Heart Society J, 1999;Suppl:54.
40. **Shechter M**, Sharir M, Platt LD, Forrester JS, Bairey Merz CN.
Is vessel flow or diameter a better measure of endothelial-dependent vasoreactivity?
Israel Heart Society J, 1999;Suppl:62.
41. **Shechter M**.
The Rationale of Magnesium as Antithrombotic Treatment for Patients with Coronary Artery disease in (Invited Lecture).
J Intern Academy Cardiol 1999;1:24.
42. **Shechter M**, C.N. Bairey Merz, M. Paul-Labrador, M.D. Molloy, R.K. Rude, P.K. Shah, S. Kaul.
Oral magnesium supplementation reduces platelet-dependent thrombosis in patients with coronary artery disease.
Eur Hear J 1999;20:237.
43. **Shechter M**, M. Paul-Labrador, C.N. Bairey Merz, S. Kaul.

- Serum glucose but not insulin modulates platelet-dependent thrombosis in patients with coronary artery disease.
Eur Heart J 1999;20:68.
44. **Shechter M**, M. Paul-Labrador, C.N. Bairey Merz, S. Kaul.
Serum glucose but not insulin modulates platelet-dependent thrombosis in patients with coronary artery disease.
J Am Coll Cardiol 2000;35:281A
45. **Shechter M**, Paul-Labrador M, Bairey Merz CN, Kaul sanjay.
Blood glucose and platelet-dependent thrombosis in coronary artery disease.
J Israel Heart Soc 2000;Suppl:56.
46. **Shechter M**, Hod H, Rabinowitz B, Boyko V, Kaplinsky E, Chouraqui P.
Long-term outcome in thrombolysis-ineligible acute myocardial infarction patients treated with intravenous magnesium.
J Israel Heart Soc 2000;Suppl:2.
47. **Shechter M**, Sharir M, Forrester J, Silver B, Bairey Merz CN.
Intracellular magnesium predict flow-mediated brachial artery vasoreactivity in patients with coronary artery disease.
J Israel Heart Soc 2000;Suppl:28.
48. **Shechter M**, Sharir M, Paul-Labrador M, Forrester J, Silver B, Bairey Merz CN.
Oral magnesium improves endothelial function in patients with coronary artery disease.
J Israel Heart Soc 2000;Suppl:3.
49. Ben Zvi S, Hod H, Agranat O, Drory Y, Kaplinsky E, **Shechter M**.
Back to active life after acute myocardial infarction – do patients want to know?
- J Israel Heart Soc 2000;Suppl:57.
- International Symposium on Intensive Care, Jerusalem, June 2000
50. **Shechter M**.
The rationale of magnesium as antithrombotic treatment for patients with coronary artery disease.
J Heart Failure 2000;6:34.
51. **Shechter M**, Bairey Merz CN, Stuhlinger HG, Sharir M, Matezky S, Pachinger O, Rabinowitz B.
Oral magnesium supplementation improves exercise duration and quality of life in patients with coronary artery disease.
Sheba Medical Center Research Day Abstract Book 2000.
52. **Shechter M**, Hod H, Rabinowitz B, Boyko V, Kaplinsky E, Chouraqui P.
Long-term outcome in thrombolysis-ineligible acute myocardial infarction patients treated with intravenous magnesium.
Sheba Medical Center Research Day Abstract Book 2000.

53. Ben Zvi S, Hod H, Agranat O, Drory Y, Kaplinsky E, **Shechter M.**
Back to active life after acute myocardial infarction – do patients want to know?
Sheba Medical Center Research Day Abstract Book 2000.
54. **Shechter M.** Sharir M, Paul-Labrador M, Forrester J, Silver B, Bairey Merz CN.
Oral magnesium improves endothelial function in patients with coronary artery disease.
Sheba Medical Center Research Day Abstract Book 2000.
55. **Shechter M.** Sharir M, Paul-Labrador M, Forrester J, Silver B, Bairey Merz CN.
Oral magnesium improves endothelial function in patients with coronary artery disease.
Circulation 2000;102:II-56.
56. **Shechter M.** Bairey Merz CN, Stuehlinger H-G, Slany J, Pachinger O, Rabinowitz B. Oral magnesium supplementation improves exercise duration and quality of life in patients with coronary artery disease.
J Am Coll Cardiol 2001;37:149A
57. **Shechter M.**
The role of magnesium as antithrombotic therapy.
Magnesium Res 2001;14:109
59. **Shechter M.** Hod H, Rabinowitz B, Boyko V, Chouraqui P. Long-term outcome in thrombolysis-ineligible acute myocardial infarction patients treated with intravenous magnesium.
Eur Heart J 2001;22:667.
60. **Shechter M.** Bairey Merz CN, Stuehlinger H-G, Slany J, Pachinger O, Rabinowitz B.
Oral magnesium supplementation improves exercise tolerance, exercise-induced angina and quality of life in patients with coronary artery disease.
Magnesium Res 2001.
61. **Shechter M.** Hod H, Rabinowitz B, Boyko V, Chouraqui P.
Long-term outcome in thrombolysis-ineligible acute myocardial infarction patients treated with intravenous magnesium.
Circulation 2001;104:II-744-5.
62. **Shechter M.** Bairey Merz CN, Stuehlinger HG, Slany J, Pachinger O, Sharir M, Matezki S, Rabinowitz B.
Oral magnesium supplementation improves exercise duration and quality of life in patients with coronary artery disease.
Isr. Heart J (Supp) 2001:69.
62. Marom RK, Klainman E, Shechter M, Grodginovsky A, Hoberfeld F, Drory Y.
Survey of cardiac rehabilitation service in Israel.
Isr. Heart J (Supp) 2001:15.
64. **Shechter M**
Effect of dobutamine on endothelial function in severe chronic heart failure.

Sackler Medical School Research Day, Tel Aviv University, Israel, March 2002.

65. **Shechter M.** Feinberg M, Matetzky S, Freimark D.
Abnormal vascular responses in chronic severe heart failure are both endothelium-dependent and -independent.
Isr Heart J, 2002, Suppl. 1:19
66. **Shechter M.** Feinberg M, Matetzky S, Freimark D.
The impact of intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure.
Isr Heart J, 2002, Suppl. 1:51.
67. **Shechter M.** Matetzky S, Feinberg M, Chouraqui P, Rotstein Z, Hod H.
Endothelial function in patients with severe coronary artery disease treated with enhanced counterpulsation therapy (ECPT).
Isr Heart J, 2002, Suppl. 1:66.
68. **Shechter M.** Matetzky S, Feinberg M, Chouraqui P, Rotstein Z, Hod H.
Endothelial function in patients with severe coronary artery disease treated with enhanced counterpulsation therapy (ECPT).
Eur Heart J, 2002;23:463.
69. **Shechter M.** Feinberg M, Matetzky S, Freimark D.
The impact of intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure.
Eur Heart J, 2002;23:712.
70. **Shechter M.**
Benefits of magnesium in chronic ischemic heart disease. 25th anniversary of the German Magnesium Society, 4th German-Austrian-Swiss Magnesium Symposium, September 2002, Fulda, Germany. Abstract Book.
71. **Shechter M.**
Magnesium therapy in patients with chronic ischemic heart disease. Current status and future studies. 2nd Scientific Conference of the Israel Society of Magnesium Research in Biology and Medicine. Sackler Faculty of Medicine, Tel Aviv University, October 2002, Israel.
Mag Res 2003;16:140.
72. **Shechter M.**
Results of Magnesium in Coronaries (MAGIC) Trial. 2nd Scientific Conference of the Israel Society of Magnesium Research in Biology and Medicine. Sackler Faculty of Medicine, Tel Aviv University, October 2002, Israel.
Magnesium Res 2003;16:140.
73. **Shechter M.**
Non-invasive assessment of endothelial function: diagnosis and treatment.
Primary care physicians and cardiologists, Macabi Health Services, Ramat Gan, November 2002, Israel.

74. **Shechter M.**
High cholesterol - an increased risk for coronary artery disease in diabetic patients.
National Israel Diabetic Faire, November 2002
75. **Shechter M.**, Matetzky S, Feinberg M, Chouraqui P, Rotstein Z, Hod H.
External counterpulsation therapy improves endothelial function in patients with severe coronary artery disease.
J Am Coll Cardiol, 2003,41:269A.
76. Goldenberg I, Jonas M, Matezki S, **Shechter M.**, Agranat O, Har-Zahav Y, Guetta V. Contrast-associated nephropathy and clinical outcome of patients with chronic renal insufficiency undergoing cardiac catheterization: Lack of additive benefit to saline hydration.
J Am Coll Cardiol, 2003,41:537A
77. Peleg E, **Shechter M.**, Einav S, Feinberg MS, Usmanov V, Leor J, Amitzur G.
A novel method of non-invasive assessment of endothelial function: Comparison with Brachial Artery Reactivity Test.
Israel Heart Society Abstract Book 2003:36.
78. **Shechter M.**, Freimark D, Usmanov V, Feinberg MS.
Is vessel diameter is a predictor of endothelial function assessed by Brachial Artery Vasoreactivity Testing?
Israel Heart Society Abstract Book 2003:59.
79. **Shechter M.**, Usmanov V, Feinberg MS.
The favorable impact of female gender on endothelial function assessed by Brachial Artery Vasoreactivity Testing (BRT).
Israel Heart Society Abstract Book 2003:64.
80. **Shechter M.**, Matetzky S, Hochberg N, Freimark D.
Refractory end-stage chronic heart failure day care service: a two-year single center experience,
Israel Heart Society Abstract Book 2003:7.
81. **Shechter M.**, Feinberg MS, Guetta V, Agranat O, Freimark D, Usmanov V, DiSegni E.
Long-term L-arginine therapy improves endothelial function assessed by a Brachial Artery Reactivity Testing in patients with normal coronary arteries.
Israel Heart Society Abstract Book 2003:69.
82. Goldenberg I, Jonas M, Matezki S, **Shechter M.**, Agranat O, Har-Zahav Y, Guetta V. Contrast-associated nephropathy and clinical outcome of patients with chronic renal insufficiency undergoing cardiac catheterization: Lack of additive benefit to saline hydration.
Israel Heart Society Abstract Book 2003:60.
83. Rosman J, Matetzky S, **Shechter M.**, Feinberg MS, Chouraqui P, Rotstein Z, Hod H.
External counterpulsation therapy in refractory angina long term follow-up.
Israel Heart Society Abstract Book 2003:59.
84. **Shechter M.**, Freimark D, Usmanov V, Feinberg MS.

- Does lowering Low-Density Lipoprotein Cholesterol to below 100 mg/dl benefit patients with coronary artery disease?
Israel Heart Society Abstract Book 2003:83.
85. Cerceck B, Shah PK, Noc M, Zahger D, Matetzky S, **Shechter M**, Zeymer U, Maurer G, Mahrer P.
The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome: the AZACS (AZithromycin in Acute Coronary Syndrome) Trial.
Israel Heart Society Abstract Book 2003:6.
86. **Shechter M**, Feinberg MS, Matetzky S, Usmanov V, Freimark D.
The impact of intermittent intravenous dobutamine therapy on endothelial function in patients with severe chronic heart failure.
Eur Heart J 2003, 24:239.
87. **Shechter M**, Feinberg MS, Guetta V, Agranat O, Freimark D, Usmanov V, DiSegni E.
Long-term L-arginine therapy improves endothelial function assessed by a brachial artery vasoreactivity testing in patients with normal coronary arteries.
Eur Heart J 2003;24:214.
88. **Shechter M**.
Does magnesium have a role in the treatment of patients with coronary artery disease?
J Am Coll Nut 2003;22:472.
89. **Shechter M**, Freimark D, Usmanov V, Feinberg MS.
Baseline brachial artery diameter is a predictor of endothelial function assessed by brachial artery vasoreactivity testing.
J Am Coll Cardiol 2004;43:451A
89. **Shechter M**, Usmanov V, Stanislava G, Feinberg MS.
Short-term sibutramine therapy improves flow-mediated endothelium-dependent vasodilation of the brachial artery in obese patients with coronary artery disease.
Israel Heart Society Abstract Book 2004:18.
91. Lavi T, Karasik A, Feinberg MS, **Shechter M**.
Carbohydrate-based meals rapidly suppress flow-mediated endothelium-dependent vasodilation of the brachial artery in healthy volunteers.
Israel Heart Society Abstract Book 2004:59.
92. **Shechter M**, Usmanov V, Stanislava G, Feinberg MS.
Reduced low-density lipoprotein cholesterol levels improve endothelial function in normal volunteers.
Israel Heart Society Abstract Book 2004:79.
93. **Shechter M**, Benderly M, Boyko V, Behar S, Jukema JW, Hellitz J, Eldar M.
Abrupt withdrawal of statin therapy does not increase the risk of cardiac events or mortality in post myocardial infarction patients.
Israel Heart Society Abstract Book 2004:59.

94. Beigel R, Barenboim E, Sofer BA, Goldstein L, **Shechter M.**
The efficacy and safety of statins for primary prevention of atherosclerosis in military air crew personnel in Israel.
Israel Heart Society Abstract Book 2004:34.
95. Amitzur G, Chaleva N, Peleg E, Feldman S, Einav S, Leor J, Feinberg MS, Usmanov V, **Shechter M.**
A novel method for non-invasive assessment of endothelial and autonomic function.
Israel Heart Society Abstract Book 2004:35.
96. Osherov A, Beinart R, Metetzky S, Hod H, Di Segni E, **Shechter M.**, Feinberg M, Elian D.
Left ventricular apical ballooning – a case series in Israeli patients.
Israel Heart Society Abstract Book 2004:53.
97. Freimark D, Koren-Morag N, Schwammenthal E, **Shechter M.**, Sela B, Fisman EZ, Weisman D, Adler A.
The impact of a supervised exercise and rehabilitation program on the relation between N-terminal pro brain natriuretic peptide and exercise tolerance.
Eur Heart J 2004;25:321.
98. Freimark D, Koren-Morag N, **Shechter M.**, Schwammenthal E, Sela B, Fisman EZ, Weisman D, Adler A.
Consistent improvement of exercise tolerance and survival in severe heart failure patients undergoing a long-term exercise and rehabilitation program.
Eur Heart J 2004;25:609.
99. **Shechter M.**, Usmanov V, Stanislava G, Feinberg MS.
Short-term sibutramine therapy improves flow-mediated endothelium-dependent vasodilation of brachial artery in obese patients with coronary artery disease.
Eur Heart J 2004;25:96.
100. Osherov A, Beinart R, Matetzky S, Hod H, Di Segni E, **Shechter M.**, Feinberg MS, Elian D.
Left ventricular apical ballooning – a case series in Israeli patients.
Eur Heart J 2004;25:294.
101. Gilman S, Feinberg MS, Guetta V, Agranat O, Freimark D, Usmanov V, DiSegni E, **Shechter M.**
Long-term L-arginine therapy improves endothelial function assessed by a brachial artery vasoreactivity testing in patients with normal coronary arteries.
Eur J Echo 2004;.
102. Tenenbaum A, Freimark D, **Shechter M.**, Schwammenthal E, Fisman EZ, Tanne D, Elmaleh E, Motro M, Adler Y.
Long-term versus short-term exercise training in advanced heart failure: effects on clinical outcomes and exercise tolerance.
Jap Circ, 2005.
103. Lavi T, Karasik A, Feinberg MS, **Shechter M.**

The acute effect of various glycemic index dietary carbohydrates on endothelial function in normoglycemic vs impaired glucose tolerance subjects.
Israel Heart Society Abstract Book 2005:8.

104. Matetzky S, Shenkman B, Fefer P, **Shechter M**, Savion N, Varon D, Hod H.
Statin confer a direct anti-platelet effect in patients with acute myocardial infarction undergoing primary PCI: ex-vivo study results.
Israel Heart Society Abstract Book 2005:10.
105. Amitzur G, Chaleva N, Peleg E, Einav S, Feinberg MS, Usmanov V, **Shechter M**.
A novel non-invasive method for endothelial function evaluation by modified cold pressor test: comparison with high-resolution ultrasound.
Israel Heart Society Abstract Book 2005:18.
106. Arad M, Lahat H, Feinberg MS, Matetzky S, **Shechter M**, Freimark D.
The role of genetic evaluation in heart failure management.
Israel Heart Society Abstract Book 2005:24.
107. **Shechter M**, Issachar A, Dvir D, Arbel Y, Beigel R, Freimark D, Usmanov V, Gilman S, Feinberg MS.
Early morning attenuation of endothelial function in healthy humans.
Israel Heart Society Abstract Book 2005:77.
108. **Shechter M**, Schwammenthal Y, Merzeliak O, Feinberg MS, Philips T, Usmanov V, Tsabari R, Chapman Y, Gilman S, Tanne D.
Short-term improvement of endothelial function assessed by brachial artery vasoreactivity in patients following acute ischemic stroke.
Israel Heart Society Abstract Book 2005:78.
109. **Shechter M**, Feinberg MS, Guetta V, Agranat O, Freimark D, Usmanov V, Gilman S, DiSegni E.
Oral L-arginine therapy improves endothelial dysfunction in patients with recurrent chest pain and normal coronary arteries.
Israel Heart Society Abstract Book 2005:45.
110. Beinart R, Matetzky S, Rosen E, **Shechter M**, Hod H, Chouraqui P.
Clinical significance of exercise-induced ST segment elevation in patients without prior Q wave myocardial infarction
Israel Heart Society Abstract Book 2005:57.
111. **Shechter M**, Marai I, Sherer Y, Marai S, Langevitz P, Sela BA, Feinberg MS, Shoenfeld Y.
Age is the single most significant coronary artery disease risk factor associated with flow-mediated vasodilation of the brachial artery in humans.
Israel Heart Society Abstract Book 2005:95.
112. **Shechter M**, Sharabi Y, Marai I, Carasso S, Marai S, Peleg E, Kamari E, Grossman E, Feinberg MS, Sela BA, Sherer Y, Shoenfeld Y.
The association of plasma adiponectin levels and forearm vascular endothelial function in healthy volunteers and patients with coronary artery disease.

- Israel Heart Society Abstract Book 2005:96.
113. **Shechter M**, Issachar A, Mrai I, Koren Morag N, Freimark D, Matetzky S, Potashnik Y, Feinberg MS.
Prognostic value of flow-mediated vasodilation of the brachial artery in humans.
Israel Heart Society Abstract Book 2005:93.
114. **Shechter M**, Issachar A, Dvir D, Arbel Y, Beigel R, Freimark D, Usmanov V, Gilman S, Feinberg MS.
Pulse pressure is a predictor of endothelial function assessed by brachial artery vasoreactivity testing in healthy volunteers.
Israel Heart Society Abstract Book 2005:93.
115. Feinberg MS, Carasso S, Marai I, Sandach A, Kuperstein R, Freimark D, Guetta V, **Shechter M**.
The association between brachial artery flow-mediated vasodilation and left ventricular diastolic function.
Eur J Echo 2005
116. Lavi T, Karasik A, Feinberg MS, **Shechter M**.
The acute effect of various glycemic index carbohydrates.
Eur Heart J 2005;26:551.
117. Sandach A, **Shechter M**, David Zadeh O, Matetzky S, Guetta V, Hod H, Behar S, Snyder M, Schwammenthal E.
Prediction of all-cause mortality at 6 months in 30-day survivors of acute coronary syndrome: prospective validation of the ACSIS score.
Eur Heart J 2005;26:
118. Dvir D, Kornowski R, **Shechter M**, Aravot D.
C-shaped versus Sigma-shaped right coronary artery: an association between morphology and atherosclerotic stenosis.
Eur Heart J 2005;26:236.
119. **Shechter M**, Issachar A, Marai I, Koren Morag N, Freimark D, Matetzky S, Usmanov V, Gilman S, Feinberg MS.
Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with not apparent heart disease.
J Am Coll Cardiol 2006;46:313A.
Israel Heart Society Abstract Book 2006.
120. Carasso S, **Shechter M**, Marai I, Sandach A, Issachar A, Kuperstein R, Freimark D, Guetta V, Feinberg MS.
The association between brachial artery flow-mediated vasodilation and left ventricular diastolic function.
Israel Heart Society Abstract Book 2006.
121. Barsheshwt A, Hod H, **Shechter M**, Sharabani-Yosef O, Rosenthal E, Barabash IM, Matetzky S, Nagler A, Leor J.

- External counter pulsation therapy (ECPT) increases number and function of circulating endothelial progenitor cells in patients with angina pectoris.
Israel Heart Society Abstract Book 2006.
122. **Shechter M.** Arad M, Gershovitz L, Matetzky S, Langerman I, Koren Morag N, Hochenberg N, Makmal Y, Freimark D.
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality in refractory end-stage chronic heart failure patients.
Israel Heart Society Abstract Book 2006.
123. **Shechter M.** Marai I, Marai S, Sherer Y, Sela BA, Feinberg MS, Rubinstein A, Shoenfeld Y.
Peripheral vascular endothelial function is associated with an increased risk of cardiovascular events in healthy subjects and patients with coronary artery disease.
Israel Heart Society Abstract Book 2006.
124. **Shechter M.** Arad M, Gershovitz L, Matetzky S, Langerman I, Koren Morag N, Hochenberg N, Makmal Y, Freimark D.
125. Barsheshet A, Hod H, **Shechter M.** Sharabani-Yosef O, Rosenthal E, Barbash IM, Matetzky S, Tal R, Betancur AG, Sela B, Nagler A, Leor J.
The effects of external counter pulsation therapy on circulating endothelial progenitor cells in patients with angina pectoris.
J Am Coll Cardiol 2007;49:333A.
126. **Shechter M.** Marai I, Sherer Y, Feinberg MS, Shoenfeld Y, Inbal A.
Circulating endothelium- and platelet-derived microparticles in healthy subjects and patients with coronary artery disease.
J Am Coll Cardiol 2007;49:335A.
127. Freimark D, Arad M, Matetzky S, Gershovitz L, Langerman I, Koren Morag N, Hochberg N, Makmal Y, **Shechter M.**
Refractory end-stage chronic heart failure day care service: a five-year single center experience.
J Am Coll Cardiol 2007;49:280A.
128. **Shechter M.** Arbel Y, Usmanov V, Gilman S, Feinberg MS, Dvir D.
Pulse pressure is a predictor of vascular endothelial function in healthy volunteers.
Israel Heart Society Abstract Book 2007;7.
129. **Shechter M.** Marai I, Sherer Y, Feinberg MS, Shoenfeld Y, Inbal A.
Circulating endothelium- and platelet derived microparticles in healthy subjects and patients with coronary artery disease.
Israel Heart Society Abstract Book 2007;42.
130. **Shechter M.** Arad M, Matetzky S, Feinberg MS, Eizenberg N, Hochenberg N, Guttman M, Makmal Y, Freimark D.
Vascular endothelial function predicts mortality risk in patients with severe ischemic chronic heart failure.
Israel Heart Society Abstract Book 2007;24.

131. **Shechter M**, Arbel Y, Feinberg MS, Eldar M, Koren Morag N, Eizenberg N, Usmanov V, Gilman S, Freimark D.
The effect of immune modulation therapy using the Celecade System on endothelial function in patients with severe chronic heart failure: data from the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) Trial.
Israel Heart Society Abstract Book 2007;72.
132. **Shechter M**, Shechter A, Fefer P, Hod H, Feinberg MS, Usmanov V, Gilman S, Matetzky S.
The association between platelet function and endothelial function of the brachial artery in healthy subjects and in patients with coronary artery disease.
Israel Heart Society Abstract Book 2007;61.
133. **Shechter M**, Sharabi Y, Marai I, Carasso S, Marai S, Peleg E, Kamari Y, Grossman E, Feinberg MS, Sela BA, Sherer Y, Shoenfeld Y.
The association of plasma adiponectin levels and forearm vascular endothelial function in healthy volunteers and patients with coronary artery disease.
Israel Heart Society Abstract Book 2007;62.
134. **Shechter M**, Ginsberg S, Scheinowitz M, Feinberg MS, Laron Z.
Obese adults with primary hormone resistance (Laron Syndrome) have normal endothelial function.
Israel Heart Society Abstract Book 2007;63.
135. Leor J, Truman S, Gruberg L, Kapelovitz M, Ben Zvi M, Nikolsky E, Turgeman Y, Suleiman K, Golan L, Jamal J, Manevich L, Maymon D, Toboul O, Shefer A, Harel S, Rosenschein U, Guetta V, Disegni I, **Shechter M**, Kaluski I, Yemima K, Vered Z, Beyar R.
Coronary intervention for persistent occlusion after myocardial infarction –Israeli perspective.
Israel Heart Society Abstract Book 2007;84.
136. **Shechter M**, Shechter A, Fefer P, Hod H, Feinberg MS, Usmanov V, Gilman S, Matetzky S.
The association between platelet function and endothelial function of the brachial artery in healthy subjects and in patients with coronary artery disease.
Eur Heart J 2007;28:483.
137. **Shechter M**, Issachar A, Marai I, Koren Morag N, Shahar Y, Freimark D, Feinberg MS.
Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects.
Eur Heart J 2007;28:481.
138. **Shechter M**, Arbel Y, Beigel R, Feinberg MS, Dvir D.
Pulse pressure is a predictor of vascular endothelial function in healthy volunteers.
Eur Heart J 2007;28:482.
139. **Shechter M**, Arbel Y, Feinberg MS, Eldar M, Koren Morag N, Eizenberg N, Usmanov V, Gilman S, Freimark D.
The effect of immune modulation therapy using on endothelial function in patients with severe chronic heart failure: data from the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) Trial.

- Eur Heart J 2007;28:483.
140. **Shechter M**, Ginsberg S, Scheinowitz M, Feinberg MS, Laron Z. Obese adults with primary hormone resistance (Laron Syndrome) have normal endothelial function. Eur Heart J 2007;28:711.
141. **Shechter M**, Guetta V, Feinberg MS, Agranat O, Freimark D, Arad M, DiSEgni E. Oral L-arginine therapy improves endothelial dysfunction in patients with recurrent chest pain and normal coronary arteries. Eur Heart J 2007;28:708.
142. **Shechter M**, Arbel Y, Feinberg MS, Eldar M, Koren Morag N, Eizenberg N, Usmanov V, Gilman S, Freimark D. The effect of immune modulation therapy using on endothelial function in patients with severe chronic heart failure: data from the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) Trial. J Am Coll Cardiol 2008;51:A45.
143. **Shechter M**, Arbel Y, Beigel R, Feinberg MS, Dvir D. Pulse pressure is a predictor of vascular endothelial function in healthy volunteers. J Am Coll Cardiol 2008;51:A330.
144. Matetzky S, Fefer P, Shenkman B, **Shechter M**, Levi N, Varon D, Savion N, Hod H. Platelet Responsiveness to Aspirin Loading in Patients With ST- Elevation Myocardial Undergoing Primary Percutaneous Intervention Is Associated With Myocardial Reperfusion and Clinical Outcome. J Am Coll Cardiol 2008;51:A204.
145. **Shechter M**, Arad M, Matetzky S, Feinberg MS, Eizenberg N, Hochenberg N, Guttman M, Makmal Y, Freimark D. Vascular endothelial function predicts mortality risk in patients with severe ischemic chronic heart failure. J Am Coll Cardiol 2008;51:A281.
146. **Shechter M**, Issachar A, Marai I, Koren-Morag N, Shahar Y, Shechter A, Feinberg MS. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Israel Heart Society Abstract Book 2008;.
147. **Shechter M**, Hammerman H, Boyko V, Hod H, Behar S, Matetzky S. The obesity paradox in acute coronary syndrome patients in Israel. Israel Heart Society Abstract Book 2008.
148. Asman A, Chouraqui P, Livne A, **Shechter M**. Ectatic coronary arteries are associated with peripheral vascular endothelial dysfunction in patients with chest pain. Israel Heart Society Abstract Book 2008.

149. **Shechter M**, Shechter A, Fefer P, Koren-Morag N, Hod H, Feinberg MS, Haratz D, Sela BA, Matetzky S.
Brachial artery endothelial function predicts platelet function in healthy subjects and in patients with coronary artery disease.
Israel Heart Society Abstract Book 2008.
150. **Shechter M**, Shechter A, Fefer P, Koren-Morag N, Hod H, Feinberg MS, Haratz D, Sela BA, Matetzky S.
Brachial artery flow-mediated dilation predicts platelet function in healthy subjects and in patients with acute coronary syndrome.
Eur Heart J 2008;29:789.
151. Freimark D, Arad M, Matetzky S, Deneen I, Gershovitz L, Koren-Morag N, **Shechter M**.
An advanced chronic heart failure day care service: a five-year single center experience.
Eur Heart J 2008;29:46.
152. **Shechter M**, Issachar I, Marai I, Koren-Morag N, Shahar Y, Shechter A, Feinberg MS.
Brachial flow-mediated dilation is associated with long-term cardiovascular events in healthy subjects.
Eur Heart J 2008;29:493.
153. **Shechter M**, Hammerman H, Boyko V, Hod H, Behar S, Matetzky S.
The obesity paradox in acute coronary syndrome patients in Israel.
Eur Heart J 2008;29:99.
J Am Coll Cardiol 2009;53:A198.
154. Shechter A, **Shechter M**, Fefer P, Koren-Morag N, Hod H, Feinberg MS, Haratz D, Sela BA, Matetzky S.
Brachial artery flow-mediated dilation predicts platelet function in healthy subjects and in patients with acute coronary syndrome.
The 13th Annual Meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis, Eilat, September 2008, Israel. (Abstract Book)
155. **Shechter M**, Arad M, Matetzky S, Feinberg MS, Freimark D.
Brachial artery endothelial function predicts mortality risk in patients with advanced ischemic chronic heart failure.
Israel Heart Society Abstract Book 2009.
156. **Shechter M**, Roth A, Atar S, Boyko V, Behar S, Matetzky S.
Outcome of acute coronary syndrome octogenarian patients in Israel.
Israel Heart Society Abstract Book 2009.
157. **Shechter M**, Shechter A, Hod H, Fefer P, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Matetzky S.
Brachial artery endothelial function predicts platelet function in healthy subjects and in patients with acute coronary syndrome.
Israel Heart Society Abstract Book 2009.
158. **Shechter M**, Karasil A, Koren-Morag N, Kanety H, Feinberg MS, Lavi T.

- The acute effect of various glycemic index dietary carbohydrates on endothelial function in non-diabetic overweight and obese subjects.
Eur Heart J 2009;30:234.
159. **Shechter M**, Matetzky S, Arad M, Feinberg MS, Freimark D.
Vascular endothelial function predicts mortality risk in patients with advanced ischemic chronic heart failure.
Eur Heart J 2009;30:362.
160. **Shechter M**, Roth A, Atar S, Boyko V, Behar S, Matetzky S.
Outcome of acute coronary syndrome octogenarian patients in Israel.
Eur Heart J 2009;30:234.
161. **Shechter M**.
The rationale for magnesium in cardiac disease.
29th Magnesium-Symposium der Gesellschaft für Magnesium-Forschung e.V. abstract book, Fulda, Germany, October 2009
162. **Shechter M**, Hirsch L, Koren-Morag N, Feinberg MS.
The impact of early compared to late morning hours on brachial endothelial function and long-term cardiovascular events in healthy subjects with no apparent coronary artery disease.
J Am Coll Cardiol 2010;55:
163. Asher E, Hod H, **Shechter M**, Beigel R, Varon D, Shenkman B, Savion N, Matetzky S.
Predictors of response to clopidogrel in patients with ACS.
Israel Heart Society Abstract Book 2010.
164. Arad M, Nussbaum T, Feinberg MS, **Shechter M**, Freimark D.
Reserve remodeling in DCM: primary report.
Israel Heart Society Abstract Book 2010.
165. Shalmon G, Chouraqui P, Sceinowitz M, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Sharabi Y, **Shechter M**.
The impact of caffeine on brachial endothelial function in healthy subjects and in patients with ischemic heart disease.
Israel Heart Society Abstract Book 2010.
166. Hirsch L, Koren-Morag N, Issachar A, Marai I, Shahar Y, Shechter A, Freimark D, Matetzky S, Arad M, Asher E, Feinberg MS, **Shechter M**.
Long-term association of brachial artery flow-mediated dilation and cardiovascular events in middle-aged subjects with no apparent heart disease.
Israel Heart Society Abstract Book 2010.
167. Hirsch L, Feinberg MS, Koren-Morag N, **Shechter M**.
The impact of early compared to late morning hours on brachial endothelial function and long-term cardiovascular events in healthy subjects.
Israel Heart Society Abstract Book 2010.
168. Beigel R, Dvir D, Arbel Y, Shechter A, Feinberg MS, **Shechter M**.

- Pulse pressure is a predictor of vascular endothelial function in middle-aged subjects with no apparent heart disease.
Eur Heart J 2010;31:245.
169. **Shechter M**, Shechter A, Hod Hm Shenkman B, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Savion N, Matetzky S.
Brachial artery endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction.
Eur Heart J 2010;31:824.
170. **Shechter M**, Shalmon G, Sceinowitz M, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Sharabi Y, Chouraqui P.
The impact of caffeine on brachial endothelial function in healthy subjects and in patients with ischemic heart disease
Eur Heart J 2010;31:685.
171. **Shechter M**, Hirsch L, Koren-Morag N, Feinberg MS.
The impact of early compared to late morning hours on brachial endothelial function and long-term cardiovascular events in healthy subjects with no apparent heart disease.
Eur Heart J 2010;31:825.
172. Arad M, Nussbaum T, Feinberg MS, **Shechter M**, Freimark D.
Prevalence and short-term implications of reverse remodeling in dilated cardiomyopathy.
Eur Heart J 2010;31:1055.
173. **Shechter M**, Shechter A, Koren-Morag N, Issachar A, Marai I, Shahar Y, Feinberg MS, Hirsch L.
Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease.
J Am Coll Cardiol 2011;
174. Buber Y, Goldenberg I, Moss A, Eldar M, Glikson M, Barsheshet A, **Shechter M**.
Treatment with statins Statin is associated with a reduction in ventricular fibrillation and fast ventricular tachycardia in patients with non ischemic cardiomyopathy.
Eur Heart J 2011;
175. Hirsch L, Shechter A, Koren-Morag N, Feinberg MS, **Shechter M**.
The association of brachial artery flow-mediated vasodilation and long-term cardiovascular events in middle-aged subjects without heart disease.
Israel Heart Society Annual Scientific Meetings 2013.
176. **Shechter M**, Saad T, Shechter A, Koren-Morag N, Matetzky S.
Short-term magnesium oxide monohydrate treatment improves lipids and inflammation in healthy subjects.
Israel Heart Society Annual Scientific Meetings 2013.
177. **Shechter M**, Shechter A, Koren-Morag N, Feinberg MS, Hirsch L.
Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease.

Eur Heart J 2013

178. Shlezinger M, Amital Y, **Shechter M**, Leventer-Roberts M.
Evaluation of adverse health effects in the Israeli population from lack of magnesium and iodine in drinking water from desalinated sea water.
179. Cohen H, Bitzur R, **Shechter M**, Harats D, Modan D.
Cardiovascular risk assessment and carotid intima-media thickness in young adults, survivors of Hodgkin's lymphoma.
The 17th Triennial Congress of the International Atherosclerosis Society (ISA) Meeting, May 2015, Amsterdam, The Netherlands.
180. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Mortality rates from acute coronary syndrome in octogenarian patients in Israel during the period 2000-2006 compared to 2008-2013.
J Am Coll Cardiol 2015;65:A16.
181. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Trends in mortality rates from acute coronary syndrome octogenarian patients in Israel during the period 2000-2013.
J Am Coll Cardiol 2015;65:A16.
182. **Shechter M**, Saad T, Shechter A, Koren-Morag N, Matetzky S.
Short-term magnesium oxide monohydrate treatment improves lipids and inflammation in healthy subjects.
J Am Coll Cardiol 2015;65:A359.
183. Herscovici R, Beigel R, Asher E, Oieru D, Shlomo N, **Shechter M**, Porter A, Kuperstein R, Goiten O, Matetzky S.
Gender differences among patients evaluating for low medium risk acute chest pain.
Israel Heart Society Abstract Book 2015; page 49.
184. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Mortality rates from acute coronary syndrome octogenarian patients in Israel during the period 2000-2013.
Israel Heart Society Abstract Book 2015; page 61.
185. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Outcome of acute coronary syndrome octogenarian patients in Israel.
Israel Heart Society Abstract Book 2015; page 63.
186. Matetzky S, Shechter A, Hod H, Beigel R, Koren-Morag N, **Shechter M**.
Platelet function predicts long-term cardiovascular events in subjects without heart disease.
Israel Heart Society Abstract Book 2015; page 65.
187. **Shechter M**, Shechter A, Hod H, Beigel R, Koren-Morag N, Matetzky S.
Usefulness of brachial flow-mediated dilation and platelet function to predict long-term events in subjects without heart disease.
Israel Heart Society Abstract Book 2015; page 66.

188. **Shechter M**, Shechter A, Koren-Morag N, Feinberg MS.
Aging is associated with endothelial dysfunction in healthy men and women.
Israel Heart Society Abstract Book 2015; page 67.
189. Chernomordik F, Freimark D, Arad M, Matetzky S, Peled A, Goldenberg I, **Shechter M**, Peled Y.
Impact of intermittent intravenous inotropes in outpatient setting on quality of life and mortality in patients with advanced chronic heart failure.
Israel Heart Society Abstract Book 2015; page 29.
190. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Trend in mortality rates from acute coronary syndrome in octogenarian patients in Israel during the period 2000-2006 compared to 2008-2013.
Israel Heart Society Abstract Book 2015; page 31.
191. **Shechter M**, Shlezinger M, Amity Y, Goldenberg I.
Temporal trends in all cause mortality patients with acute myocardial infarction in regions with compared to without desalinated drinking water from the Acute Coronary Syndrome Israeli Survey (AC SIS).
Eur Heart J, 2015;36:114.
192. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Trend in mortality rates from acute coronary syndrome in octogenarian patients in Israel during the period 2000-2006 compared to 2008-2013.
Eur Heart J, 2015;36:977
193. **Shechter M**, Shechter A, Hod H, Beigel R, Koren-Morag N, Matetzky S.
Usefulness of brachial flow-mediated dilation and platelet function to predict long-term events in subjects without heart disease.
Eur Heart J, 2015;36:256.
194. **Shechter M**, Goldenberg I, Matetzky S on behalf of the ACSIS investigators.
Outcome of acute coronary syndrome octogenarian patients in Israel.
Eur Heart J, 2015;36:979.
195. Shlezinger M, **Shechter M**, Goldenberg I, Amital Y.
The association of desalinated drinking water and all-cause mortality in hospitalized patients with acute myocardial infarction from the Acute Coronary Syndrome Israeli Survey 2002-2013.
Israel Heart Society Annual Meetings, Tel Aviv, Israel, April 2016.
196. Shlezinger M, Amital Y, Goldenberg I, **Shechter M**.
The association between supply of desalinated drinking water and all-cause mortality in hospitalized patients with acute myocardial infarction from the Acute Coronary Syndrome Israeli Survey 2002-2013.
Environment and Health Fund, Tel Aviv, Israel, April 2016.
197. Shlezinger M, Amital Y, Goldenberg I, **Shechter M**.

- The association between supply of desalinated drinking water and all-cause mortality in hospitalized patients with acute myocardial infarction from the Acute Coronary Syndrome Israeli Survey 2002-2013.
Public Health Symposium, Ramat Gan, Israel, June 2016.
198. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Endothelial function predicts 1-year clinical outcome in patients hospitalized in chest pain unit.
ESC Annual Meetings, Rome, Italy, August 2016.
199. Shlezinger M, Amital Y, Goldenberg I, **Shechter M**.
The association of desalinated drinking water and all-cause mortality in hospitalized patients with acute myocardial infarction from the Acute Coronary Syndrome Israeli Survey 2002-2013.
The 21st annual meeting of the Israeli Society for Research, Prevention & Treatment of Atherosclerosis. October 27-30, Haifa, Israel, 2016.
200. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Endothelial function predicts 1-year clinical outcome in patients hospitalized in chest pain unit.
American Heart Association Scientific Sessions, New Orleans, Louisiana, USA, Nov 12-16, 2016.
201. Shlezinger M, Amital Y, Goldenberg I, **Shechter M**.
The association between supply of desalinated drinking water and all-cause mortality in hospitalized patients with acute myocardial infarction from the Acute Coronary Syndrome Israeli Survey 2002-2013.
Israel Heart Society Abstract Book 2017.
202. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Endothelial function predicts 1-year clinical outcome in patients hospitalized in chest pain unit.
Israel Heart Society Abstract Book 2017.
203. Mazin I, Beigel R, Rozenberg N, **Shechter M**, Asher E, Matetzky S.
The impact of aspirin withdrawal in acute coronary syndrome patients treated with novel P2Y₁₂ inhibitors – A Platelet Reactivity Study.
Israel Heart Society Abstract Book 2017.
204. **Shechter M**, Metetzky S, Prasad M, Koren-Morag N, Lerman A.
Peripheral endothelial function predicts 1-year adverse clinical outcome in patients hospitalized in the emergency department.
J Am Coll Cardiol 2018.
205. Rubinstein R, Matetzky S, Beigel R, Iakobishvili Z, **Shechter M** on behalf of the ACSIS investigators.
Outcome of acute coronary syndrome in women ≥ 80 years versus those < 80 years in Israel from 2000-2016.
Israel Heart Society Abstract Book 2018.
206. **Shechter M**, Metetzky S, Prasad M, Goiten O, Goldkorn R, Naroditsky M, Koren-Morag N, Lerman A.

Peripheral endothelial function predicts 1-year adverse clinical outcome in patients with chest pain hospitalized in the emergency department.
Israel Heart Society Abstract Book 2018.

E. Items in Encyclopedias

- - - NONE - - -

F. Books Edited

- - - NONE - - -

G. OTHER PUBLICATIONS (Reports; Letter to Editors; Collaborators; Guidelines, etc.)

G-1. **Shechter M.**

Magnesium and coronary artery disease (letter).
Hospimedica 1990;8:14.

G-2. **Shechter M.**

Pulmonary embolectomy in the thrombolytic era (letter).
Harefuah 1991;120:489.

G-3. **Shechter M.**

Polymorphous ventricular tachycardia with long QT interval in patients treated with phenothiazin and diuretics (letter).
Harefuah 1992;122:686.

G-4. **Shechter M.**

Right heart pulmonary emboli-in-transit (letter).
Am Heart J 1992;124:1963.

G-5. **Shechter M.** Kaplinsky E.

Magnesium effect in electromechanical dissociation (EMD) (letter).
Arch Intern Med 1993;153:1271.

G-6. **Shechter M.**

Hypermagnesemia: Elderly over-the-counter drug users at risk (letter).
Arch Fam Med 1996;5:323.

G-7. **Shechter M.**

Myocardial infarction and magnesium.
In: Hamilton K and Simpson K, eds.: The role of nutrition in Medicine. The Experts Speak 1997; I. T. services 1997, pp 96-97.

- G-8. **Shechter M.**
Myocardial infarction and magnesium.
Clinical Pearls News, 1997; Supl. Sep.:1-2.
- G-9. **Shechter M.**
Additional ST-Segment Elevation After Reperfusion: A Beneficial Sign in Patients with Acute Myocardial Infarction?
Am J Cardiol, 1998;81:1066 (letter).
- G-10. **Shechter M.**, Sherer Y.
Endothelial dysfunction: a crystal ball prediction for enhanced cardiovascular risk?
Isr Med Assoc J 2003;5:736-738 (Editorial).
- G-11. **Shechter M.**
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation.
Circulation 2003; 107:210e (letter)
- G-12. **Shechter M.**
Do statins really interfere with clopidogrel-induced platelet function?
Eur Heart J 2004;25:448 (letter).
- G-13. **Shechter M.**
A walnut diet improves endothelial function in hypercholesterolemic subjects. A randomized crossover trial.
Circulation 2004;110 (5):e58 (letter).
- G-14. **Shechter M.**
Intensive lipid-lowering therapy:obvious benefits, possible risks.
Isr Med Assoc J 2007;9:133 (letter).
- G-15. **Shechter M.**
Association of haptoglobin genotype in adolescents with type I diabetes mellitus and endothelial function: an unresolved issue.
Isr Med Assoc J 2007;9:671-673 (Editorial).
- G-16. **Shechter M.**
ENHANCE study
www.emed.co.il (e-Med online) April 10, 2008 (Editorial)
- G-17. **Shechter M.**
CASHEMERE study - Editorial - guest
www.emed.co.il e-Med online July 13, 2008 (Editorial) Hebrew
- G-18. **Shechter M.**
SEAS study
www.emed.co.il e-Med online July 24, 2008 (Editorial) Hebrew
- G-19. **Shechter M.**
Do statins/ezetimibe increase the incidence of malignancy?

www.emed.co.il e-Med online September 27, 2008 (Editorial) Hebrew

G-20 **Shechter M.**

What have we learned from JUPITER study and where do we stand in primary prevention of coronary artery disease?

www.emed.co.il e-Med online November 11, 2008 (Editorial) Hebrew

G-21 **Shechter M.**

Blood lipids – clinical trails in prevention.

Walla.co.il Health May 13, 2009 Hebrew

G-22. **Shechter M.**

The acute effect of carbohydrates glycemic index on endothelial function in non-diabetic obese volunteers.

www.emed.co.il e-Med online June 9, 2009. Hebrew

G-23. **Shechter M.**

Your Arteries on Wonder Bread. The American Friends of Tel Aviv University Home Page, June 25, 2009

<http://www.aftau.org/site/News2?page=NewsArticle&id=9919> June 25, 2009

Since last promotion

G-24. **Shechter M.**

The FDA warning regarding high dose of simvastatin.

www.emed.co.il e-Med online April 6, 2010.

G-25 **Shechter M.**, Hammerman H, Boyko V, Hod H, Behar S, Matetzky S.

The obesity paradox in hospitalized acute coronary syndrome in Israel: A national Survey. CVD Prevention and Control 2010;5:81-87.

(No IF listing)

G-26. **Shechter M.**

Statins should be given to all diabetic patients above age 40.

www.emed.co.il e-Med online October 3, 2010. Hebrew

G-27. **Shechter M.**

The cloud over ezetimibe has not been removed yet.

www.emed.co.il e-Med online May 29, 2011 (Editorial)

G-28. **Shechter M.**

Re: The Doctors' Status – Where to? / A Guest Opinion by Prof. Michael Schechter (*)

<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=280091>

June 20, 2011 (Opinion) Hebrew

- G-29. **Shechter M.**
This Time we Strike to the End. Israel Medical Association Web Site (Opinion).
<http://doctorsonly.co.il/2011/06/11699/>
June 24, 2011 (Opinion) Hebrew
- G-30. **Shechter M.**
The interns lie on the fence for the doctors of Israel / a guest article by Prof. Michael Schechter, a senior physician in the public system
<http://www.e-med.co.il/emed/new/usersite/PrintArticle.asp?ContentID=293626>
October 6, 2011 Hebrew
- G-31. **Shechter M.**
Editorial: Israel's greatest crisis of faith in leadership.
<http://www.emed.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=299926>
November 18, 2011 Hebrew
Editorial
- G-32. **Shechter M.**
An editorial: Children exposed to parental smoking (= passive smoking) are associated with decreased endothelial function in the brachial artery in young adults.
<http://www.emed.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=316586>
March 19, 2012 Hebrew
Editorial
- G-33. **Shechter M.**
Magnesium - the mineral that has not been cured by Prof. Michael Schechter (*), editor of cardiology
<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=322014>
April 26, 2012 Hebrew
- G-34. **Shechter M.**
Editorial: Referring to an article by Primum non nocere 10/06/2012 In primary prevention / by Prof. Schechter
The Heart - editorial refers to this article recently published in which reported the study from Major bleeding with aspirin in primary prevention underestimated (Source 7) JAMA
<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=328403>
June 10, 2012. Hebrew
Editorial
- G-35. **Shechter M.**
Editorial: Is the PCSK9 antibody is the next generation of statins?
<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=329949>
June 18, 2012 Hebrew
Editorial

- G-36. **Shechter M.**
Editorial:Can Ranolazine Before PCI May Reduce Myocardial Damage?
<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=330553>
June 23, 2012. Hebrew
Editorial
- G-37. **Shechter M.**
Editorial:Lack of magnesium in diabetic patients.
<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=330752>
June 24, 2012. Hebrew
Editorial
- G-38. **Shechter M.**
Editorial :Coffee protects against heart failure.
<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=332121>
July 2, 2012. Hebrew
Editorial
- G-39. **Shechter M.**
Editorial :The risk of acute coronary events decreases in adults taking antipsychotics.
<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=332995>
July 9, 2012. Hebrew
Editorial
- G-40. **Shechter M.**
Reply to the letter: "what is the correct magnesium supplement?"
by Kisters [1]. Magnes Res. 2013 Jan-Feb;26(1):42-5. doi: 10.1684/mrh.2013.0335. PubMed
PMID: 23615032.
Comment/ letter
- G-41. **Shechter M.**
Opinions Article: Prepare well to prevent Ebola eruption In Israel
<http://www.doctoronly.co.il/2014/10/85907/>
October 20, 2014 Hebrew
- G-42. **Shechter M.**
Opinions Article: Proper regulation is the foundation of good medicine
<http://doctoronly.co.il/2014/11/87080/>
November 10, 2014 Hebrew
- G-43. **Shechter M.**
Opinions Article: At the expense of the patient and the doctor
<http://www.haaretz.co.il/opinions/letters/1.2509060>
December 11, 2014
- G-44. **Shechter M.**
Opinions Article: The new generation of drugs to lower LDL
<http://doctoronly.co.il/2015/06/98306/>
June 17, 2015

- G-45. **Shechter M.**
Opinions Article: Why do they want to limit only the doctors' salaries?
Doctorsonly.co.il
July 23, 2015 Hebrew
- G-46. **Shechter M.**
Opinions Article: To fight the proposed Arrangements Law - doctors are not to blame for the health costs
<http://doctorsonly.co.il/2015/08/100458/>
August 2015 Hebrew
- G-47. **Shechter M.**
Opinions Article: To fight against the proposal to restrict insureds to "arrangement lists"
<http://doctorsonly.co.il/2015/10/102918/>
October 25, 2015. Hebrew
- G-48. **Shechter M.**
We must act to correct the mistaken image of statins.
<http://doctorsonly.co.il/2015/12/105215/>
December 14, 2015. Hebrew
- G-49 **Shechter M.**
Opinions Article: To prevent heart disease, should be expanded
The struggle beyond junk food
<http://doctorsonly.co.il/2016/04/110477/>
April 24, 2016. Hebrew
- G-50 **Shechter M.**
Stigmatizing About the Junk Food- Is that so?
<http://doctorsonly.co.il>
April 25, 2016 Hebrew
- G-51 **Shechter M.**
Opinions Article: Think about creative solutions to make it easier On the plight of interns
<http://doctorsonly.co.il/2016/06/111783/>
June 2016 Hebrew
- G-52 **Shechter M.**
Opinions Article: The Arrangements Law will not lead to a reduction in medicine but to profits for the insurance companies.
<http://doctorsonly.co.il/2016/07/112916/>
July 2016. Hebrew
- G-53 **Shechter M.**
Opinion article: The Ministry of Health's double game regarding doctors' shifts.
<http://doctorsonly.co.il/2016/08/113910/>
August 1, 2016 Hebrew

- G-54 **Shechter M.**
Opinion article: Why the Ministry of Health does not help interns in the struggle?
<http://www.calcalist.co.il/articles/0,7340,L-3694854,00.html>
August 5, 2016 Hebrew
- G-55 **Shechter M.**
Opinion: This strike is because of the malice of those who humiliate doctors.
<http://doctorsonly.co.il/2016/08/114204/>
August 10, 2016 Hebrew
- G-56 **Shechter M.**
Opinion article: Doctors must fight the negative image of statins in the media.
<http://doctorsonly.co.il/2016/11/116559/>
November 2, 2016 Hebrew
- G-57 Adler Y, **Shechter M.**
Opinion article: Treatment with Rafata reduces life-threatening cardiac events
Haaretz April 2017
- G-58 **Shechter M.**
Opinion article: The guidelines for treating blood lipids in heart patients must be updated immediately and the LDL level reduced to 30 mg / dL.
Emed.co.il
April 20, 2017 Hebrew
- G-59 **Shechter M.**, Adler Y
Opinion article: The future drug that will reduce or prevent heart disease. The future is already here: Scientists have developed a drug for a rare genetic mutation that may prevent heart disease in humans. This is part of the development of personalized drugs based on genetic variations.
<http://www.ynet.co.il/articles/0,7340,L-4969905,00.html>
June 1, 2017 Hebrew
- G-60 **Shechter M.**
Opinion article: Is there a medical justification for the policy of limiting saturated fat in food?
<http://www.e-med.co.il/emed/new/usersite/content.asp?CatID=2&ContentID=635268>
June 7, 2017. Hebrew
- G-61 **Shechter M.**
Opinion article: Limiting the passage of doctors between the HMOs: further harming our freedom of occupation. Is it right for a democratic regime to prevent doctors from moving from one place of work to another according to the proposed wage? Where is the doctor's rights as a citizen of the state?
<https://doctorsonly.co.il/2017/07/128042/>
July 23, 2017. Hebrew
- G-62. **Shechter M.**
New Age in the Treatment of Cholesterol - What Have We Learned from the FOURIER Study of Herpetta? Article in the section "Cholesterol"

<https://cholesterol.doctoronly.co.il/2017/08/128965/>

August 23, 2017 Hebrew

G-63 **Shechter M.**

Opinion Article: How can we compare our healthcare system with that in Switzerland?

<https://doctoronly.co.il/2017/10/131298/>

October 30, 2017 Hebrew

G-64 **Shechter M.**

Opinion Article: The bill to prevent competition between the HMOs: The doctors are again accused.

<https://doctoronly.co.il/2017/11/132202/>

November 20, 2017 Hebrew

G-65 **Shechter M.**

Opinion Article: How to treat the results of the study on catheterization and stable angina?

<https://doctoronly.co.il/2017/11/132278/>

November 23, 2017 Hebrew

G-66 **Shechter M.**

Opinion Article: The distorted data of the Ministry of Finance and the need to raise the basic wage.

<https://doctoronly.co.il/2018/01/135575/>

January 31, 2018 Hebrew

G-67 **Shechter M.**

The Odyssey study results reinforce the need to update guidelines and lower LDL-C levels below 50 mg / dL in heart patients.

med.co.il March 11, 2018 Hebrew

H. Member of Editorial Board/ Reviewer (International Journals)

2017-2018 Guideline reviewer,
 ESC National Cardiac Societies: Israel Heart Society - review process of 2018 ESC/ESH Guidelines for the management of arterial hypertension.
 European Society of Hypertension (ESH) and European Society of Cardiology (ESC)

| <i>Period</i> | <i>Journal Name</i> | | <i>Role</i> |
|---------------|---------------------------------|---------|-----------------|
| 1994-to date | Journal fur Mineralstoffwechsel | Austria | Editorial Board |
| 2002-to date | Magnesium Bulletin | Germany | Editorial Board |
| 2002-to date | Trace Elements and Electrolytes | Germany | Editorial Board |
| 2006-to date | Magnesium Research | France | Editorial Board |

| | | | |
|--------------|---------------------------|--------|-------------------|
| 2011-to date | ISRN Vascular Medicine | Israel | Editorial Board |
| 2012-2014 | eMED.co.il | Israel | Cardiology Editor |
| 2012-to date | Current Treatment Options | USA | Editorial Board |

Medical Journal Reviewer

| | |
|----------------|--|
| 1995 - to date | Aviation Space and Environmental Medicine |
| 1995 - to date | Magnesium Research |
| 1995 – to date | Harefuah |
| 1998 - to date | Journal of Cardiac Failure |
| 1998 - to date | Israel Medical Association Journal (IMAJ) |
| 2000 – to date | Am J Clin Nutrition |
| 2000 – to date | ISRN Vascular Medicine |
| 2000 – to date | Vascular Medicine |
| 2000 - to date | American Journal of Cardiology |
| 2001 – to date | Circulation Heart Failure |
| 2001 - to date | Circulation |
| 2001 - to date | Journal of the American College of Cardiology |
| 2001 - to date | Eur Heart J |
| 2002 - to date | American Heart Journal |
| 2002 - to date | Arteriosclerosis Thrombosis and Vascular Biology |
| 2002 - to date | BioMed Central |
| 2002 - to date | Nutrition Journal |
| 2003 – to date | Am J Hypertension |
| 2003 - to date | Thrombosis Research |
| 2004 – to date | International Journal of Vascular Medicine |
| 2010 – to date | Nutrition |
| 2010 – to date | Metabolism & Cardiovascular Diseases |

IF/WOS 10/7/2017

INNA